

**REACTIVITY STUDIES OF ARENE-CIS-DIOLS IN  
CYCLOADDITIONS AND POTASSIUM PERMANGANATE  
OXIDATIONS: SYNTHESIS OF THE CORRESPONDING  
ARENE-TRANS-DIOLS AND AN APPROACH TO THE  
SYNTHESIS OF (+)-PANCRATISTATIN.**


by


Bryan P. McKibben


Dissertation submitted to the Faculty of the  
Virginia Polytechnic Institute and State University  
in partial fulfillment of the requirements for the degree of


Doctor of Philosophy  
in  
Chemistry


Approved:

  
Dr. Tomas Hudlicky, Chairman

  
Dr. James Tanko

  
Dr. David Kingston

  
Dr. Joseph Merola

  
Dr. Richard Gandour

October 1994

C.2

LD

5655

V856

1994

M437

C.2

**REACTIVITY STUDIES OF ARENE-*CIS*-DIOLS IN  
CYCLOADDITIONS AND POTASSIUM PERMANGANATE  
OXIDATIONS: SYNTHESIS OF THE CORRESPONDING  
ARENE-*TRANS*-DIOLS AND AN APPROACH TO THE  
SYNTHESIS OF (+)-PANCRASTATIN.**

by

Bryan P. McKibben

Dr. Tomas Hudlicky, Chairman

Chemistry

(Abstract)

Potassium permanganate oxidations and novel cycloaddition chemistry of the arene-*cis*-diols (**7**) were investigated. It was found that permanganate oxidation of arene-*cis*-diols yielded a mixture of 2 products, (**157a**) and (**157b**) in low yield. The influence of the C1-substituent on the outcome of the reaction was found to be a complex mixture of steric and electronic effects. In the area of cycloaddition chemistry of protected (**7**), this thesis describes novel [4+2] cycloadditions with quinones along with the first published report of benzyne and nitrile oxide cycloadditions of these homochiral molecules. The structure of the cycloadducts were elucidated by nOe as well as 2D-NMR analysis and were supported by Frontier Molecular Orbital theory. Finally, arene-*trans*-diols (**200**) were synthesized from (**7**) by a multistep stereoselective protection/deprotection sequence utilizing the Diels-Alder reaction. These compounds serve as intermediates in an approach to the amaryllidaceae alkaloid (+)-pancratistatin (**12**).

## ACKNOWLEDGMENTS

I would like to give special thanks to those who helped me achieve the status of Ph.D. First, to my two advisors, Dr. David Becker and Dr. Tomas Hudlicky, who helped develop me into the chemist I am today. Dr. Becker's enthusiasm or should I say zest for chemistry will always be remembered. I am grateful to Dr. Tomas Hudlicky who accepted me into his group during my third year. I enjoyed being his graduate student and thank him for his support and guidance during my stay at Virginia Tech. I would also like to thank the members of my committee, Drs. Richard Gandour, David Kingston, Joseph Merola and James Tanko for their patience and support.

I would like to thank past and present members of Dr. T. Hudlicky's group. Their day to day interaction made research more enjoyable and intellectually stimulating. I would like to thank my undergraduate assistant, George Barnosky, who worked diligently on one of my doctoral projects. I would like to specifically acknowledge Dr. Stephen Fearnley for his valuable advice. He demonstrated that organic synthesis is both a challenging and an enjoyable endeavor.

I wish to express my gratitude to William Bebout, Geno Iannaccone and Thomas Glass in Analytical services for their help with the NMR spectrometers and to Kim Harich for obtaining the mass spectra.

Finally, I thank Denise Hammond-McKibben, who has put up with all of the late nights and early mornings of scientific research-you have always understood.

...to the four most important people in my life-

my wife - Denise  
my father and mother -Robert and Janice McKibben  
and my grandmother- Mary Louise Pflaum

Thanks for the support.

## TABLE OF CONTENTS

I. INTRODUCTION	1
II. HISTORICAL	
1. Cycloaddition Chemistry of Arene- <i>Cis</i> -Diols	
1.1 Diels-Alder Cycloadditions	6
1.2 Miscellaneous Cycloadditions	16
2. Potassium Permanganate Oxidations in Organic Synthesis	
2.1 Oxidation of Mono-Alkenes	23
2.2 Oxidation of Conjugated and Unconjugated Dienes	26
3. Arene- <i>Trans</i> -Diols	
3.1 Biological Activity	33
3.2 Synthesis	35
3.3 Reactivity and Utility	39
4. Pancratistatin: An Amaryllidaceae Alkaloid	
4.1 Isolation, Structure Determination and Biological Activity	43
4.2 Biogenesis	45
4.3 Total Synthesis and Synthetic Approaches	48
III. DISCUSSION	
1. Introduction	56
2. Novel Cycloadditions of a 1-Chloro-Arene- <i>Cis</i> -Diol Derivative	
2.1 With Quinones, Thermal and Photolytic	58
2.2 With Benzynes	62
2.3 With Acetonitrile Oxide	63
3. Oxidation of Arene- <i>Cis</i> -Diols with Potassium Permanganate	
3.1 Effect of Diene Substitution	67
3.2 Effect of Solvent	70
4. Arene- <i>Trans</i> -Diols	
4.1 Development of the Methodology	74
4.2 Successful Synthesis	79
4.3 Mechanistic Interpretations of Cycloreversion	85
4.4 Approach to the Synthesis of (+)-Pancratistatin	91
4.5 Future Work	93
IV. CONCLUSION	96
V. EXPERIMENTAL	99
VI. SELECTED SPECTRA	119
VII. APPENDIX	156
VIII. REFERENCES	157
IX. VITA	165

## LIST OF FIGURES

Figure 1.	Use of Biocatalysis in Organic Synthesis	2
Figure 2.	Biooxidation of Aromatic Compounds by <i>Pseudomonas putida</i>	3
Figure 3.	Use of Arene- <i>Cis</i> -Diols in Organic Synthesis	3
Figure 4.	Retrosynthetic Analysis of (+)-Pancratistatin ( <b>12</b> )	4
Figure 5.	Dimerization of 1-Etheno-Arene- <i>Cis</i> -Diol Derivative	8
Figure 6.	Cycloaddition of ( <b>17</b> ) with a Triazoline Derivative	8
Figure 7.	Cycloaddition of ( <b>7</b> ) with ( <b>20</b> ) and Mosher Diester Formation	9
Figure 8.	Proof of Nitrosyl Cycloaddition Regiochemistry	11
Figure 9.	Route to Conduramine A1 ( <b>29</b> )	11
Figure 10.	Intramolecular Diels-Alder Reaction as a Model for Morphine ( <b>30</b> )	13
Figure 11.	Intramolecular Diels-Alder Reaction in a Proof of Stereochemistry	14
Figure 12.	Total Synthesis of (-)-Zeylana	15
Figure 13.	Dimerization of Arene- <i>Cis</i> -Diols	18
Figure 14.	[4+2] Reaction with Cyclopentadiene	18
Figure 15.	Higher Order Cycloadditions with Tropone	19
Figure 16.	Mechanism of Alkene Oxidation by Potassium Permanganate	24
Figure 17.	Selective Oxidation of Dicyclopentadiene Using PTC	25
Figure 18.	Permanganate Oxidation of 1,4-Cyclohexadiene	27
Figure 19.	Permanganate Oxidation of 1,5-Dienes to Tetrahydrofurans	28
Figure 20.	Permanganate Oxidation of Cyclic 1,3-Dienes	29
Figure 21.	Sable <i>et al.</i> Mechanism of Cyclopentadiene Oxidation	29
Figure 22.	Other Reports of Permanganate Oxidation of 1,3-Dienes	30
Figure 23.	Hudlicky <i>et al.</i> Mechanism of 1,3-Diene Oxidation	32
Figure 24.	Metabolism of Benzene in Eukaryotic Cells	33
Figure 25.	Racemic Synthesis of Benzene- <i>Trans</i> -Diol ( <b>96</b> )	36

Figure 26.	Synthesis of Chiral Benzene- <i>trans</i> -diol with PLE	37
Figure 27.	Synthesis of an Arene- <i>Trans</i> -Diol ( <b>99</b> )	38
Figure 28.	Selective Epoxidation of Arene- <i>Trans</i> -Diol ( <b>106</b> )	39
Figure 29.	Cycloaddition of ( <b>107</b> ) with Singlet Oxygen	40
Figure 30.	Cycloaddition of ( <b>110</b> ) with 1-Chloro-1-nitrosocyclohexane	40
Figure 31.	Several Biologically Active Amaryllidaceae Alkaloids	44
Figure 32.	Biogenesis of Narciclasine	46
Figure 33.	Isolation of 7-Deoxynarciclasine and Pancratistatin	47
Figure 34.	Danishefsky Synthesis of Pancratistatin Part A	49
Figure 35.	Danishefsky Synthesis of Pancratistatin Part B	50
Figure 36.	7-Deoxypancratistatins as Intermediates in the Synthesis of Lycoricidine	51
Figure 37.	Retrosynthetic Analysis of Clark and Souchet Model Study	52
Figure 38.	Optimized Conditions for Condensation	53
Figure 39.	Heathcock <i>et al.</i> Model Study	55
Figure 40.	Potassium Permanganate Oxidation of Arene- <i>Cis</i> -Diols	57
Figure 41.	Retrosynthetic Analysis of (+)-Pancratistatin ( <b>12</b> )	57
Figure 42.	Photolytic Formation of Spiropyrans ( <b>161</b> )	59
Figure 43.	Mechanism of Spiropyran Formation ( <b>161</b> )	60
Figure 44.	Napthoquinone Cycloadduct ( <b>165</b> ) and Structurally Similar Anitibiotics	62
Figure 45.	Cycloaddition with Benzyne	63
Figure 46.	Cycloaddition of with Acetonitrile Oxide	64
Figure 47.	FMO Energies of Dipole and Dipolarophile	65
Figure 48.	FMO Interaction of the Dipole with the Dipolarophile	65
Figure 49.	C1-Substituent Effect on the Selectivity of OsO <sub>4</sub> Dihydroxylation	68
Figure 50.	Expected Substituent Effect on Permanganate Oxidation	69
Figure 51.	Product Distribution of Potassium Permanganate Oxidation	70
Figure 52.	Synthetic Methodology for the Production of Arene- <i>Trans</i> -Diols	74



Figure 53.	Elimination Reaction of Arene- <i>Cis</i> -Diols	75
Figure 54.	Selective Diprotection of Arene- <i>Cis</i> -Diol ( <b>190</b> )	80
Figure 55.	Protection of 1,3-Diene System by ( <b>20</b> )	80
Figure 56.	Deprotection of the C5-Hydroxyl	81
Figure 57.	<sup>1</sup> H-NMR Evaluation of ( <b>194a</b> ) and ( <b>196a</b> )	82
Figure 58.	First Attempt at Cycloreversion	83
Figure 59.	Mechanism for Cycloreversion at Elevated Temperature	85
Figure 60.	General Mechanism of LAH Mediated Cycloreversion	86
Figure 61.	Formation Of Hydrazine ( <b>205</b> )	87
Figure 62.	General Mechanism For Alkaline Mediated Cycloreversion	87
Figure 63.	Plausible Mechanisms for Debromination During Cycloreversion	89
Figure 64.	Retrosynthesis of (+)-Pancratistatin ( <b>12</b> )	91
Figure 65.	Synthesis of Aryltriflate ( <b>214</b> )	92
Figure 66.	Two Attempts at Stille Cross Coupling	93
Figure 67.	Future Work in the Synthesis of (+)-Pancratistatin ( <b>12</b> )	95
Figure 68.	Potential Stereoselective Reactions of Arene- <i>Trans</i> -Diols ( <b>200</b> )	96

## LIST OF TABLES

Table 1.	Dimerization of Substituted Arene- <i>Cis</i> -Diols	7
Table 2.	Cycloaddition of (14e) with Substituted Maleimides	10
Table 3.	Diels-Alder Reactions with Various Linear Dienophiles	12
Table 4.	Diels-Alder Reaction of (42) with Singlet Oxygen	15
Table 5.	Cyclopropanation of Substituted Arene- <i>Cis</i> -Diols (14)	17
Table 6.	[2+2] and [4+2] Cycloadditions of (14) with Ketenes	17
Table 7.	Natural Products Synthesized by Cycloaddition with Substituted Arene- <i>Cis</i> -Diols	20
Table 8.	Effect of Varying Conditions on the Oxidation of 1,3-Dienes	31
Table 9.	Studies on Epoxide Hydration using Rabbit Liver Hydrase	34
Table 10.	Natural Products Synthesized by Cycloaddition with Arene- <i>Trans</i> -Diols	41
Table 11.	Optimization of Lewis Acid Catalysis Conditions	53
Table 12.	Solvent Effect on Potassium Permanganate Oxidation	71
Table 13.	Attempts at Cycloaddition of Arene- <i>Cis</i> -Diols with DEAD	76
Table 14.	Attempts at Cycloaddition of Arene- <i>Cis</i> -Diols with Sulfur Dioxide	77
Table 15.	Protection/Deprotection of Ergosterol with 4-Phenyl-triazoline-3,5-dione	78
Table 16.	Cycloreversion Conditions	79
Table 17.	Inversion Conditions	82
Table 18.	Protection and Second Attempt at Cycloreversion	84
Table 19.	Experimental Variations in Hydrolytic Cycloreversion	88

## I. INTRODUCTION

The area of biotransformations is a growing field. It represents a unification of two distinct areas of research, chemistry and microbiology. Biotransformations or biocatalysis<sup>1</sup> are chemical transformations mediated by either purified enzymes or by whole cell organisms (for example, bacteria, fungi, plant or mammalian tissue culture). Included under this broad title are stereoselective hydrolysis, esterification, oxidation, and reduction reactions catalyzed by enzymes. There are several advantages and disadvantages involved with using biocatalysis in chemical synthesis.<sup>2</sup>

### Advantages

1. Enzymes catalyze a broad spectrum of reactions with high turnover numbers. Rate enhancements approach  $10^{12}$  fold.
2. Enzymes may accept a wide range of substrates.
3. Enzymes are highly regio and stereoselective.
4. Enzyme reactions take place under mild conditions, room temperature at pH 6-8, this minimizes problems of isomerization, racemization and epimerization.

### Disadvantages

1. Instability of some enzyme systems, which can be overcome by immobilization/membrane encapsulation
2. Cofactor requirements for some enzyme systems.

Despite these disadvantages, biotransformations have become a primary means of generating chiral starting materials which otherwise would be impossible to make. Organic chemists have utilized biotransformations to generate chiral starting materials or intermediates for stereospecific syntheses.<sup>3</sup> Robert's<sup>4</sup> synthesis of carbovir (**4**), a potential HIV inhibitor, and the preparation of (**5**), a synthon for hypocholesteremics, exemplify their use (Figure 1). The key step in the synthesis of both (**4**) and (**5**) is the

enzyme mediated hydrolysis of the racemic propyl ester which yields two asymmetric products (**3** and **2**; each possessing > 95% enantiomeric excess (ee)).




Figure 1. Use of Biocatalysis in Organic Synthesis

Recently, it has been suggested that biotransformations could be used to remove toxic aromatic waste from the environment.<sup>5</sup> It has been known for years that the soil bacterium *Pseudomonas putida* oxidatively degrades aromatic compounds (**6**) to catechols (**8**) and ultimately to muconates (Figure 2). In 1970 Gibson<sup>6</sup> isolated a mutant strain of bacteria (*Pseudomonas putida* 39D) that arrested the oxidation to catechols at the stage of the substituted cyclohexadiene-*cis*-diol or arene-*cis*-diol (**7**). These bacterial metabolites are >95% enantiomerically pure. Industrially, aromatic waste such as benzene and chlorobenzene (over 3 million tons of each produced annually)<sup>7</sup> could be converted into chiral synthons of type (**7**) which is useful to organic chemists as a chiral synthon.




Figure 2. Biooxidation of Aromatic Compounds by *Pseudomonas putida*

Chemists have realized the synthetic utility of compounds possessing the general structure (7). In 1986, Ley<sup>8</sup> published the total synthesis of (+/-)-pinitol (10) utilizing the *meso*-cyclohexadiene-*cis*-diol as a chiral synthon. Since then, the use of these synthons in enantioselective synthesis has grown dramatically (Graph 1). Compounds such as (7) have found use in the enantioselective synthesis of a structurally diverse set of compounds, included are PGE<sub>2</sub>α (9),<sup>9</sup> (+)-pinitol (10)<sup>10</sup> and (+)-kifunensine (11) (Figure 3).<sup>11</sup> Because demand for these chiral synthons has increased appreciably, some of the arene-*cis*-diols are now available commercially.<sup>12</sup>




Figure 3. Use of Arene-*Cis*-Diols in Organic Synthesis

This thesis describes the synthetic utility of the arene-*cis*-diols in several oxidative and cycloaddition processes culminating in an enantioselective approach to the synthesis of the potential chemotherapeutic compound (+)-pancratistatin (**12**). Also included in this thesis is a general methodology for the synthesis of arene-*trans*-diols (**13**), possessing high enantiomeric excess, from the arene-*cis*-diols through a protection-deprotection sequence. Arene-*trans*-diol (**13**) represents the key intermediate in the synthesis of (+)-pancratistatin (**12**).





Figure 4. Retrosynthetic Analysis of (+)-Pancratistatin (**12**)



Graph 1. Growth of Arene-Cis-Diol Use in Synthesis and Isolation

## II. HISTORICAL

### 1. Cycloaddition Chemistry of Arene-*Cis*-Diols


#### 1.1 Diels-Alder Cycloadditions

Over the last five years there has been a plethora of research published concerning [4 +2] cycloadditions with substituted arene-*cis*-diols. Most of the work describes the reactivity trends of these diene systems in cycloaddition reactions. Some of these complex, polycyclic cycloadducts have been used in the synthesis of natural products.<sup>26-30,36</sup> Presented in this section is a comprehensive review of the [4+2] cycloaddition chemistry of 1-substituted-arene-*cis*-diols.


The dimerization of the isopropylidene protected arene-*cis*-diols shows that the diene system can act both as a diene and a dienophile in [4+2] cycloaddition chemistry. Three research groups<sup>13-15</sup> have reported the dimerization of these compounds. In general, the dimerization is stereoselective and yields a single isomeric product (Table 1). Hudlicky *et al.*<sup>15</sup> studied the rate of such dimerizations with compounds (**14b**) and (**14c**). Table 1 shows dimerization occurs readily neat at 0°C and in solution at elevated temperature. The dimers (**15**) result from bond formation *anti* to the sterically bulky isopropylidene group with the electron rich 3-4 olefin acting as the dienophile. NMR methods<sup>13,14</sup> and X-ray crystallography<sup>14-17</sup> have been used for structural assignment. X-Ray crystallography of (**15b**) also confirmed the absolute configuration of the 1-bromo-arene-*cis*-diol.<sup>14,15</sup>



Table 1. Dimerization of Substituted Arene-*Cis*-Diols



14



15

a:R = CF<sub>3</sub>

b:R = Br

c:R = Cl

Isopropylidene	Dimerization Conditions	Yield (recovered 14)
14b	neat, 0°C, 15d	32 (61)
14c	neat, 0°C, 23d	49 (51)
14b	neat, rt, 8d	80
14c	neat, rt, 8d	71
14b	CDCl <sub>3</sub> , 60°C, 8d (sealed tube)	70
14b	CDCl <sub>3</sub> , 100°C, 2d (sealed tube)	---
14c	CDCl <sub>3</sub> , 100°C, 6d (sealed tube)	95

1-Ethenyl-cyclohexadiene-5,6-*cis*-diol protected as the isopropylidene (**14d**) has been shown to dimerize stereoselectively but not regioselectively (Figure 5).<sup>16</sup> Dimerization occurs over two to three weeks at room temperature and yields three products; (**16a**), (**16b**) and (**16c**), in a 4:3:3 ratio, respectively. The lack of regioselectivity can be attributed to the reactive exocyclic diene system. The structure of adducts (**16b**) and (**16c**) were established by <sup>1</sup>H-NMR studies. The structure of compound (**16a**) was assigned on the basis of <sup>1</sup>H-NMR studies and confirmed by X-ray crystallography.




Figure 5. Dimerization of 1-Etheno-Arene-*Cis*-Diol Derivative

Hetero-[4 + 2] cycloaddition chemistry has been used to establish the absolute configuration of other *P. putida* 39-D metabolites. Protected or unprotected arene-*cis*-diols have reacted readily under mild conditions with 4-aryl-1,2,4-triazoline-3,5-diones, 13,18-20 which have been previously described as one of the most reactive dienophiles known.<sup>17</sup> In 1973, Gibson<sup>18</sup> published the cycloaddition of the diacetox derivative of 1-methyl-arene-*cis*-diol (**17**) with 4-(*p*-bromophenyl)-1,2,4-triazoline-3,5-dione (**18**). The reaction occurred instantaneously at 0°C to yield stereoselectively one cycloadduct (**19**). The absolute configuration of (**19**) was proven by X-ray crystallography. X-Ray diffraction confirmed initial speculation that cycloaddition occurred from the less hindered  $\alpha$ -face of the diene.




Figure 6. Cycloaddition of (**17**) with a Triazoline Derivative

Years later, Boyd<sup>19</sup> showed that various unprotected arene-*cis*-diols react with 4-phenyl-1,2,4-triazoline-3,5-dione (**20**) (Figure 7). Esterification of the resulting cycloadduct with Mosher acid chloride (MTPA-Cl) produced the Mosher diester. Cycloaddition occurs from the  $\beta$ -face, directed by the hydroxyls as shown by X-Ray crystallography.





Figure 7. Cycloaddition of (**7**) with (**20**) and Mosher Diester Formation

The Diels-Alder reactions of other dienophiles with substituted arene-*cis*-diols and their derivatives have not been as selective.<sup>13,21-25</sup> N-phenyl and N-ethylmaleimide (**NPM** and **NEM**) react to give various ratios of cycloadducts. The product ratio of the cycloadducts was found to be determined by a combination of solvent and steric factors (Table 2).<sup>20</sup> These results contrast the results of cycloadditions with 4-phenyl-1,2,4-triazoline-3,5-dione (**20**). Burnell<sup>25</sup> hypothesized that the difference may arise in the transition state leading to the products. As (**20**) approaches in an *endo* manner and *syn* to the hydroxyls, Burnell believes this must lead to an unfavorable electrostatic interaction between the nitrogen's and the oxygen's lone pairs of electrons. This hypothesis does not fit with the X-ray crystallography data showing (**20**) reacted *syn* to the unprotected arene-*cis*-diols. As in epoxidation reactions, the hydroxyls must direct (**20**) to the  $\beta$ -face through electrostatic interactions.

Table 2. Cycloaddition of (14e) with Substituted Maleimides



Dienophile	Solvent	Product Ratio (endo-syn:endo-anti)	Yield (%)
NPM	CHCl <sub>3</sub>	60:40	---
NPM	C <sub>6</sub> H <sub>6</sub>	52:48	86
NPM	H <sub>2</sub> O	33:67	85
NPM	(CH <sub>2</sub> OH) <sub>2</sub>	27:73	95
NEM	CHCl <sub>3</sub>	50:50	98
NEM	C <sub>6</sub> H <sub>6</sub>	39:61	96
NEM	H <sub>2</sub> O	18:82	79
NEM	(CH <sub>2</sub> OH) <sub>2</sub>	12:88	73

The nitrosyl-Diels-Alder reaction of 1-substituted-arene-*cis*-diols has been one of the most useful cycloaddition reactions. The resulting cycloadducts have been used in the synthesis of aminoconduritols<sup>26-29</sup> and alkaloids<sup>30</sup> through short enantiospecific reaction sequences.

The Diels-Alder reaction of nitroso compounds with 1-substituted-arene-*cis*-diols has been shown to be regioselective. Hudlicky and Olivo<sup>26,27</sup> studied the reactions of substituted-arene-*cis*-diols with various nitrosyl compounds. The results are shown in Figure 8. The halogenated dienes all reacted in a similar manner generating cycloadducts where the nitrosyl oxygen is bonded to C1. This contradicts FMO theory which predicted the bromo (14b) and fluoro derivatives (14f) would yield compounds of opposite

regiochemistry. The regiochemistry was proven by reductive cleavage of the labile N-O bond of the two cycloadducts (**24a**) and (**24c**) yielding a common intermediate (**25**). Confident of the regiochemistry of cycloaddition, Hudlicky and Olivo synthesized conduramine A1 (**29**),<sup>26</sup> dihydroconduramine A1<sup>26</sup> and lycoricidine<sup>30</sup> using the nitrosyl-Diels-Alder reaction as the key step in the reaction sequences.




Figure 8. Proof of Nitrosyl Cycloaddition Regiochemistry

An asymmetric nitrosyl-Diels-Alder reaction with the *meso*-arene-*cis*-diols has been used by both Piepersburg, (**26a**) (R = -C(CH<sub>3</sub>)<sub>2</sub>),<sup>28</sup> and Werbitzky, (**26b**) (R = Ac).<sup>29</sup> The dienophile, nitrosyl- $\alpha$ -D-manno-furanosyl chloride (**27**), reacted with the protected arene-*cis*-diols to yield cycloadducts (**28a**) and (**28b**). The bicyclic dihydro-1,2-oxazines (**28a**, **28b**) were then used by both groups in the synthesis of conduramine A1 (**29**).





Figure 9. Route to Conduramine A1 (**29**)

The stereochemistry of addition, *syn* or *anti* mode, has been shown to depend on the nature of the arene-*cis*-diol protecting group, substrate, and reaction conditions. Table 3 shows examples of the isopropylidene protected arene-*cis*-diol reacting with some linear dienophiles. In all of these cases, cycloaddition occurs *anti* to the sterically demanding isopropylidene group.

Table 3. Diels-Alder Reactions with Various Linear Dienophiles



R	R <sub>1</sub>	W	X	Y	Z	% Yield	Ref.
H	C(CH <sub>3</sub> ) <sub>2</sub>	CH <sub>2</sub>	CHCO <sub>2</sub> Me	--	--	80	18
H	C(CH <sub>3</sub> ) <sub>2</sub>	CHCN	CHCN	--	--	52	18
H	C(CH <sub>3</sub> ) <sub>2</sub>	CHCO <sub>2</sub> Me	CHCO <sub>2</sub> Me	--	--	70	18
H	C(CH <sub>3</sub> ) <sub>2</sub>	C(CN) <sub>2</sub>	C(CN) <sub>2</sub>	--	--	71	18
H	C(CH <sub>3</sub> ) <sub>2</sub>	NCCO <sub>2</sub> Et	NCCO <sub>2</sub> Et	--	--	100	18
H	C(CH <sub>3</sub> ) <sub>2</sub>	--	--	CH	CCO <sub>2</sub> Me	86	18
H	C(CH <sub>3</sub> ) <sub>2</sub>	--	--	CCO <sub>2</sub> Me	CCO <sub>2</sub> Me	70	18
CF <sub>3</sub>	C(CH <sub>3</sub> ) <sub>2</sub>	--	--	CH	CCO <sub>2</sub> Me	54	19
CF <sub>3</sub>	C(CH <sub>3</sub> ) <sub>2</sub>	--	--	CCO <sub>2</sub> Me	CCO <sub>2</sub> Me	83	18
F	C(CH <sub>3</sub> ) <sub>2</sub>	--	--	CCO <sub>2</sub> Et	CH	78	20
Cl	C(CH <sub>3</sub> ) <sub>2</sub>	--	--	CCO <sub>2</sub> Et	CH	40	20
Br	C(CH <sub>3</sub> ) <sub>2</sub>	--	--	CCO <sub>2</sub> Et	CH	61	20
I	C(CH <sub>3</sub> ) <sub>2</sub>	--	--	CCO <sub>2</sub> Et	CH	58	20

The 1-substituted-arene-*cis*-diol has been used in the intramolecular Diels-Alder reaction. This reaction has been used as a model system directed towards the total synthesis of morphine (**30**) and as a method for the determination of absolute stereochemistry of an *o*-chlorostyrene metabolite.<sup>34</sup> Figure 10 (path a) was envisioned for the synthesis of the non-aromatic portion of morphine (**31**) from 1-methyl-arene-*cis*-

diol (**7a**). However, the intramolecular Diels-Alder reaction did not proceed as expected. Instead, the tricyclodecene system (**33**) was produced via cycloaddition of the cyclic diene system (C1-C2, C3-C4) with the sorbyl olefin (C9-C10). The tricyclic system (**31**) was produced in two more steps by oxidation of the alcohol to the ketone followed by a Cope rearrangement of the ketone.




Figure 10. Intramolecular Diels-Alder Reaction as a Model for Morphine (**30**)

A similar intramolecular Diels-Alder reaction has been conducted with metabolites of the biooxidation of *o*-chlorostyrene (**34**) and styrene (**7d**).<sup>35</sup> In a proof of the absolute stereochemistry and enantiopurity of the *o*-chlorostyrene metabolite, both (**34**) and (**7d**) were transformed in three steps to the same tricyclic intermediate (**36**). In this convergent synthesis, the intramolecular Diels-Alder reaction was the key step.




Figure 11. Intramolecular Diels-Alder Reaction in a Proof of Stereochemistry

Hudlicky and Seoane have published a formal total synthesis of (-) zeylena (Figure 12),<sup>36</sup> a unique hydrocarbon, through a Diels-Alder strategy. The synthesis began with 1-ethenyl-arene-*cis*-diol (**7d**). Mitsunobu inversion at C3 in the presence of the reactive triene system proved problematic. Protection of the triene system through the Diels-Alder reaction solved the problem. The more reactive diene (C1-C2, C7-C8) reacted with diethyl azodicarboxylate or its derivatives (**37b**: bis-(2,2,2-trichloroethyl)-azodicarboxylate, **37c**: bis-((trimethylsilyl)-ethyl)-azodicarboxylate) at 0°C. Manipulation of the diols gave compound (**38**) in four steps. The latent diene system was regenerated (**39**) in low yield by the treatment with Zn(Cu) in 90% AcOH (**38b**) or Bu<sub>4</sub>NF in THF (**38c**). The tetraene (**39**) underwent an intramolecular Diels-Alder reaction in 94% yield in benzene at 110°C. The synthesis of zeylena acetate (**41**) was accomplished in two more steps. This represented a formal synthesis of (-) zeylena.

The arene-*cis*-diols also underwent 1,4 reaction with singlet oxygen,<sup>37-40</sup> which can be perceived as a hetero-Diels-Alder reaction (Table 4). Contrasting most [4+2] reactions of the free diols, singlet oxygen adds preferentially from the  $\alpha$ -face (anti to the hydroxyls). Prior to reaction with singlet oxygen, protection of both alcohols as *t*-butyl-dimethylsilyl ethers or as an isopropylidene leads to exclusive formation of the anti-*endo*-peroxide (**43e**, **43g**) and in the case of the *t*-butyl-dimethylsilyl ethers, the hydroperoxide



(44) was also formed. These highly oxygenated bicyclic compounds have been used in the synthesis of conduritols.<sup>40,41,42</sup>





Figure 12. Total Synthesis of (-)-Zeylena

Table 4. Diels-Alder Reaction of (42) with Singlet Oxygen



Arene-*cis*-diols and their derivatives have been used extensively in the Diels-Alder reaction. The [4+2] cycloadditions have been used to determine the reactivity characteristics of these 1,3-diene systems. Application of these cycloadducts to the synthesis of natural products has been limited to a few examples (Table 7).


## 1. Cycloaddition Chemistry of Arene-*Cis*-Diols

### 1.2 Miscellaneous Cycloadditions

In the cycloaddition chemistry of arene-*cis*-diols, the Diels-Alder reaction or the [4+2] cycloaddition reaction has been the most thoroughly investigated. However, there are some cases of [2+2]<sup>43,44</sup> and higher order cycloadditions<sup>24,33</sup> of the arene-*cis*-diols in the literature. This section will give a comprehensive review of cycloadditions reactions, other than the [4+2] variety, involving the arene-*cis*-diols.


Isopropylidene protected arene-*cis*-diols reacted with carbenes in what formally can be considered a [2+1] cycloaddition reaction. Dichlorocarbene generated *in situ* reacted with protected arene-*cis*-diols (Table 5).<sup>24,45,46</sup> Addition of the carbene always proceeds selectively *anti* to the isopropylidene protecting group. Regioselectivity is determined by the electronic effect of the substituent on the cyclohexadiene ring. Protected 1-trifluoromethyl-arene-*cis*-diol reacted with dichlorocarbene regioselectively at the less substituted olefin to give compound (**46a**). 1-Substituents consisting of hydrogen, methyl and fluoro yielded mixtures of the two regioisomeric products.

Table 5. Cyclopropanation of Substituted Arene-*Cis*-Diols (**14**)



The reaction of arene-*cis*-diols with ketenes has been briefly investigated.<sup>24</sup> Diphenylketene reacted with protected *meso*-arene-*cis*-diol to yield a mixture of [2+2] and [4+2] cycloadducts (**48a**, **49a**). Compound (**49a**) was unexpected since dienes and ketenes rarely react in a [4+2] manner.<sup>48</sup> Interestingly, the reaction of protected 1-fluorocyclohexadiene-2,3-*cis*-diol with diphenyl ketene gave more of the [4+2] cycloadduct, whereas methylphenyl ketene reacted with *meso*-arene-*cis*-diol to give exclusively [2+2] product formation.

Table 6. [2+2] and [4+2] Cycloadditions of (**14**) with Ketenes



*Meso*-cyclohexadiene-2,3-*cis*-diol (**7e**) has been shown to undergo a photosensitized [2+2] dimerization (Figure 13)<sup>44</sup> to yield an interesting tricyclic compound (**50**). Deoxygenation of (**50**) leads to the benzene dimer (**51**).




Figure 13. Dimerization of Arene-*Cis*-Diols

Protected 1-trifluoromethyl-arene-*cis*-diol (**14a**) reacted as a dienophile with cyclopentadiene to yield a single cycloadduct (**52**).<sup>48</sup>




Figure 14. [4+2] Reaction with Cyclopentadiene

Roberts<sup>24</sup> (**53e**) and Hudlicky<sup>33</sup> (**53c**) have independently reported the [6+4] cycloaddition of arene-*cis*-diols with tropone.




Figure 15. Higher Order Cycloadditions with Tropone

The substituted-arene-*cis*-diols react in [2+1], [2+2] and [6+4] manners to yield interesting polycyclic compounds. Application of these cycloadditions to the synthesis of natural products is expected in the near future.

Table 7. Natural Products Synthesized by Cycloaddition with Substituted Arene-*Cis*-Diols










Diene	Cycloadduct	Natural Product	References
		 conduitol A	41
		 conduritol D	40
		 (-)-conduramine A1	50
		 (-)-conduramine A1	49

Table 7. Natural Products Synthesized by Cycloaddition with Substituted Arene-*Cis*-Diols



















Diene	Cycloadduct	Natural Product	References
		 <p data-bbox="841 688 925 720">pinitol</p>	37
		 <p data-bbox="751 1014 1051 1045">(-) dihydroconduritol C</p>	42
		 <p data-bbox="793 1346 1001 1377">conduramine A1</p>	26, 28, 29
		 <p data-bbox="793 1724 986 1755">(+) lycoricidine</p>	30

Table 7. Natural Products Synthesized by Cycloaddition with Substituted Arene-*Cis*-Diols

Diene	Cycloadduct	Natural Product	References
		 <p data-bbox="872 779 1011 814">(-) zeylena</p>	36
		 <p data-bbox="872 1182 1011 1218">(-) zeylena</p>	36



## 2. Potassium Permanganate Oxidations in Organic Synthesis

### 2.1 Oxidation of Mono-Alkenes

The potassium permanganate oxidation of alkenes dates back to the nineteenth century. Wagner<sup>51</sup> published the dihydroxylation of alkenes using potassium permanganate in 1895. Since then, the use of potassium permanganate in organic chemistry has been underutilized as noted by a recent review on the subject.<sup>52</sup> The reason for its underuse is that a great deal of functional groups are either incompatible with or are themselves oxidized by potassium permanganate. Selectivity is therefore a problem. The experimental,<sup>52</sup> mechanistic,<sup>54</sup> and synthetic<sup>53</sup> aspects of alkene oxidation have been addressed. Recently, the addition of organic cosolvents (i.e. acetone and ethanol), magnesium sulfate,<sup>55</sup> and phase transfer catalysis (PTC)<sup>56</sup> has optimized the permanganate oxidation of some alkenes.

The mechanism of potassium permanganate oxidation of alkenes has drawn widespread attention.<sup>54</sup> It is generally accepted that the cyclic manganese ester (**55**) is the first intermediate in the oxidation (Figure 16, path b). Recently, Sharpless, Rappe and Goddard<sup>57</sup> have proposed the initial formation of a metallocyclooxetane intermediate (**54**) via [2+2] insertion of the alkene  $\pi$  bond into the metal oxo bond of the manganese (path a). The metallo intermediate then undergoes rearrangement to the cyclic manganese ester (**55**). Once the intermediate cyclic manganese ester (**55**) is formed, pH values, substrate structure as well as other factors determine the structure of the product. These possible products include glycols (**56**),  $\alpha$ -hydroxy ketones (**57**) and products resulting from C-C bond cleavage (**58**).

The Lemieux-von Rudloff reagent (sodium periodate-potassium permanganate) gives selective C-C bond cleavage of alkenes. Mechanistically, the reaction proceeds through the cyclic manganese ester (**55**).<sup>58</sup> The permanganate is the actual oxidant in the reaction and is continuously being regenerated from its reduced state by sodium periodate.




Figure 16. Mechanism of Alkene Oxidation by Potassium Permanganate

As mentioned above, the selectivity of potassium permanganate oxidation in moderately functionalized molecules is very low. Potassium permanganate has been reported to oxidize alcohols, aldehydes, ketones, sulfides, thiols, alkynes and alkenes among other functional groups.<sup>52</sup> However, there are published examples of selective oxidations using potassium permanganate. For example, homogeneous PTC selectively generate oxidation products in high yield. In these systems the product is protected against further oxidation by permanganate through the formation of a stable organomanganese species in non-aqueous media. The oxidation of dicyclopentadiene illustrates this point. Ogino<sup>59</sup> selectively oxidized dicyclopentadiene (**59**) under homogeneous PTC in high yield to either tricyclic diol (**60**) or the bicyclic dialdehyde (**61**). Ogino manipulated the pH of the reaction to selectively give the two desired products.




Figure 17. Selective Oxidation of Dicyclopentadiene Using PTC

The oxidation of alkenes with potassium permanganate is a synthetically useful yet underutilized reaction. Experimental improvements such as PTC catalysis<sup>56</sup> have readily improved yields and selectivity of this reaction and such improvements are expected to increase the use of potassium permanganate in organic synthesis. The oxidation of highly functionalized compounds is still troublesome due to unwanted functional group oxidations. The next section describes the oxidation of bifunctional molecule, ie., unconjugated and conjugated dienes.

## **2. Potassium Permanganate Oxidations in Organic Synthesis**

### **2.2 Oxidation of Conjugated and Unconjugated Dienes**

The potassium permanganate oxidation of dienes has been briefly studied. Potassium permanganate oxidation of conjugated dienes at one time was reported to be uncontrollable and the only products isolated were the result of full oxidative cleavage.<sup>60</sup> The mechanism in the oxidation of unconjugated dienes is usually identical to the oxidation of simple alkenes (Section II.1). However, the permanganate oxidation of acyclic 1,5-dienes and cyclic 1,3-dienes yield products which do not fit the accepted mechanism for mono-alkenes. Several theories have been developed to explain these anomalies.

There are several publications which describe the potassium permanganate oxidation of unconjugated alkenes. The oxidation of dicyclopentadiene (**59**) was mentioned earlier.<sup>59</sup> In this case, products resulted from oxidation of only one olefin in the diene system. In 1965, Sable *et al.*<sup>61</sup> studied the oxidation of 1,4-cyclohexadiene and reported the isolation of two products in low yield, the tetraol (**62**) and diol (**63**).




Figure 18. Permanganate Oxidation of 1,4-Cyclohexadiene

The oxidation of acyclic 1,5 dienes has also been studied. In general, only tetrahydrofuran adducts are isolated in yields up to 80% (Figure 19). Rojahn<sup>62</sup> proposed a mechanism which involved the internal migration in the initially formed manganese ester (**65**) (path a). The cyclic  $\text{Mn}^{\text{IV}}$  ester (**66**) is then hydrolyzed to yield the tetrahydrofuran skeleton. In this mechanism Rojahn believed the permanganate is the sole source of the oxygens in tetrahydrofuran product. However, five years later, Ingold<sup>63</sup> provided indirect evidence by  $^{18}\text{O}$  labeling experiments that the reaction may proceed through a penta-coordinated (**67a**) or hexa-coordinated (**67b**) manganese species (path b). The resulting tetrahydrofurans were found to possess two oxygens from the permanganate and one from the solvent ( $\text{H}_2^{18}\text{O}$ ). The mechanism of rearrangement from the highly coordinated manganese species to the resulting tetrahydrofuran has not been proposed.




Figure 19. Permanganate Oxidation of 1,5-Dienes to Tetrahydrofurans

Conjugated systems are known to react much faster than the unconjugated variety.<sup>61</sup> There are four examples of potassium permanganate oxidation of 1,3 dienes. Sable *et al.* has described the oxidation of cyclopentadiene (69a) and cyclohexadiene (69b).<sup>61,64</sup> Both reacted to give *cis*-epoxy-diols (70) as the major products in low yield. Sable proposed that the initial manganese ester (72) rearranged to an anhydride species of mixed oxidation states (73) which acts to oxidize the vicinal olefin intramolecularly (Figure 21). In support of their mechanism the minor product, (71a), was further subjected to potassium permanganate oxidation and less than 5% of the epoxy-diol (70a) was formed. Therefore, diol (71a) is not an intermediate in the oxidation as Sable had originally believed.




Figure 20. Permanganate Oxidation of Cyclic 1,3-Dienes




Figure 21. Sable *et al.* Mechanism of Cyclopentadiene Oxidation

In most cases, the epoxy-diols are isolated in less than 30% yield. Occidentalol (**75**)<sup>65</sup> was subjected to potassium permanganate oxidation and yielded the epoxy diol (**76**). In a third example, the epoxy diol (**78**) was generated from the 1,3 diene system of a steroid (**77**).<sup>66</sup>





Figure 22. Other Reports of Permanganate Oxidation of 1,3-Dienes

Recently, Hudlicky and Mandel<sup>67</sup> have subjected the protected-arene-*cis*-diol (**14c**) to potassium permanganate oxidation conditions. They found the product distribution to be very sensitive to the reaction conditions. For example, epoxy diol (**80**) (Table 8) formation was favored by high concentrations, low reaction temperatures and short reaction times whereas glycol (**79**) was favored by lower concentrations, higher reaction temperatures and slower addition of reagents. Along with (**80**), PTC also produced products (**81**) and (**82**) which were isolated in less than 15% yield (**82** was only isolated under PTC conditions). Hudlicky and Mandel proposed a mechanism in which the product distribution depends on the rate of 1,2 vs 1,4 addition of the permanganate to the polarized diene system. In this case, 1,4 addition can be considered formally as a [4+2] cycloaddition reaction. Support for 1,4 addition lies in the ease and regioselectivity with which (**14**) undergoes [4+2] cycloaddition reactions. The competition between 1,4 and 1,2-addition serves to explain the sensitivity of the product distribution on the reaction



conditions. Hudlicky believes that kinetic 1,4 addition of permanganate to the diene is followed by rearrangement to either of the normal 1,2 adducts, which establishes equilibrium of the proposed intermediates (**83**), (**84**) and (**85**) (Figure 23), compounds from which all observed products can be easily derived. In all cases, it is believed that reoxidation of the manganese species occurs fast from another equivalent of permanganate. Further mechanistic studies need to be performed to explain these fascinating oxidations.

Table 8. Effect of Varying Conditions on the Oxidation of 1,3-Dienes



T/°C	KMnO <sub>4</sub> (equiv)	%79	%80	%81 + %82
-5	0.85	45	45	10
-5	2.10	30	60	10
25	0.85	60	30	10




Figure 23. Hudlicky *et al.* Mechanism of 1,3-Diene Oxidation

The potassium permanganate oxidation of olefins has been used sparingly since its inception in the late nineteenth century. The major problem lies in functional group compatibility. Experimental methods including PTC have been used to improve selectivity and ultimately the yields of the products. The mechanism of the oxidation of 1,3-dienes or 1,5-dienes is not completely understood at the time of this writing.

### 3. Arene-*Trans*-Diols

#### 3.1 Biological Activity

The interest in arene-*trans*-diols originates in their proposed intermediacy in the metabolism of aromatic compounds in eukaryotic cells.<sup>68</sup> The multistep pathway of metabolic activation of benzene to the toxic compound that ultimately is responsible for its carcinogenic effects is not fully understood. It has been established that benzene is metabolized to benzene oxide (**86**) by a class of nonspecific monooxygenases known as cytochrome P-450 (Figure 24).




Figure 24. Metabolism of Benzene in Eukaryotic Cells

In the metabolic pathway, benzene oxide can undergo several distinct reactions: a spontaneous isomerization to phenol (**87**) via a NIH shift (path a) or an enzyme catalyzed

hydration to the *trans*-dihydrodiol (**88**) (path b) or an addition of glutathione which occurs both nonenzymatically and through catalysis by soluble glutathione-S-epoxide transferases (path c) or addition of cellular macromolecules such as DNA, RNA and proteins (path d). It has been accepted that pathways a, b and c act to eliminate toxic benzene oxide from the cell and prevent cell mutagenesis which occurs by the reaction of (**86**) with DNA, RNA and proteins (path d). Recently Berchtold<sup>69</sup> has suggested that the true toxic agents are the epoxydiols (**89a** and **89b**). His studies involving bacterial mutagenesis indicate that these compounds are toxic towards cells and may also play a role in the carcinogenic effect of benzene.

According to the accepted theory,<sup>68</sup> epoxide hydrases play a major role in removing the toxic benzene oxides and other arene oxides from the cell. It has been suggested and experimentally supported that the monooxygenases and epoxide hydrases are closely associated in the microsomal membranes. This association allows the cell to remove the toxic oxides immediately upon their formation.

The specificity and selectivity of these epoxide hydrases have drawn considerable attention in the literature.<sup>70</sup> Various epoxide hydrases have been isolated and experimentally examined for both specificity and selectivity. Jerina<sup>70</sup> has carried out hydration studies involving rabbit liver hydase (RLH) (Table 9).

Table 9. Studies on Epoxide Hydration using Rabbit Liver Hydase

Substrate ( $\mu\text{mol}$ )	% conversion to diol	Observed $\alpha_D^{25}$ of diol (deg)	$\alpha_D^{25}$ of resolved diol (deg)
cyclohexene oxide (250)	2	-32.6	-46.5
benzene oxide (110)	11	-250 $\pm$ 25	250
1,2-naphthalene oxide (100)	30	-47 $\pm$ 5	-159
9,10-phenanthrene oxide (50)	38	-87	-138
styrene oxide (100)	18	18	62

The stereospecificity of RLH was investigated by examining the stereochemistry of optically active *trans*-diol produced from various oxides. In the carefully controlled reaction conditions, nonenzymatic opening of the oxides did not occur in any appreciable amount. These studies indicate that the stereospecificity of enzymatic hydration of oxides is very substrate dependent. The optical purities of the resulting *trans*-diol range from 70% (cyclohexene oxide) to < 1% (styrene oxide) with benzene oxide estimated to be approximately 50% optically pure.


### 3. Arene-*Trans*-Diols

#### 3.2 Synthesis

The synthetic utility of arene-*trans*-diols has been slower to mature than that of the corresponding arene-*cis*-diols. The reason for this is the fact that *Psuedomonas putida* 39D oxidizes a wide variety of aromatic compounds in high enantiomeric excess. To date, over 200 arene-*cis*-diols have undergone biooxidation. Contrasting this, Section III.1 showed the substrate dependence of the epoxide hydrase and low enantiomeric excess of the resulting arene-*trans*-diols. Several chemical syntheses of arene-*trans*-diols have been reported.<sup>36,69,71,72</sup> These syntheses will be presented in this section along with their reactivity and synthetic utility as chiral synthons.

Plah and Oesch<sup>71</sup> in 1977 published the synthesis of *trans*-1,2-dihydroxy-1,2-dihydrobenzene or simply benzene-*trans*-diol (Figure 25). The five step synthesis uses cheap starting materials and reagents and is designed to produce large amounts of racemic benzene-*trans*-diol (**96**) (51% overall yield). The synthesis begins with the Birch reduction of benzene producing 1,4-cyclohexadiene which is then monobrominated at

-70°C to yield (**92**) in 92% yield. The olefin (**92**) was then *trans*-dihydroxylated by the action of performic acid in formic acid followed by acidic methanolysis. Attempts to debrominate (**93**) under various basic conditions proved unsuccessful. However, debromination of the diacetoxyl-protected dibromide (**94**) with lithium chloride and lithium carbonate produced diene (**95**) in 80% yield. Removal of the acetates takes place at -30°C upon treatment with lithium tetrahydroaluminate. This method has been utilized for the synthesis of benzene-*trans*-diol and Carless<sup>73</sup> has applied this methodology to the synthesis of racemic conduritol B, myo-inositol, chiro-inositol and other chiro-inositol derivatives (Table 10).




i) Br<sub>2</sub>, CHCl<sub>3</sub>, -70°C, 92% ii) a) H<sub>2</sub>O<sub>2</sub>, HCO<sub>2</sub>H, CHCl<sub>3</sub>, -30°C b) MeOH, p-TsOH, reflux, 86%  
 iii) AcCl, pyridine, 93% iv) LiCl, Li<sub>2</sub>CO<sub>3</sub>, HMPT, 100°C v) LiAlH<sub>4</sub>, Et<sub>2</sub>O, -5°C, 87%

Figure 25. Racemic Synthesis of Benzene-*Trans*-Diol (**96**)

There have been two methods developed for the synthesis of chiral arene-*trans*-diols. Both methods are limited in that they have been specifically tailored for the production of a single *trans*-diol. The first method<sup>69</sup> involves sequential enzymatic hydrolysis of the diacetate (**95**) derived from benzene (Figure 26). Porcine liver esterase


(PLE) hydrolyzes only one diacetate isomer in modest enantiomeric excess. Repeating the hydrolysis procedure on the enriched product yields both enantiomers of benzene-*trans*-diol in high optical purity.




i) PLE ii) AcCl, Pyridine, DMAP iii) NaOH, H<sub>2</sub>O

Figure 26. Synthesis of Chiral Benzene-*trans*-diol with PLE

Another specialized enantioselective synthesis of an arene-*trans*-diol (**99**) has been developed as an intermediate in the synthesis of (+)-pipoxide (**100**) and (+)-β-senepoxide (**101**).<sup>72</sup>



The synthesis begins with carboxylic acid (**102**) which undergoes bromolactonization to produce (**103**). Compound (**103**) is reduced with  $\text{LiAlH}_4$  and acetylated to produce the diacetate (**104**). Cleavage of the anhydro-ring with  $\text{HBr}$  in acetic acid at  $90^\circ\text{C}$  gave the tribromide (**105**). The arene-*trans*-diol (**99**) was produced from (**105**) through a four-step sequence involving debromination, bromination, benzoate formation and subsequent debromination.



i)  $\text{Br}_2$ ,  $\text{CHCl}_3$ ,  $0^\circ\text{C}$  ii) a)  $\text{LiAlH}_4$  b)  $\text{AcCl}$ , Pyridine,  $0^\circ\text{C}$ , 84% iii)  $\text{HBr}$ ,  $\text{AcOH}$ ,  $90^\circ\text{C}$ , 71%  
 iv)  $\text{Zn}$ ,  $\text{AcOH}$ , 80% v) a)  $\text{NBS}$ ,  $\text{CCl}_4$ ,  $\text{AIBN}$ ,  $80^\circ\text{C}$  b) sodium benzoate,  $\text{DMF}$ , 44%  
 vi)  $\text{Zn}$ ,  $\text{AcOH}$ ,  $70^\circ\text{C}$ , 91%

Figure 27. Synthesis of an Arene-*Trans*-Diol (**99**)

The three enantioselective syntheses of arene-*trans*-diols (**99**), (**100**) and (**101**) represent specialized methods which gain access to these highly functionalized compounds. However, a general method which could be applied to the synthesis of a



wide range of arene-*trans*-diols is needed. Section III.4 will describe a general methodology for producing arene-*trans*-diols from the corresponding arene-*cis*-diols.

### 3. Arene-*Trans*-Diols

#### 3.3 Reactivity and Utility

Since the initial synthesis of benzene-*trans*-diol in 1977,<sup>71</sup> there has not been a great deal of effort describing the reactivity of arene-*trans*-diols. Few papers have been published which describe the reactivity and synthetic utility of these chiral synthons.<sup>73</sup> This section will describe the known reactivity of these compounds.

Ogawa<sup>72</sup> utilized selective epoxidation as the last step in the synthesis of (+)-pippoxide (**100**). As expected, epoxidation of mono-protected *trans*-diol (**106**) results in oxidation of the  $\beta$ -face (Figure 28). In general, the regiochemistry of epoxidation is controlled by the C1-substituent. Similar selectivity has been ascribed to the arene-*cis*-diols.




Figure 28. Selective Epoxidation of Arene-*Trans*-Diol (**106**)

Carless and Piepersburg<sup>73</sup> have both utilized the hetero-Diels-Alder reaction in the synthesis of natural products. Carless showed that the arene-*trans*-diol undergoes

cycloaddition with singlet oxygen. The *endo*-peroxide (**108**) is reduced to the diol ether (**109**) *in situ* by the action of thiourea in methanol. This diol ether (**109**) served as a useful intermediate in the synthesis of various inositol phosphates (Table 10).




Figure 29. Cycloaddition of (**107**) with Singlet Oxygen

Piepersburg<sup>73</sup> has utilized the hetero-Diels-Alder reaction with racemic *trans*-diol (**110**) to give the bicyclic dihydro-1,2-oxazine (**111**) which was reduced to the amino alcohol and subsequently acetylated to give (**112**). Compound (**112**) served as an intermediate in the synthesis of various aminocyclitols (Table 10). These three examples serve to show the synthetic utility of these molecules in organic synthesis.




Figure 30. Cycloaddition of (**110**) with 1-Chloro-1-nitrosocyclohexane

Table 10. Natural Products Synthesized by Cycloaddition with Arene-*Trans*-Diols
















<i>Trans</i> -diol	Natural Product	References
 <p>(+/-)</p>	 <p>R = H or PO<sub>3</sub>H<sub>2</sub></p>	73b
	 <p>R = H or PO<sub>3</sub>H<sub>2</sub></p>	73b
	 <p>R = PO<sub>3</sub>H<sub>2</sub></p>	73a
 <p>(+/-)</p>	 <p>•2HCl</p>	73e
		73d

Table 10. Natural Products Synthesized by Cycloaddition with Arene-*Trans*-Diols

<i>Trans</i> -diol	Natural Product	References
		72
		72
		72
		36

## 4. Pancratistatin: An Amaryllidaceae Alkaloid

### 4.1 Isolation, Structure Determination and Biological Activity

The treatment of cancer with Amaryllidaceae family of plants dates back to the fourth century BC. Greek physician Hippocrates of Cos used the oil of the daffodil *Narcissus poeticus L.* to treat cancer.<sup>74</sup> More than thirty other plants of the Amaryllidaceae family representing eleven genera have also found application in folk medicinal management of cancer.<sup>75</sup> The first chemical investigations of the Amaryllidaceae family of plants (*Hymenocallis littoralis* species) were performed by Gorter in 1920.<sup>75</sup> Gorter describes the isolation of an alkaloid, lycorine (**114**), which was the first alkaloid isolated from the Amaryllidaceae family of plants. Compound (**114**) is known to inhibit growth of the murine P-388 lymphocytic leukemia (PS system). *H. littoralis* activity was reevaluated by Pettit *et al.*<sup>76</sup> 55 years later. They found that the antineoplastic activity resides in the n-butanol fraction rather than the lycorine containing methylene chloride fraction (Figure 33). Further purification of the extract guided by a bioassay (PS *in vivo* and *in vivo* systems) led to the isolation of two principle antineoplastic components, 7-deoxynarciclisine (**115a**, 0.022%) and pancratistatin (**12**, 0.014%).

The structure of pancratistatin (**12**), a phenanthridone alkaloid, was determined by detailed NMR and mass spectral analysis.<sup>76,77</sup> A X-ray crystal structure of its 7-methyl ester derivative was utilized to make the stereochemical assignments and confirm the overall structure.




Figure 31. Several Biologically Active Amaryllidaceae Alkaloids

Narciclasine (**115b**), 7-deoxynarciclasine and pancratistatin, compounds bearing highly oxygenated phenanthridone nucleus, are all biologically active compounds. 7-deoxynarciclasine and narciclasine have been shown to inhibit growth of *Avena coleoptile* (rice seedling test), tobacco plant tissue cultures and murine Ehrlich carcinoma.<sup>78</sup> Narciclasine has displayed other types of antineoplastic activity and is undergoing evaluation by NCI. Pancratistatin displays antineoplastic activity that is more potent and diverse than narciclasine. Pancratistatin shows activity against murine P-388 lymphocytic leukemia (38-106% life extension at 0.75-12.5 mg/kg dose levels) and *in vivo* murine M5076 ovarian sarcoma (53-84% life extension at 0.38-3.0 mg/kg dose levels).<sup>76,77</sup> Pettit suggests that the activity displayed by the hydroxylated phenanthridone units in pancratistatin and narciclasine may become useful as a chemotherapeutic drug and/or other medicinal areas.

To date there is no information on the mechanism of antineoplastic action of pancratistatin (**12**). However, the mechanism of action of narciclasine (**115b**), a structurally similar but less pronounced antineoplastic compound has been deduced.<sup>79</sup> Studies indicate that the mechanism of action of narciclasine involves the inhibition of

the growth of eukaryotic cells by the disruption of protein biosynthesis. In eukaryotic cells, it has been concluded that narciclasine inhibits the binding of t-RNA to the peptidyl transferase center of the 60S ribosomal subunit. The correlation of the biological activities between narciclasine and pancratistatin remains to be determined.

#### **4. Pancratistatin: An Amaryllidaceae Alkaloid**

##### **4.2 Biogenesis**

The biogenesis of pancratistatin (**12**) has not yet been elucidated; however, the biosynthesis of a structurally related and more abundant alkaloid, narciclasine (**115b**), has been evaluated. Fuganti<sup>80</sup> has deciphered the biosynthesis through elegant radioactive feeding experiments of <sup>3</sup>H and <sup>13</sup>C labeled compounds. Fuganti's data suggests that norbelladine (**118**), which is biosynthesized ultimately from phenylalanine (**116**) and tyrosine (**117**), is a precursor to narciclasine (**115b**). Narciclasine is biosynthesized from norbelladine through alkaloid intermediates oxocrinine (**120**) and crinine (**121**).




Figure 32. Biogenesis of Narciclasine






Figure 33. Isolation of 7-Deoxynarciclasine and Pancratistatin

## 4. Pancratistatin: An Amaryllidaceae Alkaloid

### 4.3 Total Synthesis and Synthetic Approaches

#### Total Synthesis

To date, there has been only one total synthesis of racemic pancratistatin by Danishefsky and Lee.<sup>81</sup> They began the synthesis of pancratistatin with pyrogallol (**122a**). Protection with triethyl orthoformate, carbamoylation and cyclization to the dioxolane (**123b**). Anionic Fries rearrangement of the trisubstituted system yielded (**124a**) in modest yield. Protection of the phenol as the t-butyldimethylsilyl (TBDMS) ether (**124b**), ortho-lithiation followed by alkylation with dimethylformamide (DMF) produced the desired piperonal derivative. The synthesis of the C-ring was begun by allyl magnesium bromide addition, elimination and Diels-Alder reaction with a masked acetylene ultimately gave the 1,4-cyclohexadiene derivative (**128**). At this point iodolactonization was attempted and proved problematic. The problem was reasoned to be the steric interaction between the TBS and the diethylamide portion of the molecule. Therefore, the TBS was deprotected and iodolactonization occurred under forced conditions via stannylation and subsequent cyclization to yield (**129a**). The benzyl ether protected compound (**129b**) was treated with osmium followed by a Moffat-like transformation to yield a mixture of (**133**) and its allylic isomer (**132**). The former was again dihydroxylated. A four step protection-deprotection sequence yielded the monobenzylated diol (**135c**). Reductive elimination furnished (**136**) which reacted to form the imidate (**137**). An Overman rearrangement was affected using the combination of high temperature and vacuum to yield (**138**) in 56%. Dihydroxylation followed by methanolic potassium carbonate generated the amino acid which underwent cyclization under standard DCC conditions. The total synthesis of pancratistatin (**12**) was completed





Figure 34. Danishefsky Synthesis of Pancreatistatin Part A



xv) OsO<sub>4</sub>, NMO, THF, 88% xvija). Bu<sub>2</sub>SnO, toluene, reflux, p-methoxybenzyl bromide, 84% xvii) benzyl bromide, Ag<sub>2</sub>O, DMF, 95%  
 xviii) DDQ, CH<sub>2</sub>Cl<sub>2</sub>, H<sub>2</sub>O, 75% xix) Zn dust, AcOH, CH<sub>2</sub>Cl<sub>2</sub>, 81% xx) NaH, CCl<sub>3</sub>CN, THF, 0°C, 74% xxi) 105°C, 0.1mm Hg, 56%  
 xxii) OsO<sub>4</sub>, NMO, THF, 75% xxiii) K<sub>2</sub>CO<sub>3</sub>, MeOH, CH<sub>2</sub>Cl<sub>2</sub>, reflux, 82% xxiv) Pd(OH)<sub>2</sub>, H<sub>2</sub>, EtOAc, 90%.

Figure 35. Danishefsky Synthesis of Pancreatistatin Part B

with deprotection of the benzyl groups using hydrogenation to give a spectra which identically matched the natural product. Danishefsky and Lee completed the synthesis of pancrastistatin in 26 steps with an overall yield of 0.183%. Danishefsky comments that the synthesis is not very efficient due to several key low yielding steps and goes on to state that a more practical route is needed.

### Synthetic Approaches

There have been only two synthetic approaches to pancrastistatin published; however, it should be noted that Ohta,<sup>84</sup> Paulsen<sup>85</sup> and Kallmerten<sup>83</sup> proceed through the 7-deoxy system (**142**), a derivatized version of pancrastistatin, in their syntheses of (+/-) and (+)-lycoricidine (**143b**). In each case dehydration of the C1 was used to complete the synthesis of lycoricidine. These syntheses should be considered as model systems for pancrastistatin. Excluding these, two other approaches to pancrastistatin have been published by Heathcock<sup>82</sup> and Clark.<sup>86</sup>




Figure 36. 7-Deoxypancratistatins as Intermediates in the Synthesis of Lycoricidine

Clark and Souchet<sup>86</sup> published a model study directed toward the total synthesis of pancrastistatin in 1990. Retrosynthetically, they had hoped to use (**145**) as the key

intermediate. Compound (**144**) would be synthesized from (**145**) by carbon-carbon bond formation and furnish pancratistatin (**12**) in several steps.





Figure 37. Retrosynthetic Analysis of Clark and Souchet Model Study

The short synthesis of (**145**) begins with the condensation of (**146**) with the functionalized imine (**147**) in refluxing methylene chloride. This generates a 1:1 mixture of diastereomers. It was found that the reaction occurred by Lewis acid induced chelation controlled addition of (**146**) to (**147**). Table 11 shows that in varying Lewis acid and temperature, a good ratio is achieved. Thus, addition of trimethylaluminum to the reaction at low temperatures increased the stereoselectivity of the chelation product. The ratio of the desired isomer was increased from 1:1 (no LA) to 10:1 (Me<sub>3</sub>Al).

Table 11. Optimization of Lewis Acid Catalysis Conditions



Lewis Acid (LA)	Solvent	Temperature	Time	Ratio 148a:148b
none	CH <sub>2</sub> Cl <sub>2</sub>	reflux	10 min	50:50
LiI	THF	reflux	10 min	60:40
ZnCl <sub>2</sub>	CH <sub>3</sub> CN	rt	2 hr	82:18
MgI <sub>2</sub>	THF	0°C	2 hr	70:30
MgI <sub>2</sub>	THF	-50 to 0°C	2 hr	80:20
MgI <sub>2</sub>	CH <sub>3</sub> CN	0°C	2 hr	83:17
MgI <sub>2</sub>	CH <sub>3</sub> CN	-30 to 0°C	24 hr	93:7
AlMe <sub>3</sub>	CH <sub>2</sub> Cl <sub>2</sub>	-78 to 0°C	5 hr	91:9

Clark and Souchet then used a racemic, but more functionalized imine (**150**) and studied the Lewis Acid chelation controlled condensation. Again, the addition of trimethylaluminum gave a similar ratio of diastereomers and furnished (**151**) in a 50% yield.





Figure 38. Optimized Conditions for Condensation

Heathcock *et al.*<sup>82</sup> published an expedient method to the synthesis of the A,B and C rings of pancratistatin in a model study (Figure 39). The synthesis began with the corresponding diethylamide of piperonal (**152**). Compound (**152**) was deprotonated, trapped as the borate ester, and oxidized to the corresponding phenol (**153a**) in one pot. The phenol was protected as the silyl ether (**153b**). The protected phenol again was subjected to ortho-lithiation conditions and reacted with 1-nitrocyclohexene to yield a pair of isomers (**154**). The cis isomer was epimerized to the thermodynamically stable trans isomer (**155**) upon treatment with triethylamine in refluxing ethanol. Reduction of the nitro group to the amine was accomplished using sonication of (**155**) in the presence of sodium borohydride-nickel chloride which was subsequently cyclized upon treatment with *s*-BuLi. Deprotection under acidic conditions furnished the desired tetracyclic phenanthridone skeleton (**156**).





a) i. *s*-BuLi, TMEDA, THF ii. (MeO)<sub>3</sub>B iii. H<sub>2</sub>O<sub>2</sub>, HOAc b) *t*-BuMe<sub>2</sub>SiCl, imidazole, CH<sub>2</sub>Cl<sub>2</sub>, 0°C  
 c) i. *s*-BuLi, TMEDA, THF ii. 1-nitrocyclohexene iii. HOAc d) Et<sub>3</sub>N, EtOH e) NaBH<sub>4</sub>, NiCl<sub>2</sub>·6H<sub>2</sub>O MeOH, ))) f) *s*-BuLi, THF, -15°C g) HCl

Figure 39. Heathcock *et al.* Model Study

Several model studies and one racemic total synthesis have been achieved. The Danishefsky total synthesis is economically unfeasible for pharmaceutical generation of pancratistatin. An enantioselective synthesis of pancratistatin is therefore needed, possibly general enough to permit the preparation of structurally related molecules.

### III. DISCUSSION

#### 1. Introduction

The oxidation of substituted benzenes by the mutant bacteria *Psuedonomas putida* 39D produces arene-*cis*-diols (**7**) in > 95% ee. These biooxidation products have been used as chiral synthons in organic synthesis.<sup>101</sup> Their synthetic utility is exemplified by the directing/hindering effect that the hydroxyl groups, both free and protected, have on subsequent stereochemical events. This manipulation is the basis for all stereospecific reactions of the arene-*cis*-diols and controls the topography of the molecule.

Cycloaddition reactions and potassium permanganate oxidations are examples of reactions in which the stereoselectivity is dictated by the chiral centers at C5 and C6. Several new modes of cycloaddition involving 1-chloro-arene-*cis*-diol have been investigated. Thermal reactions with quinones yield [4+2] cycloadducts resulting from addition to the less hindered face and in an *endo* fashion. Photolytically, benzoquinone undergoes a hetero-[4+2] cyclization with the diene system. Generation of benzyne and nitrile oxide *in situ* lead to the isolation of their [4+2] and [3+2] cycloadducts. The potassium permanganate mediated oxidation of various protected 1-substituted arene-*cis*-diols has been briefly examined. In general, compounds (**157a**) and (**157b**), where oxidation occurs *anti* to the acetonide group, were the only isolated products (Figure 40). The effect of the R substituent both electronically and sterically on the reactive diene system and thus the ratio of (**157a**):(**157b**) will be presented.




Figure 40. Potassium Permanganate Oxidation of Arene-*Cis*-Diols

Also included in this thesis will be a discussion detailing the development of a protection, inversion and cycloreversion methodology of arene-*cis*-diols as a route to the desired arene-*trans*-diol. An arene-*trans*-diol (**159**) serves as a chiral intermediate in an enantioselective approach to the amaryllidaceae alkaloid (+)-pancratistatin (**12**). The two key steps in this approach are the generation of the arene-*trans*-diol system and the cross coupling between the arene-*trans*-diol (**159**) and appropriate functionalized piperonylic acid derivative to give (**158**).





Figure 41. Retrosynthetic Analysis of (+)-Pancratistatin (**12**)

## 2. Novel Cycloadditions of a 1-Chloro-Arene-*Cis*-Diol Derivative

As discussed in Section II.1, some cycloadditions of 1-chloro-5,6-*cis*-isopropylidenedioxy-1,3-cyclohexadiene or acetonide protected 1-chloro-arene-*cis*-diol (**14c**) have already been examined. In general, the cycloadducts result from approach of the dienophile from the less hindered face and in an *endo* manner. The cycloadducts from [4+2] nitrosyl Diels-Alder reaction have found use in the total synthesis of several natural products, ie. aminocyclitols<sup>26,49,50</sup> and lycoricidine.<sup>30</sup> This section focuses on a preliminary investigation of novel cycloaddition reactions of (**14c**) with various compounds. Frontier molecular orbital (FMO) theory and electron density will be used to support spectroscopic evidence concerning regiochemistry and stereochemistry of both [4+2]<sup>87,88</sup> and [3+1]<sup>89-91</sup> cycloaddition reactions.



14c

## 2. Novel Cycloadditions of a 1-Chloro-Arene-*Cis*-Diol Derivative

### 2.1. With Quinones, Thermal and Photolytic

In general, 1,4-benzoquinone reacts photolytically with olefins to yield the oxetanes and/or cyclobutane adducts.<sup>92</sup> Reports of 1,3-dienes reacting with 1,4-benzoquinone under photolytic conditions also exist.<sup>93</sup>




Figure 42. Photolytic Formation of Spiropyrans (**161**)

In 1965, Baltrop *et. al.* showed in an elegant study that 1,4-benzoquinone undergoes cycloaddition with various dienes to yield spiropyrans of type (**161**) (Figure 42).<sup>93</sup> They discovered that the product distribution is directly related to the wavelength of light used in the reaction. Irradiation below 400nm results in excitation of the carbonyl moiety of the quinone ( $n \rightarrow \pi^*$  transition), and isolation of spiropyrans in low yield (30%). Irradiation above 400nm led to a complex mixture of products. In mechanistic terms, 1,4 addition of radicals to 2,3-dimethylbutadiene via a resonance stabilized diradical, (**162**), can be invoked to rationalize the formation of the spiropyran (Figure 43).

As expected, a degassed benzene solution containing 1,4-benzoquinone and (**14c**) reacted under photolytic conditions (360nm monochromatic light) to yield one spiropyran adduct (**163**) (16%) and unreacted starting material (45%).<sup>96</sup> Increase in the number of equivalents of 1,4-benzoquinone did not lead to a higher yield of (**163**) and the excess 1,4-benzoquinone made flash chromatographic purification difficult. [It should be noted that irradiation with a 400 watt Hanovia gave an intractable mixture of products.]






Figure 43. Mechanism of Spiropyran Formation (161)

Regiochemistry of photolytic cycloaddition was assumed to be (163a) on the grounds of steric factors. In the transition state leading to (163b), there is a steric interaction between the chlorine atom and the approaching quinone. This interaction is not present in the transition state that produces compound (163a).



The regiochemistry was proven by heteronuclear multibond correlation (HMBC), HMBC is a 2D NMR technique that gives long range proton-carbon correlations (up to three bonds). The HMBC of compound (**163**) shows a correlation between C-4 and C-10. This is possible in (**163a**) but not in its regioisomer (**163b**).

Because they are planar and contain the electron withdrawing carbonyls, quinones make excellent dienophiles in the Diels-Alder reaction.<sup>87,92</sup> In refluxing benzene, 1,4-benzoquinone and 1,4-naphthoquinone reacted with (**14c**) to yield the polycyclic compounds (**164**) and (**165**) in 53% and 40% respectively.<sup>96</sup> The stereoselectivity of this reaction merits some discussion. The quinones approach the diene from the less hindered face. FMO theory supports the experimental evidence that quinones react through the more stable *endo* transition state. This is due to secondary orbital interactions of the carbonyl moiety with the diene. This reaction proved to be no exception as shown by a positive nuclear Overhauser effect (nOe) in the product. In the benzoquinone cycloadduct, irradiation of H<sub>3</sub> showed 6-10% enhancement of signals due to H<sub>2</sub>, H<sub>5</sub> and H<sub>6</sub>. This nOe enhancement of proximal protons is only possible with the *endo* structure. The naphthoquinone cycloadduct was shown to be *endo* following similar reasoning and spectroscopic analysis.



These cycloadditions with quinones generated interesting polycyclic molecules which are possibly applicable to natural product synthesis. Specifically compound (**165**) could undergo stoichiometric ozonolysis to yield (**166**), which is structurally similar to a class of anthraquinone antibiotics of which altersolanol A and dactylariol are members (Figure 44).




Figure 44. Naphthoquinone Cycloadduct (**165**) and Structurally Similar Antibiotics

## 2. Novel Cycloadditions of a 1-Chloro-Arene-Cis-Diol Derivative

### 2.2. With Benzyne

Dehydrobenzene or benzyne is a reactive intermediate which is useful in organic synthesis.<sup>95</sup> Benzyne has an unperturbed aromatic system with a weak extra double bond orthogonal to its plane. Because of its inherent ring strain, benzyne undergoes substitution and cycloaddition reactions readily.<sup>95,96</sup>






Figure 45. Cycloaddition with Benzyne

Benzyne is readily prepared from anthranilic acid which undergoes diazotization and concomitant loss of carbon dioxide and nitrogen. In the presence of (**14c**), benzyne (Figure 45) reacted to give the expected cycloadduct (**167**) in respectable yield (66%).

## 2. Novel Cycloadditions of a 1-Chloro-Arene-*Cis*-Diol Derivative

### 2.3. With Acetonitrile Oxide

Nitrile oxides can also be viewed as dipolar species.<sup>97</sup> They are ambivalent intermediates composed of two resonance forms, a propargyl (**168a**) and an allenyl (**168b**) hybrids. The carbon-nitrogen bond length of nitrile oxides, in general, approaches that of hydrogen cyanide, suggesting that the nitrilium oxide (**168a**) structure predominates.<sup>89</sup> This fact is responsible for the relatively high dipole moment (3.15D). 1,3-Dipolar species, such as nitrile oxides, react with polarized olefins to yield products resulting from [3 + 2] cycloaddition reactions. The rate of the reaction depends directly upon the extent of polarization of the olefin.

Mukaiyama and Hoshino developed a mild method for the generation of nitrile oxides *in situ*.<sup>97</sup>




Figure 46. Cycloaddition of with Acetonitrile Oxide

Following this protocol, nitroethane was dehydrated and formed the intermediate nitrile oxide which reacted with (14c) to yield the novel bicyclic isoxazole (Figure 46). Electron density (Appendix) obtained from AM1 calculations<sup>94</sup> have shown the C3-C4 olefin to be the more polarized olefin in the 1,3-diene of (14c). Regiochemistry was rationalized by invoking the dominant nitrilium oxide hybrid (168a) and an incipient positive charge at C-3 of the diene, as predicted by electron density calculations. FMO theory also supports this regiochemistry. In order to predict regiochemistry, the FMO energy and coefficients of the dipole and the dipolarophile must be known or approximated. Houk<sup>98,99</sup> has shown that the coefficients and energy of the FMOs of unsubstituted nitrile oxide are similar to those of substituted cases and therefore constitute a good qualitative measure in predicting regiochemistry. The olefin must be classified as electron deficient (dipole-LUMO controlled, ie. lower energy of HOMO/LUMO) or electron rich (dipole-HOMO controlled, ie., raise energy of HOMO/LUMO). The C3-C4 olefin is electronically neutral due to an inductive electron withdrawing effect and conjugation which counteract each other. The olefin is similar in energy to ethylene where the smallest energy gap is between the HOMO (dipolarophile) and LUMO (dipole), as illustrated in Figure 47. This is supported by the calculated energy of the HOMO and the LUMO (Appendix, Figure 48). The lowest energy gap is between the HOMO of the diene and the LUMO of the dienophile.




Figure 47. FMO Energies of Dipole and Dipolarophile

The largest coefficients (appendix) of the HOMO (dipolarophile) and LUMO (dipole) interact in the transition state and lead to the regiochemistry shown (Figure 48). This regiochemistry was proven by  $^1\text{H-NMR}$  decoupling studies.




Figure 48. FMO Interaction of the Dipole with the Dipolarophile

Presented here are the first examples of quinones, benzyne or acetonitrile oxide reacting with the homochiral 1-chloro-arene-*cis*-diol (**14c**). These and other stereoselective cycloadditions of (**14**) generate highly functionalized polycyclic molecules. Future work involving cycloaddition chemistry of (**14**) will focus on the utilization of the resulting cycloadducts in organic synthesis. Section III.4 works towards this end. It describes the development of a cycloaddition-cycloreversion strategy to the synthesis of arene-*trans*-diols. One of these arene-*trans*-diols will serve as an intermediate in an enantioselective approach to the synthesis of the amaryllidaceae alkaloid (+)-pancratistatin. The next section discusses the potassium permanganate oxidations of 1-substituted-arene-*cis*-diols, which can be formally considered as a [3+2] cycloaddition reaction.

### 3. Oxidation of Arene-*Cis*-Diols by Potassium Permanganate


The potassium permanganate oxidation of alkenes dates back to 1895.<sup>51</sup> Section II.2.1 showed how the structure of the resulting product is dependent on pH, substrate structure as well as other factors. Selectivity in the potassium permanganate oxidation is a major concern. Potassium permanganate oxidizes a wide variety of functional groups and therefore has been used little in the area of organic synthesis. The oxidation of 1,3-dienes has only been investigated relatively recently. Section II.2.2 described two mechanisms for the oxidation of 1,3-dienes which are theoretically based on the product distribution. Mandel and Hudlicky<sup>67</sup> have reported that the oxidation of 1-halo-arene-*cis*-diols yield a mixture of products, diol (**157a**) and epoxydiol (**157b**). The product distribution was found to be very sensitive to the reaction conditions (ie. temperature, concentration etc.). These halo-epoxydiols have been used extensively in the synthesis of inositols.<sup>67</sup> This section will describe the effect the diene substituent has on the course of the oxidation. Also, the effect of solvent will be briefly discussed.

### 3. Oxidation of Arene-*Cis*-Diols by Potassium Permanganate

#### 3.1 Effect of Diene Substituent

Hudlicky and Mandel<sup>67</sup> have reported on the potassium permanganate oxidation of 1-halo-arene-*cis*-diols. Since the original oxidations were performed only on halo-diols, we postulated that the 1,3-diene substituent may play a key role in the oxidative mechanism and thus on the product distribution. We set out to oxidize several acetonide protected arene-*cis*-diols each possessing a different C1-substituent. These were chosen because of availability and the nature of the C1-substituent, both steric and electronic.

The parent diols of **(14h)** and **(14i)** were obtained from Genencor International Inc. Compounds **(14g)** and **(14j)** were prepared in our labs.



At the outset, it was reasoned that the electronics of potassium permanganate dihydroxylation should be similar to osmium tetroxide (OsO<sub>4</sub>) dihydroxylation. It has been shown in our labs that in osmium tetroxide dihydroxylation reactions of the arene-*cis*-diols, electron withdrawing groups at the C1-position (R = Cl) deactivate the 1,2-alkene and the 3,4-alkene is selectively oxidized (**157a**). However, when the C1-position possesses an electron donating group (R = CH<sub>3</sub>), a mixture of oxidation products is isolated (**157a:170**; 1:2).<sup>100</sup>




Figure 49. C1-Substituent Effect on the Selectivity of OsO<sub>4</sub> Dihydroxylation

We believe that initially the regiochemistry of the manganese ester formation should parallel that of the osmate ester. From the intermediate manganese ester, it is expected to

rearrange and oxidize the second olefin following the Hudlicky or Sable mechanisms (Section II.2, Figures 21 and 23). Therefore, it is our presupposition that electron donating R groups should increase the amount of (171a) and (171b) (Figure 50, path a) and electron withdrawing R groups should increase the amount of (157a) and (157b) (Figure 50, path b).




Figure 50 Expected Substituent Effect on Permanganate Oxidation

Examining the product distribution of the permanganate oxidations, this rationale seems to be unsubstantiated (Figure 51). As in all permanganate mediated oxidations of (14), the yields of products are low and this makes any hypothesis involving substitution effects suspect. However, examining the yields and ratios of products we believe that electronically the substituent plays little role in the oxidation. A possible reason for this irregularity may be steric effects. Permanganate has been shown to be very sensitive to sterics.<sup>52</sup> These effects may play an important role in the oxidation of an electron rich disubstituted olefin in the presence of an equally electron rich trisubstituted one.




Figure 51. Product Distribution of Potassium Permanganate Oxidation

### 3. Oxidation of Arene-*Cis*-Diols by Potassium Permanganate


#### 3.2 Effect of Solvent

Potassium permanganate oxidation reactions can be performed in a number of aqueous solvent systems.<sup>52</sup> However, there are several requirements. The solvent must be inert towards permanganate oxidation, miscible with water and potassium permanganate must show appreciable solubility in the solvent system. Common solvents include acetone/water and ethanol/water mixtures. Other solvents have been reported, for example, pyridine/water and THF/water. Keeping all other variables constant, the effect of different aqueous solvents on the permanganate oxidation of 1-chloro-arene-*cis*-diol was examined. The results are shown in Table 12. Entry 3 appears to be an exciting result; however, the yield of permanganate oxidation product was less than 5%. Entries 1, 2 and 4 show an interesting effect. All yield products in approximately 20% yield but



in a different ratio. This solvent effect can be explained by the solubility of the permanganate in the aqueous solvent system. It seems permanganate is most soluble in aqueous acetone and least soluble in aqueous THF. Mandel<sup>67</sup> found that the concentration of permanganate in solution has a direct effect on the product distribution.

Table 12. Solvent Effect on Potassium Permanganate Oxidation



Entry	Solvent(aq)	Ratio (176a):(176b)	Yield(%)
1	acetone/water	1:4.5	25
2	ethanol/water	1:1.5	22
3	pyridine/water	100:0	5
4	THF/water	2:1	20

The potassium permanganate oxidation has been used sparingly in the area of organic synthesis. Selectivity is the fundamental problem with permanganate oxidations. This section described the potassium permanganate oxidation of substituted arene-*cis*-diols. Diols and epoxydiols were isolated as the major products in low yields. Substituent changes alter the product ratio which suggests that a complex mixture of electronic and steric effects are operating. The oxidation of 1,3-dienes remains a perplexing reaction. Although the potassium permanganate oxidation of (14) is mechanistically interesting, it will not be a practical reaction in organic synthesis because of low yields and complex mixtures of products. The next section will describe the application of [4+2] cycloaddition chemistry of arene-*cis*-diols to the synthesis of arene-

*trans*-diols. One of these molecules serves as an intermediate in an enantioselective approach to the alkaloid (+)-pancratistatin.

#### 4. Arene-*Trans*-Diols

The availability of arene-*cis*-diols through the biooxidation of substituted aromatic compounds has led to their common use as chiral synthons.<sup>101</sup> Sections II.1, II.2, III.2 and III.3 described their use in the areas of cycloaddition and permanganate mediated oxidation. Both of these areas have produced highly functionalized intermediates which have been used in short, enantioselective synthesis of a variety of natural products, including alkaloids<sup>30,37</sup> and inositols.<sup>67</sup>

The synthetic methods available for producing arene-*trans*-diols were discussed in Section II.3. These specific methods are limited to the synthesis of three arene-*trans*-diols. Benzene-*trans*-diol (**96**) has proven to be a valuable intermediate in the synthesis of several inositol phosphates<sup>73</sup> and aminocyclitols<sup>73</sup> (Section II.3). The development of a general methodology for the synthesis of arene-*trans*-diols will enhance their use as chiral synthons in natural product synthesis.

Presented in this section are the syntheses of arene-*trans*-diols from the corresponding 1-chloro or 1-bromo arene-*cis*-diols. The methodology employed in this synthesis is shown in Figure 52. Protection of the 1,3-diene moiety through the Diels-Alder reaction, selective inversion at the C5 hydroxyl, followed by cycloreversion will produce the desired arene-*trans*-diol (**180**). Included in this discussion will be the choice of protecting groups, inversion of the sterically hindered alcohol (**178**) as well as optimum conditions found for the cycloreversion reaction. Mechanistic interpretations explaining the product distribution of the cycloreversion will also be given. Finally, the

arene-*trans*-diols serve as an intermediate in an approach to the chemotherapeutic agent (+)-pancratistatin (Section II.4).




Figure 52. Synthetic Methodology for the Production of Arene-*Trans*-Diols

## 4. Arene-*Trans*-Diols

### 4.1 Development of the Methodology

In the development of a general methodology for the synthesis of arene-*trans*-diols from the corresponding arene-*cis*-diol an important restriction becomes evident at the outset. Attempts at inversion of either hydroxyl group on the cyclohexadiene ring leads to immediate aromatization. Upon the generation of a leaving group at C5 or C6 (**182**), elimination occurs which is driven by the enthalpic force of aromatization (Figure 53). Therefore, in order to synthesize the arene-*trans*-diols, the 1,3-diene system must be protected. Diels-Alder cycloaddition, selective inversion at C5 and subsequent cycloreversion will produce the required arene-*trans*-diol in enantioselective fashion.





Figure 53. Elimination Reaction of Arene-*Cis*-Diols

Several reviews<sup>102</sup> have been written about the cycloreversion reaction. Many methods involving cycloreversion, which lead to the generation of 1,3-dienes, have been developed. However, most cycloreversions occur under harsh conditions and in most cases require temperatures exceeding 200°C. It is questionable whether the labile arene-*trans*-diols would survive such strenuous reaction conditions. In this methodology, three known methods were tried for the protected/deprotection sequence of the 1,3-cyclohexadiene system. These methods were selected according to their comparatively mild conditions.

The choice of the 1,3-diene protecting group is critical to the success of the synthetic methodology. In 1989 Hudlicky and Seoane<sup>36</sup> published the synthesis of (-)-zeylena (Section II.1, Figure 12). In this synthesis, the diene system was protected under mild conditions utilizing the Diels-Alder reaction with DEAD derivatives. After inversion of the C5 hydroxyl, the diene system was regenerated upon treatment with zinc/copper couple in acetic acid. The synthesis of (-)-zeylena was finished in several subsequent steps. The major problem encountered in the (-)-zeylena synthesis was the reproducibility of the cycloreversion reaction. Yields of the cycloreverted products ranged from 10% to 60% which depended directly on the activity of the zinc/copper couple.

Even with the problem of reproducibility in the (-)-zeylena synthesis, the DEAD protection-deprotection sequence served as the initial idea in the development of the methodology for the synthesis of arene-*trans*-diols. We believed that the DEAD cycloreversion step could be optimized and therefore began the synthesis by trying the first step in the reaction sequence, the DEAD cycloaddition reaction. Problems immediately arose with the DEAD protection sequence. The diene system in these halogenated cyclohexadiene systems was found to be much less reactive than the triene system encountered in the (-)-zeylena synthesis. All attempts to generate Diels-Alder cycloadducts of arene-*cis*-diols with DEAD led to the isolation of starting material, aromatic byproducts and/or products of arene-*cis*-diol dimerization (Table 13). The use of DEAD as a protecting group in the methodology for the production of arene-*trans*-diols was abandoned. Other 1,3-diene protecting groups were subsequently attempted.

Table 13. Attempts at Cycloaddition of Arene-*Cis*-Diols with DEAD




Entry	Diene	DEAD Equivalents	Conditions	Product (yield)
1	184a	1.1	THF, 0°C-→rt, 1day	184a (90)
2	184a	5.0	Benzene, reflux, 6 hours	Aromatics
3	184b	2.2	THF, 0°C, 4 days	Dimer (70) + 184a (20)
4	184b	2.2	THF, reflux, 2 days	Dimer (87)

Since before 1950<sup>102</sup> sulfur dioxide has been reported as a protecting group for 1,3-dienes. Sulfur dioxide undergoes a six electron [4+2] cycloaddition with 1,3-dienes to yield sulfolenes. Sulfolenes undergo thermal cycloreversion at temperatures near

150°C. It has been reported that sulfur dioxide reacts with both reactive dienes and unreactive dienes.<sup>102</sup> However, in the case of the free arene-*cis*-diol or its protected version, starting material or aromatic compounds were the only compounds isolated upon reaction with sulfur dioxide at atmospheric pressure. Obviously, the dienes were not reactive enough to furnish cycloadducts with sulfur dioxide. In the presence of moderate pressures of sulfur dioxide, normally unreactive dienes can be forced to react. Sealed in a stainless steel bomb under 40psi of sulfur dioxide, the arene-*cis*-diols still did not undergo cycloaddition (Table 14, entries 2 and 4). The arene-*cis*-diols only aromatize under these forcing conditions. It was initially believed that any moisture would react with sulfur dioxide and produce sulfonic acid which could catalyze deprotection and subsequent elimination of the arene-*cis*-diol. Even with the addition of 2 equivalents of triethyl amine, aromatization still occurred (entry 4). Protection of the arene-*cis*-diols with 4-phenyl-1,2,4-triazoline-3,5-dione (**20**) was examined next and proved successful.


Table 14. Attempts at Cycloaddition of Arene-*Cis*-Diols with Sulfur Dioxide



Entry	Diene	Conditions	Product
1	186b	Et <sub>2</sub> O, bubbling SO <sub>2</sub> , rt, 2hr	NR
2	186b	Et <sub>2</sub> O, SO <sub>2</sub> (40 psi), rt, 2 days	Aromatics
3	186a	Benzene, bubbling SO <sub>2</sub> , rt, 1hr	Aromatics
4	186a	Benzene, SO <sub>2</sub> (40 psi), NEt <sub>3</sub> , 1day	Aromatics
5	186c	Benzene, bubbling SO <sub>2</sub> , rt, 12hr	NR

In 1970, Barton<sup>103</sup> published his first in a series of seminal papers<sup>104</sup> relating to a Diels-Alder/retro-Diels-Alder strategy in the synthesis of steroids and steroidal metabolites. In this paper, ergosterol acetate reacted readily with 4-phenyl-1,2,4-triazoline-3,5-dione (**20**) at room temperature in 87% yield. The cycloreversion step was found to proceed under a variety of conditions (Table 15). Treatment of the cycloadduct with excess lithium aluminum hydride gave the best yields in the cycloreversion reaction. The mechanism of cycloreversion is reagent dependent and will be discussed in Section III.4.3.

Table 15. Protection/Deprotection of Ergosterol with 4-Phenyl-triazoline-3,5-dione



Entry	Reagent	Conditions	Yield of Ergosterol
1	LiAlH <sub>4</sub>	THF, reflux, 8 hr	99 (188a)
2	Heat	235°C, 0.045mm Hg	36 (188b)
3	Na	EtOH, reflux, 24 hr	53 (188a)
4	NH <sub>2</sub> NH <sub>2</sub> ·H <sub>2</sub> O	EtOH, reflux, 14 hr	30 (188a)

Since 1970, many other research groups have utilized this protection/deprotection sequence.<sup>102</sup> In that time period, researchers have developed more conditions which effect cycloreversion. A complete list of cycloreversion conditions to date is presented below (Table 16). The yields of product (1,3-diene) range from 99% to 60%.




Table 16. Cycloreversion Conditions

Entry	Reagent	Conditions
1	LiAlH <sub>4</sub>	THF, 67°C, 18hr
2	15N KOH	EtOH, 78°C, 15hr
3	2.1 N KOH	EtOH, 78°C, 1.5hr
4	2.1 N KOH	EtOH, rt, 36hr
5	K <sub>2</sub> CO <sub>3</sub>	DMSO, 120°C, 7hr
6	DBN	Pyridine, 115°C, 18hr
7	Imidazolidinone	120°C, 1-5-hr
8	Collidine	175°C, 15min
9	tetramethylguanidine	180°C, 15min

#### 4. Arene-*Trans*-Diols

##### 4.2 Successful Synthesis


In the beginning, we believed that using the methodology depicted in Figure 52, we would successfully gain access to arene-*trans*-diols. In this methodology (Figure 52), the C5- and C6-hydroxyl protecting groups play an important role. Both hydroxyls must be selectively protected in order to avoid the separation of mixtures. Also, the C5-hydroxyl protecting group ultimately must be deprotected and inverted in the presence of the C6-protecting group (ie. stable to bases and fluoride ion). A protection route similar to the (-)-zeylena synthesis<sup>36</sup> was chosen. The 1-bromo or chloro-arene-*cis*-diol (**190**) was selectively protected with hexyldimethylsilyl chloride (THSCl) at the least hindered C5-hydroxyl. The C6-hydroxyl was then protected as a methoxymethyl (MOM) derivative following a procedure developed by Stork.<sup>105</sup> Both of these protection steps proceeded selectively and in high yield (Figure 54).



i) THSCl, imidazole, CH<sub>2</sub>Cl<sub>2</sub>, 0°C, 94% ii) a) Chloromethyl ethyl ether, EtN(i-Pr)<sub>2</sub>, 0°C b) CH<sub>2</sub>Cl<sub>2</sub>, 93%

Figure 54. Selective Diprotection of Arene-*Cis*-Diol (**190**)

Cycloaddition of (**192**) with 4-phenyl-1,2,4-triazoline-3,5-dione (**20**) proceeds stereoselectively at low temperatures and in high yield. The two bulky protecting groups shield the β-face and only allow cycloaddition to occur selectively from the α-face. Experimentally, the triazoline is added dropwise to a cold solution of the (**192**) in methylene chloride. The reaction is complete when the characteristic red color of the triazoline persists in the reaction medium. The product (**193**) displays the characteristic <sup>1</sup>H-NMR, <sup>13</sup>C-NMR and IR of these cycloadducts (Section VI).



i) 4-phenyl-triazoline-3,5-dione (**25**), CH<sub>2</sub>Cl<sub>2</sub>, -60°C, 89%

Figure 55. Protection of 1,3-Diene System by (**20**)

The THS-protecting group was readily deprotected upon treatment with tetrabutylammonium fluoride (TBAF) at low temperatures. At this point, the inversion of the free hydroxyl was carried out but proved to be problematic.





Figure 56. Deprotection of the C5-Hydroxyl

The Mitsunobu reaction is the standard method for inverting an alcohol. There have been several recent reviews published on the Mitsunobu reaction.<sup>106</sup> These reviews describe at great lengths its mechanism and usefulness in organic synthesis. However, alcohol (**194a**), under standard Mitsunobu conditions, was never inverted (Table 17, entry 1). Other carboxylic acids used in place of benzoic acid gave similar results (Table 17, entries 2 and 3). A possible explanation for the inability of (**194a**) to react under Mitsunobu conditions is that the alcohol is in a sterically demanding environment that impedes the intermediate alkoxy-phosphonium salt formation. The Mitsunobu reaction was abandoned in the hope that other inversion techniques would prove successful.


Sulfonate formation followed by inversion with a nucleophile was the next obvious choice. This technique has been described to work even on sterically hindered alcohols.<sup>106</sup> Hart<sup>107</sup> found that treatment of a mesylate with potassium acetate in hot DMF produced inversion products in cases where the Mitsunobu reaction failed. In our hands, this method returned only unreacted mesylate (Table 17, entry 4). However, formation of a triflate followed by inversion with cesium acetate in the presence of 18-crown-6<sup>108</sup> proceeded in 15 minutes to give inverted products in hot DMF (Table 17, entry 5).

Table 17. Inversion Conditions



Entry	Inversion Conditions	% Product
1	THF, PPH <sub>3</sub> , benzoic acid, DEAD, 0°C	NR
2	Benzene, PPH <sub>3</sub> , p-nitrobenzoic acid DEAD, 0°C->rt	NR
3	THF, PPH <sub>3</sub> , NaO <sub>2</sub> CH, DEAD, 0°C->rt	NR
4	a) Tf <sub>2</sub> O, pyridine, CH <sub>2</sub> Cl <sub>2</sub> , 0°C b) KOAc, 18-crown-6, DMF, 0°C->rt	NR
5	a) Tf <sub>2</sub> O, pyridine, CH <sub>2</sub> Cl <sub>2</sub> , 0°C b) DMSO, KO <sub>2</sub> , 18-crown-6, rt	---
6	a) Tf <sub>2</sub> O, pyridine, CH <sub>2</sub> Cl <sub>2</sub> , 0°C b) CsOAc, 18-crown-6, DMF, 70°C	95

Comparison of the <sup>1</sup>H-NMR of (194a) with (196a) showed expected differences in the splitting patterns and coupling constants of the C5 and C6-protons. In this rigid system, the coupling constants suggest that the C5- and C6-substituents are forced into an eclipsed conformation (Figure 57). The inversion step was later optimized so that triflate formation, inversion and subsequent acetate hydrolysis were accomplished in >90% combined yield.

Figure 57. <sup>1</sup>H-NMR Evaluation of (194a) and (196a)

At this point, the cycloreversion reaction was attempted. Treatment of (**196a**) with 2.1N KOH in EtOH (Table 16, entry 4) led to the isolation of an unknown product in low yield. Analysis by  $^1\text{H-NMR}$  showed the compound contained a disubstituted alkene, the N-phenyl moiety of the triazoline and the ether linkage of the MOM group. According to this spectroscopic data, the product was assumed to be (**198**), resulting perhaps from intramolecular hydrolysis of a portion of the triazoline (Figure 58).





Figure 58. First Attempt at Cycloreversion

In order to prevent this intramolecular hydrolysis, the inverted hydroxyl was protected as a t-butyldimethylsilyl (TBDMS) ether (**199**). Treatment of this diprotected cycloadduct (**199a**) under cycloreversion conditions (2.1N KOH in EtOH) furnished an inseparable 11:1 mixture of arene-*trans*-diols (**200c**) and (**200a**) in 68% yield. The other 32% of the mass balance was accountable as aromatic byproducts resulting from decomposition of

the products. Interestingly, subjecting (**199b**) to the cycloreversion conditions yielded chloro-*trans*-diol (**200b**) exclusively in 65% isolated yield. None of the dechlorinated compound (**200c**) was isolated.

Table 18. Protection and Second Attempt at Cycloreversion



i) TBDMSTf, 2,6-lutidine, CH<sub>2</sub>Cl<sub>2</sub>, 0°C→rt, 90% ii) see below

Starting material	Conditions	Product (a:b:c)	Yield
199a	2N KOH (aq), EtOH, air	1:0:11	65%
199a	Collidine, 175°C, 22hr	100:0:0	22%
199b	2N KOH (aq), EtOH, air	0:100:0	60%

Attempts at cycloreversion using other conditions also yielded interesting results. When (**199a**) was dissolved in collidine and heated to 175°C for 22 hours, purification of the reaction mixture yielded (**200a**) in low yield. Due to the different ratios of products in the case of (**199a**), we believe that the two cycloreversion conditions (KOH, EtOH or Collidine at 175°C) are mechanistically distinct from one another. Presented in the next section is a mechanistic discussion on the cycloreversion reaction.

## 4. Arene-*Trans*-Diols

### 4.3 Mechanistic Interpretations of Cycloreversion

This section will present what is known about the triazoline cycloreversion along with experiments which were run to discern the mechanism of debromination. The mechanism for cycloreversion of (**199a**) in collidine at 175°C is believed to occur through a retro-[4+2] reaction followed by decomposition of the 4-phenyl-1,2,4-triazoline-3,5-dione (Figure 59). The thermally unstable triazoline would not survive such high temperatures. We propose that the triazoline (**20**) decomposed at 175°C and produced one molecule of nitrogen, carbon dioxide and phenyl isocyanate.




Figure 59. Mechanism for Cycloreversion at Elevated Temperature

Mechanistic insights into the cycloreversion reaction of triazoline cycloadducts come from two sources. First, in the cycloreversion with lithium aluminum hydride (LAH), Barton<sup>104</sup> used gas chromatographic (GC) analysis of the reaction mixture to gain some understanding of the reaction. The GC showed three compounds were present in a 1:7:1 ratio. These compounds were found to be *N,N*-dimethylaniline, *N*-methylaniline, aniline and accounted for 62% of the *N*-phenyl-triazoline system. The mechanism which accounts for these anilines being formed is shown in Figure 60. It involves complete reduction of the triazolo system to the corresponding hydrazine (**202**). Barton proposed

that the intermediate hydrazine (**202**) undergoes cycloreversion through air oxidation to the azo compound followed by loss of nitrogen or loss of hydrazine via a retro-Diels-Alder reaction to regenerate the 1,3-diene system.




Figure 60. General Mechanism of LAH Mediated Cycloreversion

Alkaline mediated cycloreversion can be postulated to follow a similar mechanism due to the work of Gilani and Triggle (Figure 61).<sup>109</sup> They were interested in the synthesis of steroidal hydrazines. Prior to hydrolysis, the olefin (**204**) was hydrogenated. Alkaline hydrolysis yielded the desired hydrazine (**205**) in quantitative yield. The two pieces of information concerning the hydrolytic mechanism lead us to believe that hydrolysis proceeds through the semicarbazide (**206**). The semicarbazide is further hydrolyzed to the hydrazine (**202**) with loss of another of  $\text{CO}_2$  molecule and one molecule of aniline. Similarly, oxidation with concomitant loss of nitrogen or loss of hydrazine via retro-[4+2] cycloaddition can be invoked to regenerate the 1,3-diene (**203**) (Figure 62).






Figure 61. Formation Of Hydrazine (**205**)





Figure 62. General Mechanism For Alkaline Mediated Cycloreversion

The mechanism depicted in Figure 62 is straightforward in nature; however, it will not account for debromination in the case of (**199a**). Experimentally, it was found that changing the reaction conditions had a profound effect on the ratio of (**200a**) to (**200c**) and thus on the mechanism of the reaction. First, 1-bromo-*trans*-diol (**200a**) was subjected to the reaction conditions (2.1N KOH, EtOH). The only products isolated from the reaction mixture contain bromine and were aromatic in nature. There was no

spectroscopic evidence implicating the formation of **(200c)**. Therefore, it is our presupposition that debromination must occur during the cycloreversion step.

Table 19. Experimental Variations in Hydrolytic Cycloreversion



Entry	Conditions	Product Ratio ( <b>200a</b> ):( <b>200c</b> )	Yield
1	2N KOH (aq), EtOH, air	1:11	65%
2	2N KOH (aq), EtOH, O <sub>2</sub>	1:6	50%
3	2N KOH (aq), EtOH, degassed	0:100	51%
4	2N KOH (aq), t-BuOH, air	0:100	58%
5	2N KOH (aq), THF, 80°C, air	1:2	45%
6	2N KOH (aq), EtOH, degassed, galvinoxyl free radical (1equiv)	1:1	50%

Others variations in reaction conditions are shown in Table 19. Interestingly, when the EtOH solution was degassed, **(200c)** was isolated exclusively. From this result it was believed oxygen may play a role in the debromination. Oxygen can either act as an oxidant or as a radical scavenger. In order to rule out or support the formation of radical intermediates, **(199a)** was first subjected to the cycloreversion conditions in the presence of oxygen. This caused a slight change in the product ratio. Next, the reaction was run in the presence of a stabilized free radical (galvinoxyl). The ratio changed again, but not drastically. If radicals are involved, we expected the presence of galvinoxyl free radical would trap any radicals and severely alter the product ratio. We believe the experimental results (Table 19) neither support nor rule out a radical mechanism. Solvent also seems to play a role in the debromination. When t-BuOH was used in place of EtOH, **(200c)**

was formed exclusively. A heterogeneous system (entry 5), also changed the ratio of products.

At this point in studying the cycloreversion of (**199a**), we have come up with three plausible mechanisms which account for the debromination (Figure 63). First, a carbenoid intermediate is proposed to result from attack of hydroxide on the bromine atom (path A). Fragmentation and quenching give the desired debrominated product (**200c**). Second, alkaline hydrolysis of (**199a**) yields the corresponding hydrazine which undergoes deprotonation and loss of bromide forming the ubiquitous bridgehead olefin (path B). Compound (**208**) rearranges to the azo compound (**210**) and subsequently loses nitrogen to give the desired trans-diol (**200c**). Lastly, we envisioned hydroxide attack on the bromine atom forming hypobromite and a stabilized anion (**211**). The anion is quenched and hydrolysis of the triazolone portion proceeds as previously described to give (**200c**). We believe all of the proposed mechanisms are possible and further experimental evidence is needed to support or rule out any of the mechanisms. The next section describes the use of (**200a**) in an enantioselective approach to the alkaloid (+)-pancratistatin (**12**).





Figure 63. Plausible Mechanisms for Debromination During Cycloreversion

B)



C)




Figure 63. Plausible Mechanisms for Debromination During Cycloreversion

## 4. Arene-*Trans*-Diols

### 4.4 Approach to the Synthesis of (+)-Pancratistatin

Section II.4 described the potent biological activity of (+)-pancratistatin (**12**) along with several synthetic ventures directed towards its synthesis. An efficient total synthesis of (+)-pancratistatin is an ongoing project of several synthetic organic groups throughout the United States.<sup>110</sup> Retrosynthetically we disconnected (**12**) into two pieces, the stannyl-*trans*-diol (**213**) and the aryltriflate (**214**), which would be coupled using the Stille cross coupling reaction to yield (**158**). The coupled product would then be stereoselectively manipulated to give the target molecule (**12**).




Figure 64. Retrosynthesis of (+)-Pancratistatin (**12**)

The two intermediates (**213**) and (**214**) were easily synthesized by known methods. The synthesis of the aryltriflate (**214**) was completed in several steps by use of an ortho-lithiation methodology. The synthesis begins with the known isopropyl ester of piperonylic acid (**215**).<sup>111</sup> Compound (**215**) was subjected to lithium tetramethylpiperidine (LiTMP) and trimethylborate under the internal quench conditions

which were developed by Corey<sup>112</sup> and later used by Martin<sup>113</sup> followed by acidic hydrolysis and subsequent oxidation yielded the corresponding phenol (**216a**) in 83% yield. Protection of the phenol as the MOM derivative proceeded in high yield. Similarly, (**216b**) reacts under internal quench conditions to yield the mono protected diphenol (**217**). Treatment of (**217**) with triflic anhydride at low temperature yielded the desired aryltriflate (**214**).





Figure 65. Synthesis of Aryltriflate (**214**)

The easily synthesized 1-bromo-arene-*cis*-diol (**192a**) was used as a model compound in the cross coupling reactions because of the scarcity of the corresponding arene-*trans*-diol. The stannyl-derivative (**218**) was synthesized in low yield following conditions described by Ley (Figure 81).<sup>114</sup> Cross coupling of (**218**) and (**214**) under standard Stille<sup>115</sup> and modified Stille conditions developed by Farina<sup>116</sup> and others<sup>117</sup> resulted in the isolation of the deprotected phenol (**220**), (**219**) and (**221**). The free phenol (**220**) should still have undergone cross coupling with (**214**). These preliminary results indicate that much more work is needed to gain access to coupled molecules such as (**158**).



i) a) *t*-BuLi, Et<sub>2</sub>O, -95°C b) Me<sub>3</sub>SnCl 25% ii) (214), Pd(PPh<sub>3</sub>)<sub>4</sub>, LiCl, THF, reflux or (CH<sub>3</sub>CN)<sub>2</sub>PdCl<sub>2</sub>, LiCl, DMF, rt-->70°C

Figure 66. Two Attempts at Stille Cross Coupling

This section accessed the recent results obtained in an enantioselective approach to (+)-pancratistatin. The approach hinges on the synthesis of two intermediate compounds the aryl unit (214) and the arene-*trans*-diol (213). The Stille coupling protocol of (214) and (218) gave unfortunate results. Future work in the area of pancratistatin synthesis as well as other uses for the arene-*trans*-diols are given in the next section.

#### 4. Arene-*Trans*-Diols

##### 4.5 Future Work

Section III.4.4 detailed the unsuccessful results of coupling (214) and (218) using the Stille methodology. Future work will focus on the coupling reaction. The Suzuki<sup>118</sup> or other organometallic coupling procedures<sup>119</sup> will be attempted and will hopefully succeed in providing ample quantities of the coupled product (158). Once the coupled

product is in hand, we believe that the synthesis of (+)-pancratistatin would be completed in 7 subsequent steps. The key step in finishing the synthesis is the stereoselective dihydroxylation of (**158**). We believe that osmylation will occur selectively on the  $\beta$ -face of the 3-4 olefin due to the steric crowding of the equally electron rich 1-2 olefin. The dihydroxylation product would next undergo selective deprotection of the MOM derivative followed by protection of the diol as an acetonide which would yield (**222**). Compounds similar to (**222**) have been found to exist in a bisected conformation because of functional group crowding, this makes further olefin functionalization impossible. Adapting the methodology of Danishefsky,<sup>81</sup> the two six-membered rings of (**222**) would be tied back as a lactone (**223**). Treatment of (**223**) with diborane followed by hydroxylamine-O-sulfonic acid would give (**224**) in which the new amine and hydrogen are in the required  $\beta$ -face, *syn*-disposition. Opening the lactone followed by cyclization to the amide using the Danishefsky protocol would yield the protected phenanthridone skeleton (**225**). Acidic deprotection would produce (+)-pancratistatin (**12**) in 16 steps from commercially available 1-bromo-arene-*cis*-diol (**190a**). If this approach is successful, it compares favorably with the published 26 step synthesis of racemic pancratistatin by Danishefsky in 0.183% overall yield.






Figure 67. Future Work in the Synthesis of (+)-Pancratistatin (12)

Ultimately, it is believed that with a general methodology to the differentially protected arene-*trans*-diols completed, these molecules will find extensive use as a chiral synthon in organic synthesis. Future studies involving the monoprotected arene-*trans*-diols will examine the availability of possible stereoselective reactions. Figure 68 shows the selective Diels-Alder, dihydroxylation and epoxidation reactions which are feasible.






Figure 68. Potential Stereoselective Reactions of Arene-*Trans*-Diols (**200**)

## IV. CONCLUSION


This thesis depicts the usefulness of the arene-*cis*-diols in organic synthesis. Their commercial availability in high enantiomeric excess and predictable reactivity make these molecules effective asymmetric building blocks. Sections III.2 and III.3 described the highly functionalized molecules available via cycloaddition and potassium permanganate oxidation reactions. In the area of cycloaddition chemistry this thesis reports the first photolytic cycloaddition and [3+2] cycloaddition yielding (**163a**) and (**169**). The regiochemistry of the cycloadducts were reasoned by NMR analysis and supported by FMO theory. The first cycloaddition of these homochiral compounds with benzyne was also described (**167**).



163a




167




169

Potassium permanganate oxidation of the arene-*cis*-diols were found to give in most cases a mixture of diol (**157a**) and epoxydiol (**157b**) in low yield. The substituent effect on the product ratio of (**157a**):(**157b**) was found to be a complex interaction of both sterics and electronics.




157a




157b


Finally, a general enantioselective route to the synthesis of arene-*trans*-diols from the corresponding arene-*cis*-diol was developed. This thesis discussed the evolution of a methodology and described how to choose a 1,3-diene protecting group, how to invert a sterically hindered alcohol and how to affect cycloreversion. The 7-step protection-deprotection sequence produced enantiopure arene-*trans*-diols (**200a**), (**200b**), and (**200c**).



200a



200b



200c

Compound (**200a**) is a key intermediate in an approach to the synthesis of (+)-pancratistatin, an amaryllidaceae alkaloid with potent biological activity toward cancer cells. Preliminary studies indicate that the Stille coupling route to intermediate (**158**) is not a viable one. Future work (Section III.4.5) will investigate the synthetic utility of (**200**) as a chiral synthon in natural product synthesis and continue with the synthesis of (+)-pancratistatin, the approach to which was fully described in this thesis.

## V. EXPERIMENTAL

Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. Tetrahydrofuran (THF), benzene and diethyl ether (Et<sub>2</sub>O) were distilled from sodium/benzophenone ketyl under argon immediately prior to use. Methylene chloride (CH<sub>2</sub>Cl<sub>2</sub>) was distilled from CaH<sub>2</sub> under argon immediately prior to use. Diisopropylethylamine (i-Pr<sub>2</sub>NEt), pyridine, 2,6-lutidine, tetramethylpiperidine (TMP), triethylamine (Et<sub>3</sub>N) and collidine were distilled from CaH<sub>2</sub> and stored over KOH pellets in a desiccator until use. Reactions involving air and/or moisture sensitive reagents were executed under an inert atmosphere of dry argon and the glassware was flame dried under vacuum. Flash chromatography was performed using Merck silica gel 60 (230-400 mesh) and indicated solvents. Infrared (IR) spectra were reported in wavenumbers (cm<sup>-1</sup>) and referenced to the 1601.8 cm<sup>-1</sup> absorption of polystyrene film. The <sup>1</sup>H and <sup>13</sup>C-nuclear magnetic resonance (NMR) spectra were obtained as solutions in deuterio-chloroform (CDCl<sub>3</sub>) unless otherwise indicated. Chemical shifts were reported in parts per million (ppm, δ) and were referenced to CHCl<sub>3</sub> at δ 7.24 for <sup>1</sup>H-NMR or to the center line of the CDCl<sub>3</sub> triplet at δ 77.0 for <sup>13</sup>C-NMR. Coupling constants were reported in hertz (Hz). Splitting patterns were designated as s, singlet; d, doublet; t, triplet; q, quartet; hp, heptet; m, multiplet; br, broad.

Photolytic reactions were performed using a Rayonet RPR-240 reactor equipped with four 12.5-W bulbs which irradiated at 360nm. Melting points were determined on a Thomas Hoover capillary apparatus and are uncorrected. IR spectra were recorded on Perkin-Elmer 1600 FTIR or Perkin-Elmer 283B. NMR spectra were recorded on Bruker WP-270 or Varian Unity 400. Optical rotations were measured on Perkin-Elmer 241 digital polarimeter. Mass spectra were determined on Varian MAT-112 instrument (low

resolution) or VG-7070 E-HF (exact mass). Elemental Analysis were performed by Atlantic Microlab Inc., P.O. Box 2288, Norcross, Georgia 30091.

**(1'R, 4'R, 5'S, 6'S)-Spiro-[2,5-cyclohexadiene-4-one-1'-chloro-5',6'-(isopropylidenedioxy)-1,3'-[2]-oxabicyclo[2.2.2]oct-7'-ene] (163a).**

To a solution of protected (**14c**) (301 mg, 1.62 mmol) in benzene (10 ml, degassed) was added 1,4-benzoquinone (192 mg, 1.78 mmol). The solution was stirred until the 1,4-benzoquinone dissolved and then transferred via cannula to a quartz photolysis apparatus. The yellow solution was photolyzed at 3600°A. After 11 hours, the reaction was diluted with Et<sub>2</sub>O (25 ml) and washed with brine (25 ml). The aqueous layer was extracted with Et<sub>2</sub>O (3 x 25 ml) and the combined organic layers were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The crude amorphous solid was chromatographed (silica, 10:1 Hexane/EtOAc) to yield 75 mg of a yellow oil (16%).

**R<sub>f</sub>**: 0.20 (Hexane/EtOAc 15:1)

**[α]<sub>D</sub><sup>25</sup>**: +163.8° (c = 0.57; CHCl<sub>3</sub>)

**IR**: (CCl<sub>4</sub>) cm<sup>-1</sup> 3005, 1680, 1640, 1360, 1390

**<sup>1</sup>H-NMR**: (CDCl<sub>3</sub>) δ 1.41 (s, 3H), 1.42 (s, 3H), 3.76 (d, 1H, J = 6.0 Hz), 4.43 (dd, 1H, J = 5.6, 0.8 Hz), 4.83 (m, 1H), 5.59 (ddd, 1H, J = 10.4, 5.6, 2.0 Hz), 6.04 (dt, 1H, J = 10.4, 0.8 Hz), 6.20 (dd, 1H, J = 10.2, 2.0 Hz), 6.26 (dd, 1H, J = 10.4, 2.0 Hz), 6.65 (dd, 1H, J = 10.4, 3.2 Hz), 7.82 (dd, 1H, J = 10.4, 3.2 Hz)

**<sup>13</sup>C-NMR**: (CDCl<sub>3</sub>) δ 26.7 (CH<sub>3</sub>), 27.9 (CH<sub>3</sub>), 51.3 (CH), 72.6 (CH), 75.8 (CH), 79.7 (C), 101.9 (C), 110.7 (C), 120.1 (CH), 128.7 (CH), 130.9 (CH), 131.5 (CH), 143.6 (CH), 146.1 (CH), 184.0 (C)

**MS**: (CI, 70eV) m/z (rel. intensity) 295 (M + 1) (15), 259 (15), 237 (50), 201 (100)

**HRMS calcd for C<sub>15</sub>H<sub>15</sub>ClO<sub>4</sub>**: 294.0659 **Found**: 294.0658 error -0.4 ppm.

**(1S, 2S, 3S, 4S, 4aR, 8aS)-1-Chloro-1,4-etheno-2,3-(isopropylidenedioxy)-1,2,3,4,4a,8a-hexahydro-naphthalene-5,8-dione (164).**

Benzoquinone (483 mg, 4.47 mmol) was added to a stirred solution of (**14c**) (554 mg, 2.98 mmol) in benzene (15 ml). The solution was refluxed. After 22 hours, the solution was cooled to room temperature and the solid precipitate was filtered to yield 464 mg of a pale yellow amorphous solid (53%).

**R<sub>f</sub>**: 0.20 (CHCl<sub>3</sub>/MeOH 100:1)

**Mp:** 196.5-197.5°C

**[ $\alpha$ ]<sub>D</sub><sup>25</sup>:** -155.8° (c=0.62, CHCl<sub>3</sub>)

**IR:** (KBr) cm<sup>-1</sup> 3000, 1730, 1620, 1390, 1080

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>)  $\delta$  1.30 (s, 3H), 1.34 (s, 3H), 2.88 (d, 1H, J = 8.8 Hz), 2.98 (dd, 1H, J = 2.7, 8.8 Hz), 3.46 (m, 1H), 4.28 (d, 1H, J = 7.0 Hz), 4.40 (dd, 1H, J = 2.8, 7.1 Hz), 6.06 (m, 2H), 6.63 (d, 1H, J = 10.5 Hz), 6.74 (d, 1H, J = 10.5 Hz)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>)  $\delta$  25.1 (CH<sub>3</sub>), 25.3 (CH<sub>3</sub>), 40.2 (CH), 45.9 (CH), 51.2 (CH), 67.7 (C), 77.6 (CH), 84.3 (CH), 110.2 (C), 130.5 (CH), 133.7 (CH), 141.8 (CH), 143.0 (CH), 193.2 (C), 195.9 (C)

**MS:** (CI, 70 eV) m/z (rel. intensity) 297 (M+1) (2), 295 (10), 267 (6), 259 (8), 237 (8)

**HRMS** calcd for C<sub>15</sub>H<sub>16</sub>ClO<sub>4</sub>: 295.0737 **Found:** 295.0725, error 3.90 ppm

**Calcd for C<sub>15</sub>H<sub>15</sub>ClO<sub>4</sub>:** C 61.13% H 5.13% **Found:** C 61.16% H 5.11%.

**(1S, 2S, 3S, 4S, 4aR, 9aS)-1-Chloro-1,4-etheno-2,3-(isopropylidenedioxy)-1,2,3,4,4a,9a-hexahydro-anthracene-9,10-dione (165).**

Napthoquinone (689 mg, 4.35 mmol) was added to a stirred solution of (14c) (578 mg, 3.11 mmol) in 1,4 dioxane (15 ml). The solution was refluxed. After 22 hours, the solution was diluted with Et<sub>2</sub>O (20 ml) and washed with water (20 ml). The aqueous layer was extracted with Et<sub>2</sub>O (2 x 20 ml). The organic phases were combined, dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Chromatography (silica, gradient Hexanes/EtOAc 10:1-4:1) yielded 430 mg of a white crystalline compound (40%).

**R<sub>f</sub>:** 0.16 (Hexanes/EtOAc 4:1)

**Mp:** 181-182 °C

**[ $\alpha$ ]<sub>D</sub><sup>25</sup>:** -99.2° (c=0.6, CHCl<sub>3</sub>)

**IR:** (KBr) cm<sup>-1</sup> 2950, 1680, 1595, 1375

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>)  $\delta$  1.31 (s, 3H), 1.32 (s, 3H), 3.10 (d, 1H, J = 9.0 Hz), 3.21 (dd, 1H, J = 9.0, 2.8 Hz), 3.54 (dddd, 1H, J = 6.2, 3.1, 3.1, 1.2 Hz), 4.35 (dd, 1H, J = 7.0, 1.4 Hz), 4.48 (ddd, 1H, J = 7.1, 3.1, 1.2 Hz), 5.79 (dd, 1H, J = 8.6, 0.61 Hz), 5.91 (ddd, 1H, J = 8.6, 6.4, 1.1 Hz), 7.68 (m, 2H), 7.88 (m, 2H)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>)  $\delta$  25.1 (CH<sub>3</sub>), 25.3 (CH<sub>3</sub>), 40.7 (CH), 46.9 (CH), 52.3 (CH), 67.9 (C), 77.8 (CH), 84.3 (CH), 110.2 (C), 126.3 (CH), 126.9 (CH), 130.4 (CH), 133.6 (CH), 134.1 (CH), 134.6 (CH), 136.0 (C), 137.1 (C), 193.1 (C), 195.0 (C)

**MS:** (EI) m/z (rel. intensity) 345 (M<sup>+</sup>)(2), 329 (20), 286 (35), 104 (100)

**HRMS calcd for C<sub>19</sub>H<sub>18</sub>ClO<sub>4</sub>: 345.0894 Found: 345.0903, error 2.80 ppm**

**Calcd for C<sub>19</sub>H<sub>17</sub>ClO<sub>4</sub>: C 66.19% H 4.97% Found: C 66.09% H 4.95%.**

**(1R, 2S, 3S, 4R)-1-Chloro-1,4-etheno-2,3-(isopropylidenedioxy)-1,2,3,4-tetrahydronaphthalene (167).**

To a two-necked flask fitted with an addition funnel and a reflux condenser was added a solution of (**14c**) (502 mg, 3.01 mmol) dissolved in dimethoxyethane (DME, 5.5 ml). Isoamyl nitrite (960 mg, 8.2 mmol) was added and the reaction was brought to reflux. A solution of anthranilic acid (1.40 g, 10.4 mmol) dissolved in DME (5.5 ml) was added dropwise over a period of 20 minutes to the refluxing solution. After the addition was complete the solution was refluxed for another 40 minutes. The reaction was cooled to room temperature, diluted with Et<sub>2</sub>O (25 ml) and washed with a 5% NaOH (aq) solution. The aqueous layer was extracted with Et<sub>2</sub>O (3 x 25 ml). The combined organic layers was dried over MgSO<sub>4</sub> and concentrated at reduced pressure. Chromatography (silica, Hexane/EtOAc 25:1) yielded 521 mg of a pale yellow oil (66%).

**R<sub>f</sub>**: 0.18 (Hexane/EtOAc 25:1)

**[α]<sub>D</sub><sup>25</sup>**: +59.7° (c= 0.83, CHCl<sub>3</sub>)

**IR**: (neat) cm<sup>-1</sup> 2995, 2940, 1620, 1470, 1270, 1100

**<sup>1</sup>H-NMR**: (CDCl<sub>3</sub>) δ 1.28 (s, 3H), 1.44 (s, 3H), 4.13 (m, 1H), 4.22 (dd, 1H, J = 7.0, 1.2), 4.36 (ddd, 1H, J = 7.1, 3.6, 1.1), 6.43 (m, 2H), 7.22 (m, 3H), 7.64 (m, 1H)

**<sup>13</sup>C-NMR**: (CDCl<sub>3</sub>) δ 25.3 (CH<sub>3</sub>), 25.7 (CH<sub>3</sub>), 44.6 (CH), 71.7 (C), 79.7 (CH), 84.5 (CH), 113.0 (C), 123.0 (CH), 124.3 (CH), 126.6 (CH), 127.1 (CH), 132.0 (CH), 136.2 (CH), 137.6 (C), 139.6 (C)

**MS**: (CI, 70eV) m/z (rel. intensity) 263 (M + 1) (25), 247 (20), 233 (15), 205 (100)

**HRMS calcd for C<sub>15</sub>H<sub>16</sub>ClO<sub>2</sub>: 263.0839 Found: 263.0843, error 1.7 ppm**

**Calcd for C<sub>15</sub>H<sub>15</sub>ClO<sub>2</sub>: C 68.57% H 5.75% Found: C 68.50% H 5.78%.**

**(3aR, 4S, 5S, 7aS)-6-Chloro-4,5-(isopropylidenedioxy)-3-methyl-3a, 4, 5, 7a-tetrahydro-1,2-benzisoxazole (169).**

Phenyl isocyanate (636 mg, 5.38 mmol) was added to a stirred solution of (**14c**) (1.0 g, 5.38 mmol), nitroethane (408 mg, 5.38 mmol) and catalytic triethylamine (3 drops) in benzene (6 ml). A total of two more equivalents ( phenyl isocyanate, nitroethane and 6



drops triethylamine) were added in one equivalent increments after 2 and 15 hours. After 27 hours, the reaction was washed with water (2 x 20 ml) and once with 10% NaOH aqueous solution (10 ml). The benzene solution was dried over MgSO<sub>4</sub> and concentrated under reduced pressure to give a brown crystalline solid. Recrystallization (Hexane/EtOAc 6:1) yields 955 mg of a white crystalline solid (73%).

**R<sub>f</sub>**: 0.17 (Hexane/EtOAc 4:1)

**Mp**: 152-153.5°C

**[α]<sub>D</sub><sup>25</sup>**: +285.2 (c=0.54, CHCl<sub>3</sub>)

**IR**: (KBr) cm<sup>-1</sup> 3005, 2950, 1660, 1632, 1115, 920

**<sup>1</sup>H-NMR**: (CDCl<sub>3</sub>) δ 1.39 (s, 3H), 1.40 (s, 3H), 2.00 (s, 3H), 3.80 (br d, 1H, J = 9.0 Hz), 4.35 (d, 1H, 4.9 Hz), 4.60 (dd, 1H, J = 5.0, 3.1 Hz), 5.12 (dd, 1H, J = 9.0, 3.2 Hz), 5.80 (d, 1H, J = 3.3 Hz)

**<sup>13</sup>C-NMR**: (CDCl<sub>3</sub>) δ 12.5 (CH<sub>3</sub>), 26.4 (CH<sub>3</sub>), 27.6 (CH<sub>3</sub>), 49.2 (CH), 72.5 (CH), 72.7 (CH), 75.0 (CH), 110.2 (C), 123.2 (CH), 135.2 (C), 154.2 (C)

**MS** : (CI, 70 eV) m/z (rel. intensity) 244 (M+ 1) (40), 228 (10), 186 (40), 59 (100)

**HRMS** calcd for C<sub>11</sub>H<sub>15</sub>ClNO<sub>3</sub>: 244.0740 **Found**: 244.0741, error 0.1 ppm

**Calcd** for C<sub>11</sub>H<sub>14</sub>ClNO<sub>3</sub>: C 54.22% H 5.79% N 5.75% **Found**: C 54.20% H 5.80%. N 5.76% .

**(3R, 4R, 5S, 6S)-1-Cyano-3,4-dihydroxy-5,6-(isopropylidenedioxy)-1,2-cyclohexene (172a).**

To a cooled flask (-10°C) charged with KMnO<sub>4</sub> (300 mg, 1.90 mmol), MgSO<sub>4</sub> (168 mg, 1.4 mmol), acetone (6.3 ml) and water (7.3 ml) was added (**14h**) (305 mg, 1.72 mmol) dissolved in acetone (6 ml) over 35 minutes. After stirring 1 hour, sodium metabisulfite (50 mg) was added and the solution was warmed to room temperature. The solution was filtered through Celite and the solid residue was washed with water (10 ml) and acetone (15 ml). The solution was saturated with NaCl and extracted with EtOAc (4 x 25 ml). The combined extracts were dried over MgSO<sub>4</sub> and concentrated under reduced pressure to yield a colorless oil. Chromatography (silica, CHCl<sub>3</sub>/MeOH 30:1) yielded 110 mg of a white solid (30%).

**R<sub>f</sub>**: 0.10 (CHCl<sub>3</sub>/MeOH 20:1)

**Mp**: 110-112°C

**[α]<sub>D</sub><sup>24</sup>**: -60.3° (c = 0.68; MeOH)

**IR:** (CCl<sub>4</sub>) cm<sup>-1</sup> 3400, 2990, 2915, 2210, 1370, 1222

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>) δ 1.38 (s, 6H), 2.92 (s, 1H), 2.98 (d, 1H, J = 7.6 Hz), 4.31 (dd, 1H, J = 6.6, 3.2 Hz), 4.44 (m, 1H), 4.48 (t, 1H, 4.8 Hz), 4.63 (dd, 1H, J = 5.1, 1.3 Hz), 6.51 (t, 1H, J = 1.7 Hz)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>) δ 26.0 (CH<sub>3</sub>), 27.5 (CH<sub>3</sub>), 65.1 (CH), 69.1 (CH), 70.7 (CH), 75.1 (CH), 110.8 (C), 114.3 (C), 117.0 (C), 144.8 (CH)

**MS:** (EI, 70eV) m/z (rel. intensity) 212 (M<sup>+</sup>) (50), 196 (100), 184 (10), 136 (70)

**HRMS calcd for C<sub>10</sub>H<sub>14</sub>NO<sub>4</sub>:** 212.0923 **Found:** 221.0929 error + 2.8 ppm.

**Calcd for C<sub>10</sub>H<sub>14</sub>NO<sub>4</sub>** C 56.87% H 6.20% N 6.63% **Found** C 56.17% H 6.15% N 6.55%.

**(1S, 2S, 3S, 4R, 5S, 6S)-3,4-dihydroxy-1,2-epoxy-5,6-(isopropylidenedioxy)-1-phenylcyclohexane (173).**

To a cooled (0°C) and stirred solution of KMnO<sub>4</sub> (890 mg, 5.61 mmol), MgSO<sub>4</sub> (166 mg, 1.40 mmol), acetone (9.0 ml) and water (10 ml) was added (**14i**) in solution (196 mg, 0.86 mmol in 9.0 ml of acetone) over ten minutes. After fifteen minutes, sodium metabisulfite was added until the excess KMnO<sub>4</sub> was quenched. The reaction was warmed to room temperature. The brown reaction was then filtered through Celite and the solid residue was washed with water (20 ml) and acetone (20 ml). The solution was saturated with NaCl and was extracted with CHCl<sub>3</sub> (5 x 20 ml). The combined extracts were dried over MgSO<sub>4</sub> and concentrated under reduced pressure to yield 230 mg of a pale yellow oil. Chromatography (silica, gradient, CHCl<sub>3</sub>/MeOH 100:1, 60:1) yields 55 mg (23%) of a white crystalline material.

**R<sub>f</sub>:** 0.11 (CHCl<sub>3</sub>/MeOH 80:1)

**Mp:** 115 -117°C

**α<sub>D</sub><sup>25</sup>:** +84.2° (c = 0.66, CHCl<sub>3</sub>)

**IR:** (CHCl<sub>3</sub>) cm<sup>-1</sup> 3300, 2980, 1320, 1200

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>) δ 1.30 (s, 3H), 1.44 (s, 3H), 3.10 (d, 1H, J = 10.0 Hz), 3.19 (d, 1H, J = 12.0 Hz), 3.70 (s, 1H), 4.06 (brd, 1H, J = 11.8 Hz), 4.36 (dd, 1H, J = 9.8, 3.7 Hz), 4.61 (dd, 1H, J = 6.4, 2.7 Hz), 4.76 (dd, 1H, J = 6.3, 1.0 Hz), 7.35 (m, 3H), 7.43 (m, 2H)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>) δ 24.2 (CH<sub>3</sub>), 27.0 (CH<sub>3</sub>), 64.6 (CH), 64.8 (CH), 65.0 (C), 69.5 (CH), 73.2 (CH), 77.6 (CH), 109.5 (C), 127.5 (2 x CH), 128.3 (2 x CH), 128.6 (CH), 136.6 (C)

**MS:** (EI, 70ev) m/z (rel. intensity) 278 (M<sup>+</sup>) (2), 263 (14), 220 (70)

**Calcd. for C<sub>15</sub>H<sub>18</sub>O<sub>5</sub>:** C 64.74% H 6.52% **Found:** C 64.48% H 6.42%.

**(3R, 4R, 5S, 6S)-3,4-Dihydroxy-1-(ethynylphenyl)-5,6-(isopropylidenedioxy)-cyclohexene (174a).**

To a cooled (0 °C) and stirred solution of KMnO<sub>4</sub> (890 mg, 5.61 mmol), MgSO<sub>4</sub> (450 mg, 3.74 mmol), acetone (9.0 ml) and water (11.0 ml) was added (**14j**) in solution (472 mg, 1.87 mmol in 9.0 ml of acetone) over ten minutes. After fifteen minutes, sodium metabisulfite was added until the excess KMnO<sub>4</sub> was quenched. The reaction was warmed to room temperature. The brown reaction was then filtered through Celite and the solid residue was washed with water (20 ml) and acetone (20 ml). The solution was saturated with NaCl and was extracted with EtOAc (4 x 30 ml). The combined extracts were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Chromatography (silica, CHCl<sub>3</sub>/MeOH 20:1) yielded 30 mg of a colorless oil (6%).

**R<sub>f</sub>:** 0.20 (CHCl<sub>3</sub>/MeOH 20:1)

**α<sub>D</sub><sup>28</sup>:** -20.9° (c = 0.58, CHCl<sub>3</sub>)

**IR:** (CHCl<sub>3</sub>) cm<sup>-1</sup> 3416, 2928, 1745, 1679

**<sup>1</sup>H-NMR:** (CHCl<sub>3</sub>) δ 1.40 (s, 3H), 1.44 (s, 3H), 2.50 (s, 1H), 4.10 (dd, 1H, J = 4.6, 4.7 Hz), 4.42 (m, 2H), 4.68 (d, 1H, J = 5.3 Hz), 6.18 (d, 1H, J = 3.7 Hz), 7.29 (m, 3H), 7.45 (m, 2H)

**<sup>13</sup>C-NMR:** (CHCl<sub>3</sub>) δ 26.0 (CH<sub>3</sub>), 27.7 (CH<sub>3</sub>), 66.0 (CH), 70.3 (CH), 73.6 (CH), 75.4 (CH), 87.3 (C), 90.3 (C), 109.9 (C), 122.7 (CH), 128.2 (2 x CH), 128.5 (CH), 131.8 (CH), 134.9 (CH)

**MS:** (CI, 70 ev) m/z (rel. intensity) 286 (M<sup>+</sup>) (10), 269 (20), 211 (100), 183 (100).

**(1S, 2S, 3S, 4R, 5S, 6S)-3,4-Dihydroxy-1,2-epoxy-1-(ethynylphenyl)-5,6-(isopropylidenedioxy)-cyclohexane (174b).**

To a cooled (0 °C) and stirred solution of KMnO<sub>4</sub> (890 mg, 5.61 mmol), MgSO<sub>4</sub> (450 mg, 3.74 mmol), acetone (9.0 ml) and water (11.0 ml) was added (**14j**) in solution (472 mg, 1.87 mmol in 9.0 ml acetone) over ten minutes. After fifteen minutes, sodium metabisulfite was added until the excess KMnO<sub>4</sub> was quenched. The reaction was warmed to room temperature. The brown reaction was then filtered through Celite and

the solid residue was washed with water (20 ml) and acetone (20 ml). The solution was saturated with NaCl and was extracted with EtOAc (4 x 30 ml). The combined extracts were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Chromatography (silica, CHCl<sub>3</sub>/MeOH 20:1) yielded 80 mg of a pale yellow solid (14%).

**R<sub>f</sub>**: 0.25 (CHCl<sub>3</sub>/MeOH 20:1)

**Mp**: 123 -126 °C

**α<sub>D</sub><sup>25</sup>**: +98.3° (c = 0.48, CHCl<sub>3</sub>)

**IR**: (CHCl<sub>3</sub>) cm<sup>-1</sup> 3450, 3000, 2210, 1495, 1220

**<sup>1</sup>H-NMR**: (CHCl<sub>3</sub>) δ 1.38 (s, 3H), 1.48 (s, 3H), 2.66 (d, 1H, J = 12.2 Hz), 2.85 (d, 1H, J = 10.3 Hz), 3.81 (m, 1H), 4.07 (ddt, 1H, J = 12.2, 3.8, 1.4 Hz), 4.29 (ddd, 1H, J = 10.2, 4.0, 0.8 Hz), 4.54 (dd, 1H, J = 5.6, 3.6 Hz), 4.60 (dd, 1H, J = 5.6, 1.2 Hz), 7.30 (m, 3H), 7.47 (m, 2H)

**<sup>13</sup>C-NMR**: (CHCl<sub>3</sub>) δ 25.2 (CH<sub>3</sub>), 27.3 (CH<sub>3</sub>), 55.9 (C), 63.9 (CH), 65.6 (CH), 68.2 (CH), 71.6 (CH), 77.1 (CH), 84.2 (C), 85.6 (C), 110.3 (C), 121.5 (C), 128.2 (2 x CH), 129.0 (CH), 132.0 (2 x CH)

**MS**: (EI, 70 ev) m/z (rel. intensity) 302 (M<sup>+</sup>) (2), 287 (5), 244 (30), 185 (60)

**HRMS calcd for C<sub>17</sub>H<sub>19</sub>O<sub>5</sub>**: 303.1232 **Found**: 303.1222, error 3.2 ppm.

**(1S, 2S, 3S, 4R, 5S, 6S)-3,4-Dihydroxy-1,2-epoxy-5,6-(isopropylidenedioxy)-1-methylcyclohexane (175).**

To a cooled (0 °C) and stirred solution of KMnO<sub>4</sub> (656 mg, 4.15 mmol), MgSO<sub>4</sub> (350 mg, 2.90 mmol), acetone (8 ml) and water (9 ml) was added (**14g**) in solution (300 mg, 1.80 mmol in 5.0 ml acetone) over ten minutes. After fifteen minutes, sodium metabisulfite was added until the excess KMnO<sub>4</sub> was quenched. The reaction was warmed to room temperature. The brown reaction was then filtered through Celite and the solid residue was washed with water (20 ml) and acetone (20 ml). The solution was saturated with NaCl and was extracted with EtOAc (4 x 30 ml). The combined extracts were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Chromatography (silica, Hexane/EtOAc gradient; 2.5:1 -> 1:1) yielded 20 mg of a pale yellow solid (5%).

**R<sub>f</sub>**: 0.26 (CHCl<sub>3</sub>/MeOH 25:1)

**Mp**: 105 -107 °C

**α<sub>D</sub><sup>24</sup>**: +25.3° (c = 0.15, CHCl<sub>3</sub>)

**IR**: (CHCl<sub>3</sub>) cm<sup>-1</sup> 3455, 2987, 2934, 1380, 1165, 1100

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>) δ 1.32 (s, 3H), 1.39 (s, 3H), 1.42 (s, 3H), 2.96 (d, 1H, J = 10.2 Hz), 3.04 (d, 1H, J = 12.0 Hz), 3.35 (d, 1H, J = 1.1 Hz), 3.98 (dddd, 1H, J = 1.7, 3.7, 3.7, 12.1 Hz), 4.17 (dd, 1H, J = 4.0, 10.1 Hz), 4.36 (dd, 1H, J = 1.1, 6.0 Hz), 4.48 (dd, 1H, J = 3.4, 6.0 Hz)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>) δ 19.4 (CH<sub>3</sub>), 24.8 (CH<sub>3</sub>), 27.1 (CH<sub>3</sub>), 62.2 (C), 64.4 (CH), 65.2 (CH), 68.8 (CH), 73.3 (CH), 77.1 (CH), 109.5 (C)

**MS:** (EI, 70eV) m/z (rel. intensity) 201 (M-15) (100), 123 (90), 115 (20)

**HRMS calcd for C<sub>10</sub>H<sub>17</sub>O<sub>5</sub>:** 217.1076 **Found:** 217.1077 error + 0.7 ppm.

**(5S, 6S)-1-Bromo-6-hydroxy-5-(thexyldimethylsilyloxy)-cyclohexa-1,3-diene (191a).**

(190a) (7.0 g, 36.65 mmol) and imidazole (3.0 g, 43.97 mmol) were dissolved in CH<sub>2</sub>Cl<sub>2</sub> (80 ml). The flask was cooled to 0°C and thexyldimethylsilyl chloride (7.86 g, 43.97 mmol) was added dropwise. After 2 days at 0°C, the solution was concentrated under reduced pressure. Water (25 ml) and Et<sub>2</sub>O (150 ml) were added to the crude reaction mixture. The layers were separated and the aqueous layer was extracted with Et<sub>2</sub>O (3 x 50 ml). The Et<sub>2</sub>O extracts were combined, dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Chromatography (silica, Hexane/EtOAc, 25:1) yielded 11.48 g of a colorless oil (94%).

**R<sub>f</sub>:** 0.19 (Hexane/EtOAc, 10:1)

**[α]<sub>D</sub><sup>25</sup>:** +92.0° (c=0.79, CHCl<sub>3</sub>)

**IR:** (neat) cm<sup>-1</sup> 3550, 2975, 1600, 1440

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>) δ 0.14 (s, 3H), 0.15 (s, 3H), 0.85 (s, 6H), 0.87 (d, 3H, J = 1.8 Hz), 0.88 (d, 3H, J = 1.8 Hz), 1.62 (m, 1H), 2.74 (d, 1H, J = 4.5 Hz), 4.12 (dd, 1H, J = 4.6, 6.2 Hz), 4.54 (d, 1H, J = 6.1 Hz), 5.76 (d, 2H, J = 3.8 Hz), 6.34 (dd, 1H, J = 2.5, 4.1 Hz)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>) δ -3.0 (CH<sub>3</sub>), -2.5 (CH<sub>3</sub>), 18.5 (CH<sub>3</sub>), 18.6 (CH<sub>3</sub>), 20.1 (CH<sub>3</sub>), 20.3 (CH<sub>3</sub>), 25.0 (C), 34.1 (CH), 70.5 (CH), 72.6 (CH), 123.4 (CH), 125.6 (C), 126.8 (CH), 129.4 (CH)

**MS:** (CI, 70 eV) m/z (rel. intensity) 334 (M<sup>+</sup>+1) (0.5), 317 (12), 231 (50), 75 (100)

**Calcd for C<sub>14</sub>H<sub>25</sub>BrO<sub>2</sub>Si:** C 50.44% H 7.56% **Found:** C 50.23% H 7.47%.

**(5S, 6S)-1-Chloro-6-hydroxy-5-(hexyldimethylsilyloxy)-cyclohexa-1,3-diene (191b)** (92%).

**R<sub>f</sub>**: 0.33 (Hexane/EtOAc, 10:1)

**[α]<sub>D</sub><sup>25</sup>**: +58.7° (c=1.06, CHCl<sub>3</sub>)

**IR**: (neat) cm<sup>-1</sup> 3540, 2990, 1650, 1475

**<sup>1</sup>H-NMR**: (CDCl<sub>3</sub>) δ 0.14 (s, 3H), 0.15 (s, 3H), 0.85 (s, 6H), 0.87 (d, 3H, J = 1.8 Hz), 0.89 (d, 3H, J = 1.8 Hz), 1.62 (m, 1H), 2.76 (s, 1H), 4.03 (d, 1H, J = 6.3 Hz), 4.56 (m, 1H), 5.69 (dd, 1H, J = 2.9, 9.6 Hz), 5.85 (ddd, 1H, J = 2.0, 5.8, 9.6 Hz), 6.10 (d, 1H, J = 5.6 Hz)

**<sup>13</sup>C-NMR**: (CDCl<sub>3</sub>) δ -3.0 (CH<sub>3</sub>), -2.5 (CH<sub>3</sub>), 18.5 (CH<sub>3</sub>), 18.6 (CH<sub>3</sub>), 20.1 (CH<sub>3</sub>), 20.3 (CH<sub>3</sub>), 25.0 (C), 34.1 (CH), 70.6 (CH), 71.5 (CH), 122.7 (2xCH), 129.0 (CH), 134.6 (C).

**(5S, 6S)-1-Bromo-6-(2-ethoxymethoxy)-5-(hexyldimethylsilyloxy)-cyclohexa-1,3-diene (192a)**.

(191a) (11.08 g, 28.10 mmol) was dissolved in *i*-Pr<sub>2</sub>NEt (21.8 g, 168.60 mmol). After 5 minutes, chloromethyl ethylether (5.74 g, 60.69 mmol) was added dropwise over several minutes. The reaction was stirred at 0°C for 1 hour and then warmed to room temperature. After 2.5 hours, CH<sub>2</sub>Cl<sub>2</sub> (10 ml) was added to the heterogeneous reaction. The reaction was stirred for 1 hour and then diluted with water (50 ml) and Et<sub>2</sub>O (75 ml). The layers were separated and the aqueous layer was extracted with Et<sub>2</sub>O (3 x 50 ml). The organic extracts were combined, dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Chromatography (silica, Hexanes/EtOAc 20:1) yielded 12.32 g of a colorless oil (93%).

**R<sub>f</sub>**: 0.38 (Hexane/EtOAc, 10:1)

**[α]<sub>D</sub><sup>26</sup>**: +33.5° (c=1.00, CHCl<sub>3</sub>)

**IR**: (neat) cm<sup>-1</sup> 2990, 1600, 1580, 1260

**<sup>1</sup>H-NMR**: (CDCl<sub>3</sub>) δ 0.13 (s, 3H), 0.15 (s, 3H), 0.85 (s, 6H), 0.86 (d, 3H, J = 1.1 Hz), 0.88 (d, 3H, J = 1.1 Hz), 1.20 (t, 3H, J = 7.1 Hz), 1.64 (m, 1H), 3.49 (dq, 1H, J = 2.3, 7.0 Hz), 3.87 (dq, 1H, J = 2.3, 7.0 Hz), 4.04 (d, 1H, J = 5.8 Hz), 4.65 (m, 1H), 4.75 (d, 1H, J = 6.9 Hz), 4.87 (d, 1H, J = 6.9 Hz), 5.76 (ddd, 1H, J = 2.8, 5.6, 9.6 Hz), 5.84 (ddd, 1H, J = 1.1, 1.1, 9.7 Hz), 6.40 (d, 1H, J = 5.6 Hz)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>) δ -2.8 (CH<sub>3</sub>), -2.7 (CH<sub>3</sub>), 14.8 (CH<sub>3</sub>), 18.5 (CH<sub>3</sub>), 18.6 (CH<sub>3</sub>), 20.0 (CH<sub>3</sub>), 20.2 (CH<sub>3</sub>), 25.0 (C), 34.0 (CH), 63.5 (CH<sub>2</sub>), 72.6 (CH), 77.9 (CH), 95.5 (CH<sub>2</sub>), 122.2 (CH), 123.0 (C), 128.5 (CH), 132.6 (CH)

**MS:** (CI, 70 eV) m/z (rel. intensity) 391 (M<sup>+</sup>) (1), 317 (100), 259 (40), 231 (100)

**HRMS calcd for C<sub>17</sub>H<sub>31</sub>BrO<sub>3</sub>Si:** 390.1226 **Found:** 390.1246, error 5.1 ppm.

**(5S, 6S)-1-Chloro-6-(2-ethoxymethyloxy)-5-(hexyldimethylsilyloxy)-cyclohexa-1,3-diene (192b).**

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>) δ 0.12 (s, 3H), 0.14 (s, 3H), 0.85 (s, 6H), 0.86 (d, 3H, J = 1.1 Hz), 0.88 (d, 3H, J = 1.1 Hz), 1.19 (t, 3H, J = 7.0 Hz), 1.63 (m, 1H), 3.48 (dq, 1H, J = 2.3, 7.0 Hz), 3.83 (dq, 1H, J = 2.3, 7.0 Hz), 3.95 (d, 1H, J = 5.8 Hz), 4.65 (d, 1H, J = 5.8 Hz), 4.74 (d, 1H, J = 6.9 Hz), 4.86 (d, 1H, J = 6.9 Hz), 5.80 (m, 2H), 6.16 (d, 1H, J = 5.3 Hz).

**(1R, 7R, 8S, 9S)-1-Bromo-9-(2-ethoxymethyloxy)-4-phenyl-8-(hexyldimethylsilyloxy)-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (193a).**

**(192a)** (1.35 g, 3.46 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (16 ml). The flask was cooled to -50°C. In another flask triazoline (**20**) (637 mg, 3.63 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (12 ml). The triazoline solution was then added dropwise via cannula to the cold diol (**192a**) solution over 10 minutes. The reaction was then warmed to room temperature. After 20 minutes, the reaction was diluted with water (20 ml). The layers were separated and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 20 ml). The organic layers were combined, dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Chromatography (silica, Hexanes/EtOAc 8:1) yielded 1.74 g of a white foam (89%).

**R<sub>f</sub>:** 0.33 (Hexane/EtOAc 4:1)

**[α]<sub>D</sub><sup>26</sup>:** +83.3° (c=0.83, CHCl<sub>3</sub>)

**IR:** (CHCl<sub>3</sub>) cm<sup>-1</sup> 2995, 1790, 1735, 1608, 1509, 1410, 1265

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>) δ 0.19 (s, 3H), 0.26 (s, 3H), 0.85 (m, 12H), 1.24 (t, 3H, J = 7.0 Hz), 1.62 (m, 1H), 3.58 (dq, 1H, J = 2.3, 7.0 Hz), 4.11 (dq, 1H, J = 2.3, 7.0 Hz), 4.38 (dd, 1H, J = 0.8, 6.7 Hz), 4.47 (ddd, 1H, J = 0.8, 3.7, 6.7 Hz), 4.73 (d, 1H, J = 7.0 Hz), 4.77 (d, 1H, J = 7.1 Hz), 4.87 (ddd, 1H, J = 1.4, 3.7, 5.8 Hz), 6.34 (dd, 1H, J = 5.7, 8.5 Hz), 6.66 (d, 1H, J = 8.4 Hz), 7.41 (m, 5H)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>) δ -3.1 (CH<sub>3</sub>), -2.5 (CH<sub>3</sub>), 14.8 (CH<sub>3</sub>), 18.4 (CH<sub>3</sub>), 18.4 (CH<sub>3</sub>), 19.9 (CH<sub>3</sub>), 20.0 (CH<sub>3</sub>), 24.8 (C), 33.8 (CH), 53.5 (CH), 64.6 (CH<sub>2</sub>), 69.1 (CH), 69.7 (C), 78.8 (CH), 94.8 (CH<sub>2</sub>), 125.5 (2xCH), 128.5 (CH), 128.7 (CH), 129.0 (2xCH), 130.8 (C), 135.6 (CH), 153.7 (C), 154.3 (C)

**MS:** (CI, 70 eV) m/z (rel. intensity) 567 (M<sup>+</sup>+1) (1), 487 (5), 305 (45)

**Calcd for C<sub>25</sub>H<sub>36</sub>BrN<sub>3</sub>O<sub>5</sub>Si:** C 53.00% H 6.40% N 7.42% **Found:** C 53.03%  
H 6.39% N 7.39%.

**(1R, 7R, 8S, 9S)-1-Chloro-9-(2-ethoxymethoxy)-4-phenyl-8-(thexyldimethylsilyloxy)-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (193b) (76%).**

**R<sub>f</sub>:** 0.12 (Hexane/EtOAc 10:1)

**[α]<sub>D</sub><sup>24</sup>:** +79.6° (c=1.18, CHCl<sub>3</sub>)

**IR:** (CHCl<sub>3</sub>) cm<sup>-1</sup> 2960, 1738, 1716, 1504

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>) δ 0.15 (s, 3H), 0.24 (s, 3H), 0.83 (s, 6H), 0.84 (s, 3H), 0.88 (s, 3H), 1.22 (t, 3H, J = 7.0 Hz), 1.62 (m, 1H), 3.54 (dq, 1H, J = 2.3, 7.0 Hz), 4.00 (dq, 1H, J = 2.3, 7.0 Hz), 4.33 (dd, 1H, J = 0.8, 6.8 Hz), 4.48 (ddd, 1H, J = 0.8, 3.6, 7.7 Hz), 4.70 (d, 1H, J = 7.0 Hz), 4.74 (d, 1H, J = 7.0 Hz), 4.84 (ddd, 1H, J = 1.4, 3.6, 5.7 Hz), 6.40 (dd, 1H, J = 5.7, 8.5 Hz), 6.53 (d, 1H, J = 8.5 Hz), 7.40 (m, 5H)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>) δ -3.0 (CH<sub>3</sub>), -2.4 (CH<sub>3</sub>), 14.8 (CH<sub>3</sub>), 18.5 (CH<sub>3</sub>), 20.0 (CH<sub>3</sub>), 20.1 (CH<sub>3</sub>), 24.8 (C), 33.9 (CH), 53.8 (CH), 64.4 (CH<sub>2</sub>), 69.0 (CH), 76.5 (CH), 79.7 (C), 94.9 (CH<sub>2</sub>), 125.7 (2xCH), 128.6 (CH), 128.8 (CH), 129.1 (2xCH), 130.9 (C), 134.0 (CH), 153.9 (C), 154.8 (C)

**MS:** (CI, 70 eV) m/z (rel. intensity) 522 (M<sup>+</sup>) (100), 477 (50), 363 (80)

**HRMS calcd for C<sub>25</sub>H<sub>37</sub>ClN<sub>3</sub>O<sub>5</sub>Si:** 522.2191 **Found:** 522.2190, error 0.2 ppm.

**(1R, 7R, 8S, 9S)-1-Bromo-9-(2-ethoxymethoxy)-8-hydroxy-4-phenyl-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (194a).**

**(193a)** (1.08 g, 1.90 mmol) was dissolved in THF (45 ml). The reaction flask was cooled to -60°C and TBAF (2.2 ml of a 1M solution, 2.2 mmol) was added dropwise. The reaction was slowly warmed to -50°C over 1 hour, quenched with water (20 ml) and warmed to room temperature. Brine was added to the emulsion and the organic layer was



separated. The aqueous layer was extracted with EtOAc (4 x 25 ml). The organic layers were combined, dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Chromatography (silica, Hexanes/EtOAc 1.5:1) yielded 754 mg of a white foam (94%).

**R<sub>f</sub>**: 0.22 (Hexane/EtOAc 1:1)

**[α]<sub>D</sub><sup>25</sup>**: -87.9° (c=0.59, CHCl<sub>3</sub>)

**IR**: (CHCl<sub>3</sub>) cm<sup>-1</sup> 3500, 2490, 1790, 1735, 1410

**<sup>1</sup>H-NMR**: (CDCl<sub>3</sub>) δ 1.26 (t, 3H, J = 7.0 Hz), 3.13 (d, 1H, J = 5.6 Hz), 3.74 (q, 2H, J = 7.0 Hz), 3.74 (q, 2H, J = 7.0 Hz), 4.33 (dd, 1H, J = 1.0, 7.3 Hz), 4.46 (m, 1H), 4.96 (d, 1H, J = 6.4), 4.99 (d, 1H, J = 6.4 Hz), 5.11 (ddd, 1H, J = 1.5, 4.0, 5.6 Hz), 6.40 (ddd, 1H, J = 0.9, 5.6, 8.4 Hz), 6.62 (ddd, 1H, J = 1.2, 1.2, 8.5 Hz), 7.42 (m, 5H)

**<sup>13</sup>C-NMR**: (CDCl<sub>3</sub>) δ 15.0 (CH<sub>3</sub>), 53.2 (CH), 65.2 (CH<sub>2</sub>), 67.7 (CH), 69.4 (C), 78.7 (CH), 97.8 (CH<sub>2</sub>), 125.7 (2xCH), 128.6 (CH), 129.1 (2xCH), 129.6 (CH), 130.9 (C), 135.2 (CH), 154.0 (C), 154.5 (C)

**MS**: (CI, 70 eV) m/z (rel. intensity) 424 (M<sup>+</sup>+1) (1), 366 (10), 307 (70), 119 (100)

**Calcd for C<sub>17</sub>H<sub>18</sub>BrN<sub>3</sub>O<sub>5</sub>**: C 48.13% H 4.28% **Found**: C 48.20% H 4.31%.

**(1R, 7R, 8S, 9S)-1-Chloro-9-(2-ethoxymethoxy)-8-hydroxy-4-phenyl-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (194b)** (89%).

**R<sub>f</sub>**: 0.25 (Hexane/EtOAc 1:1)

**[α]<sub>D</sub><sup>29</sup>**: -64.2° (c=1.10, CHCl<sub>3</sub>)

**IR**: (CHCl<sub>3</sub>) cm<sup>-1</sup> 3500, 2495, 1788, 1730, 1407

**<sup>1</sup>H-NMR**: (CDCl<sub>3</sub>) δ 1.23 (t, 3H, J = 7.2 Hz), 3.12 (d, 1H, J = 5.8 Hz), 3.70 (q, 2H, J = 7.0 Hz), 4.30 (dd, 1H, J = 1.0, 7.4 Hz), 4.45 (m, 1H), 4.91 (d, 1H, J = 6.6 Hz), 4.96 (d, 1H, J = 6.6 Hz), 5.08 (ddd, 1H, J = 1.7, 3.8, 5.5 Hz), 6.46 (ddd, 1H, J = 0.9, 5.5, 8.4 Hz), 6.50 (ddd, 1H, J = 1.1, 1.7, 8.4 Hz), 7.39 (m, 5H)

**<sup>13</sup>C-NMR**: (CDCl<sub>3</sub>) δ 15.0 (CH<sub>3</sub>), 53.4 (CH), 65.2 (CH<sub>2</sub>), 67.4 (CH), 77.9 (CH), 79.3 (C), 97.6 (CH<sub>2</sub>), 125.7 (2xCH), 128.7 (CH), 129.1 (2xCH), 129.6 (CH), 129.0 (C), 133.9 (CH), 154.0 (C), 154.9 (C)

**MS**: (CI, 70 eV) m/z (rel. intensity) 380 (M<sup>+</sup>+1) (50), 334 (50), 261 (50)

**HRMS calcd for C<sub>17</sub>H<sub>19</sub>ClN<sub>3</sub>O<sub>5</sub>**: 380.1013 **Found**: 380.1001, error 3.3 ppm.

**(1R, 7R, 8R, 9S)-1-Bromo-9-(2-ethoxymethoxy)-8-hydroxy-4-phenyl-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (196a).**

(194a) (506 mg, 1.2 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (13 ml). The reaction mixture was cooled to 0°C. Pyridine (650 mg, 7.74 mmol) and triflic anhydride (839 mg, 3.0 mmol) were then added dropwise. After 1.5 hours, water (8 ml) was added and the reaction mixture was warmed to room temperature. The layers were separated and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (4 x 30 ml). The organic layers were combined, dried over MgSO<sub>4</sub> and concentrated under reduced pressure to yield 700 mg of the corresponding crude triflate as a foam.

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>) δ 1.25 (t, 3H, J = 6.9 Hz), 3.74 (dq, 1H, J = 2.1, 7.1 Hz), 3.86 (dq, 1H, J = 2.1, 7.1 Hz), 4.49 (d, 1H, J = 6.9 Hz), 4.93 (d, 1H, J = 6.6 Hz), 5.01 (d, 1H, J = 6.6 Hz), 5.25 (m, 1H), 5.49 (dd, 1H, J = 4.0, 6.6 Hz), 6.38 (dd, 1H, J = 5.8, 8.5 Hz), 6.81 (d, 1H, J = 8.5 Hz), 7.44 (m, 5H).

The crude triflate (700 mg), 18-crown-6 (1.26 g, 4.77 mmol) and cesium acetate (915 mg, 4.77 mmol) were dissolved in DMF (19.8 ml). The reaction mixture was heated to 70°C. After 15 minutes, the reaction was cooled to room temperature and diluted with water (15 ml) and EtOAc (45 ml). The layers were separated and the aqueous layer was extracted with EtOAc (3 x 45 ml). The organic layers were combined, dried over MgSO<sub>4</sub> and concentrated under reduced pressure to yield 596 mg of the crude acetate.

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>) δ 1.16 (t, 3H, J = 7.0 Hz), 2.10 (s, 3H), 3.60 (q, 2H, J = 7.0 Hz), 4.15 (s, 1H), 4.79 (d, 1H, J = 7.1 Hz), 4.87 (d, 1H, J = 7.1 Hz), 4.90 (m, 1H), 5.10 (dd, 1H, J = 2.4, 6.3 Hz), 6.49 (dd, 1H, J = 6.4, 8.3 Hz), 6.61 (d, 1H, J = 8.3 Hz), 7.40 (m, 5H).

The crude acetate was placed in a flask followed by 95% EtOH (40 ml) and K<sub>2</sub>CO<sub>3</sub> (1.59 g). After 2.5 hours of vigorous stirring, the reaction was diluted with water (15 ml) and CHCl<sub>3</sub> (45 ml). The layers were separated and the aqueous layer was extracted with CHCl<sub>3</sub> (3 x 45 ml). The organic layers were combined, dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Chromatography (silica, Hexanes/EtOAc 1:1) yielded 475 mg of a white foam (94%).

**R<sub>f</sub>:** 0.20 (Hexane/EtOAc 1:1)

**[α]<sub>D</sub><sup>25</sup>:** +50.3° (c=0.90, CH<sub>3</sub>OH)

**IR:** (CHCl<sub>3</sub>) cm<sup>-1</sup> 3440 (br), 2995, 1780, 1720, 1600, 1500

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>) δ 1.22 (t, 3H, J = 7.0 Hz), 3.21 (d, 1H, J = 5.6 Hz), 3.684 (q, 1H, J = 7.0 Hz), 3.687 (q, 1H, J = 7.0 Hz), 3.87 (m, 1H), 3.94 (s, 1H), 4.84 (s, 2H), 4.95 (dd, 1H, J = 2.7, 5.6 Hz), 6.41 (dd, 1H, J = 6.2, 8.4 Hz), 6.54 (d, 1H, J = 8.4 Hz), 7.39 (m, 5H)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>) δ 14.9 (CH<sub>3</sub>), 56.3 (CH), 64.4 (CH<sub>2</sub>), 68.4 (C), 74.9 (CH), 83.4 (CH), 95.4 (CH<sub>2</sub>), 126.0 (2xCH), 128.2 (CH), 128.7 (CH), 129.1 (2xCH), 131.0 (C), 136.4 (CH), 153.4 (C), 155.5 (C)

**MS:** (CI, 70 eV) m/z (rel. intensity) 424 (M<sup>++</sup>) (1), 366 (14), 305 (60)

**Calcd for C<sub>17</sub>H<sub>18</sub>BrN<sub>3</sub>O<sub>5</sub>:** C 48.13% H 4.28% **Found:** C 48.41% H 4.48%.

**(1R, 7R, 8R, 9S)-1-Chloro-9-(2-ethoxymethoxy)-8-hydroxy-4-phenyl-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (196b)** (86%).

**R<sub>f</sub>:** 0.22 (Hexane/EtOAc 1:1)

**[α]<sub>D</sub><sup>26</sup>:** -51.8° (c=1.03, CHCl<sub>3</sub>)

**IR:** (CHCl<sub>3</sub>) cm<sup>-1</sup> 3445 (br), 2976, 1770, 1716, 1698, 1503

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>) δ 1.20 (t, 3H, J = 7.0 Hz), 3.64 (m, 2H), 3.83 (m, 1H), 3.94 (s, 1H), 4.82 (d, 1H, J = 7.0 Hz), 4.84 (d, 1H, J = 7.0 Hz), 4.94 (ddd, 1H, J = 1.5, 2.8, 5.1 Hz), 6.41 (d, 1H, J = 7.9 Hz), 6.46 (dd, 1H, J = 6.0, 8.4 Hz), 7.40 (m, 5H)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>) δ 14.8 (CH<sub>3</sub>), 56.4 (CH), 64.2 (CH<sub>2</sub>), 74.8 (CH), 79.2 (C), 82.8 (CH), 95.3 (CH<sub>2</sub>), 125.9 (2xCH), 128.0 (CH), 128.7 (CH), 129.1 (2xCH), 130.9 (C), 135.0 (CH), 153.4 (C), 155.8 (C)

**MS:** (CI, 70 eV) m/z (rel. intensity) 380 (M<sup>++</sup>) (40), 316 (80), 304 (80), 261 (70)

**HRMS calcd for C<sub>17</sub>H<sub>19</sub>ClN<sub>3</sub>O<sub>5</sub>:** 380.1013 **Found:** 380.1000, error 3.8 ppm.

**(1R, 7R, 8R, 9S)-1-Bromo-8-(t-butyldimethylsilyloxy)-9-(2-ethoxymethoxy)-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (199a).**

(196a) (580 mg, 1.37 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (13 ml). The reaction was cooled to 0°C. 2,6-Lutidine (732 mg, 6.84 mmol) and t-butyldimethylsilyl chloride ( 1.08 g, 4.10 mmol) were added dropwise. After 4 hours, water (15 ml) was added and the reaction was warmed to room temperature. The layers were separated and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 50 ml). The organic layers were combined, dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Chromatography (silica, gradient: Hexanes/EtOAc 10:1->5:1) yielded 662 mg of white solid (90%).

**R<sub>f</sub>:** 0.27 (Hexane/EtOAc 4:1)

**Mp:** 137–138° C

**[α]<sub>D</sub><sup>26</sup>:** +68.4° (c=0.90, CHCl<sub>3</sub>)

**IR:** (CHCl<sub>3</sub>) cm<sup>-1</sup> 2910, 1770, 1715, 1590, 1395, 1250

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>) δ 0.12 (s, 3H), 0.13 (s, 3H), 0.84 (s, 9H), 1.21 (t, 3H, J = 7.0 Hz), 3.68 (m, 2H), 3.96 (dd, 1H, J = 0.9, 3.0 Hz), 4.03 (s, 1H), 4.82 (ddd, 1H, J = 1.2, 2.9, 8.9 Hz), 4.89 (s, 2H), 6.45 (dd, 1H, J = 6.3, 8.4 Hz), 6.54 (ddd, 1H, J = 1.0, 1.1, 8.2 Hz), 7.32 (m, 1H), 7.44 (m, 4H)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>) δ -5.0 (CH<sub>3</sub>), -4.5 (CH<sub>3</sub>), 14.9 (CH<sub>3</sub>), 18.0 (C), 25.6 (3xCH<sub>3</sub>), 56.4 (CH), 64.6 (CH<sub>2</sub>), 68.0 (C), 76.2 (CH), 84.4 (CH), 95.8 (CH<sub>2</sub>), 125.5 (2xCH), 128.1 (CH), 128.3 (CH), 128.9 (2xCH), 131.4 (C), 137.0 (CH), 152.4 (C), 153.7 (C)

**MS:** (CI, 70 eV) m/z (rel. intensity) 540 (M<sup>+</sup>+1) (40), 492 (40), 464 (100), 406 (50)

**HRMS calcd for C<sub>23</sub>H<sub>33</sub>BrN<sub>3</sub>O<sub>5</sub>Si:** 538.1372 **Found:** 538.1357, error 2.90 ppm

**Calcd for C<sub>23</sub>H<sub>32</sub>BrN<sub>3</sub>O<sub>5</sub>Si:** C 51.30% H 5.99% N 7.80% **Found:** C 51.47%  
H 6.09% N 7.73%.

**(1R, 7R, 8R, 9S)-1-Chloro-8-(t-butyltrimethylsilyloxy)-9-(2-ethoxymethoxy)-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (199b)** (86%).

**R<sub>f</sub>:** 0.22 (Hexane/EtOAc 4:1)

**Mp:** 137–138° C

**[α]<sub>D</sub><sup>29</sup>:** +35.1° (c=1.13, CHCl<sub>3</sub>)

**IR:** (CHCl<sub>3</sub>) cm<sup>-1</sup> 3019, 2930, 1775, 1720, 1600, 1403

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>) δ 0.13 (s, 6H), 0.87 (s, 9H), 1.21 (t, 3H, J = 7.0 Hz), 3.66 (m, 2H), 3.93 (dd, 1H, J = 0.9, 2.9 Hz), 3.99 (s, 1H), 4.81 (ddd, 1H, J = 1.3, 3.0, 6.2 Hz), 4.87 (d, 1H, J = 6.7 Hz), 4.90 (d, 1H, J = 6.7 Hz), 6.41 (d, 1H, J = 8.4 Hz), 6.51 (dd, 1H, J = 6.3, 8.4 Hz), 7.33 (m, 1H), 7.44 (m, 4H)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>) δ -5.0 (CH<sub>3</sub>), -4.5 (CH<sub>3</sub>), 14.8 (CH<sub>3</sub>), 17.9 (C), 25.6 (3xCH<sub>3</sub>), 56.4 (CH), 64.4 (CH<sub>2</sub>), 76.0 (CH), 79.0 (C), 83.9 (CH), 95.8 (CH<sub>2</sub>), 125.5 (2xCH), 128.0 (CH), 128.1 (CH), 128.9 (2xCH), 131.3 (C), 135.5 (CH), 152.6 (C), 154.2 (C)

**MS:** (CI, 70 eV) m/z (rel. intensity) 495 (M<sup>+</sup>+1) (50), 418 (100), 362 (60), 316 (60)

**HRMS calcd for C<sub>23</sub>H<sub>33</sub>ClN<sub>3</sub>O<sub>5</sub>Si:** 494.1878 **Found:** 494.1866, error 2.5 ppm.

**(5R, 6S)-1-Bromo-5-(*t*-butyldimethylsilyloxy)-6-(2-ethoxymethyloxy)-1,3-cyclohexadiene (200a).**

(199a) (65 mg, 0.12 mmol) was dissolved in collidine (1 ml) and heated to 175°C. After 12 hours, the reaction was cooled to room temperature and diluted with a Hexane/EtOAc solution (20:1; 2 ml). Chromatography (silica, Hexane/EtOAc 20:1) of the solution yielded 4.5 mg of a colorless oil (10% conversion, 22% based on recovered starting material).

**R<sub>f</sub>**: 0.29 (Hexanes/EtOAc 25:1)

**[α]<sub>D</sub><sup>24</sup>**: - 220.5° (c=0.19, CHCl<sub>3</sub>)

**IR**: (neat) cm<sup>-1</sup> 2928, 1471, 1110, 1030

**<sup>1</sup>H-NMR**: (CDCl<sub>3</sub>) δ 0.81 (s, 3H), 0.10 (s, 3H), 0.87 (s, 9H), 1.22 (t, 3H, J = 7.0 Hz), 3.61 (dq, 1H, J = 2.4, 7.0 Hz), 3.78 (dq, 1H, J = 2.4, 7.0 Hz), 4.28 (d, 1H, J = 3.8 Hz), 4.36 (dd, 1H, J = 3.9, 3.9 Hz), 4.82 (s, 2H), 5.88 (m, 2H), 6.41 (d, 1H, J = 5.3 Hz)

**<sup>13</sup>C-NMR**: (CDCl<sub>3</sub>) δ -4.6 (CH<sub>3</sub>), -4.3 (CH<sub>3</sub>), 15.0 (CH<sub>3</sub>), 25.8 (3 x CH<sub>3</sub>), 64.0 (CH<sub>2</sub>), 70.6 (CH), 81.1 (CH), 94.6 (CH<sub>2</sub>), 123.2 (C), 123.9 (CH), 127.5 (CH), 127.7 (CH)

**MS**: (CI, 70 eV) m/z (rel. intensity) 362 (M<sup>+</sup>+1) (5), 287 (25), 177 (40), 89 (100)

**HRMS calcd for C<sub>15</sub>H<sub>27</sub>BrO<sub>3</sub>Si**: 362.0913 **Found**: 362.0894, error 5.2 ppm.

**(5R,6S)-5-(*t*-Butyldimethylsilyloxy)-1-chloro-6-(2-ethoxymethyloxy)-1,3-cyclohexadiene (200b).**

(199b) (30 mg, 0.06 mmol) was dissolved in 2N KOH/95% EtOH solution. After 3 hours, the reaction was diluted with cold water (10 ml) and CH<sub>2</sub>Cl<sub>2</sub> (20 ml). The layers were separated and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 10 ml). The combined organic layer was dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Chromatography (silica, Hexane/EtOAc 25:1) yielded 11 mg of a colorless oil (57%).

**R<sub>f</sub>**: 0.29 (Hexanes/EtOAc 25:1)

**[α]<sub>D</sub><sup>29</sup>**: +35.0° (c=1.13, CHCl<sub>3</sub>)

**IR**: (neat) cm<sup>-1</sup> 2930, 1585, 1255, 1215

**<sup>1</sup>H-NMR**: (CDCl<sub>3</sub>) δ 0.80 (s, 3H), 0.11 (s, 3H), 0.87 (s, 9H), 1.22 (t, 3H, J = 7.0 Hz), 3.61 (dq, 1H, J = 2.4, 7.0 Hz), 3.76 (dq, 1H, J = 2.4, 7.0 Hz), 4.18 (d, 1H, J = 3.8 Hz), 4.36 (dd, 1H, J = 4.1, 4.2 Hz), 4.82 (s, 2H), 5.83 (dd, 1H, J = 4.6, 9.5 Hz), 5.93 (dd, 1H, J = 6.0, 9.5 Hz), 6.17 (d, 1H, J = 6.0 Hz)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>) δ -4.6 (2xCH<sub>3</sub>), 18.1 (C), 25.8 (4xCH<sub>3</sub>), 63.8 (CH<sub>2</sub>), 70.6 (CH), 79.9 (CH), 94.5 (CH<sub>2</sub>), 123.3 (CH), 123.4 (CH), 127.2 (CH), 132.8 (C)  
**MS:** (CI, 70 eV) m/z (rel. intensity) 318 (M<sup>+1</sup>) (10), 259 (25), 103 (40)  
**HRMS calcd for C<sub>15</sub>H<sub>27</sub>ClO<sub>3</sub>Si:** 318.1418 **Found:** 318.1422, error 1.3 ppm.

**(5R, 6R)-5-(t-Butyldimethylsilyloxy)-6-(2-ethoxymethoxy)-1,3-cyclohexadiene (200c).**

In a dry flask under argon, (**199a**) (45 mg, 0.08 mmol) was dissolved in degassed 2N KOH/95% EtOH solution. After 40 minutes, the reaction was diluted with cold water (10 ml) and CH<sub>2</sub>Cl<sub>2</sub> (20 ml). The layers were separated and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 10 ml). The combined organic layer was dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Chromatography (silica, Hexane/EtOAc 10:1) yielded 12.3 mg of a colorless oil (51%).

**R<sub>f</sub>:** 0.29 (Hexane/EtOAc, 25:1)

**[α]<sub>D</sub><sup>24</sup>:** -192.24° (c=0.76, CHCl<sub>3</sub>)

**IR:** (neat) cm<sup>-1</sup> 3050, 2960, 2860, 1473, 1406, 1258

**<sup>1</sup>H-NMR:** (CDCl<sub>3</sub>) δ 0.7 (s, 6H), 0.90 (s, 9H), 1.20 (t, 3H, J = 7.1 Hz), 3.59 (dq, 1H, J = 2.5, 7.1 Hz), 3.70 (dq, 1H, J = 2.5, 7.1 Hz), 4.40 (d, 1H, J = 10.5 Hz), 4.53 (dd, 1H, J = 1.8, 10.5 Hz), 4.79 (s, 2H), 5.80 (m, 3H)

**<sup>13</sup>C-NMR:** (CDCl<sub>3</sub>) δ -4.6 (CH<sub>3</sub>), 15.1 (CH<sub>3</sub>), 18.3 (C), 25.8 (CH<sub>3</sub>), 63.3 (CH<sub>2</sub>), 73.1 (CH), 79.7 (CH), 95.1 (CH<sub>2</sub>), 123.4 (CH), 124.2 (CH), 129.1 (CH), 131.7 (CH)

**MS:** (CI, 70 eV) m/z (rel. intensity) 284 (M<sup>+1</sup>) (20), 225 (40), 209 (30), 151 (80)

**HRMS calcd for C<sub>15</sub>H<sub>28</sub>O<sub>3</sub>Si:** 284.1808 **Found:** 284.1813, error 1.8 ppm.

**Calcd for C<sub>15</sub>H<sub>28</sub>O<sub>3</sub>Si:** C 63.33% H 9.92% **Found:** C 63.46% H 10.01%.

**Isopropyl 2-hydroxy-3,4-methylenedioxy-benzoate (216a).**

TMP (4.92 g, 34.8 mmol) was dissolved in THF (60 ml). n-BuLi (34.8 mmol) was then added dropwise at such a rate that refluxing did not occur. After the addition was complete, the LiTMP solution was stirred for another 10 minutes. In another dry flask, the (**215**) (4.83 g, 23.2 mmol) and trimethyl borate (3.86 g, 37.1 mmol) were dissolved in THF (115 ml). Both flasks were then cooled to -78°C and the LiTMP solution was added over 10 minutes (via cannula) to the (**215**) solution. The solution was stirred at -78°C for

45 minutes and then warmed to 0°C. After 45 minutes, acetic acid (3 ml) and 30% H<sub>2</sub>O<sub>2</sub> (6 ml) were added. The reaction was warmed to room temperature and stirred for 18 hours. The reaction solution was then washed with a saturated solution of NH<sub>4</sub>Cl containing 10% ferric ammonium sulfate (2 x 50 ml). The organic layer was washed with brine (1 x 100 ml), dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Chromatography (silica, Hexane/EtOAc 20:1) yielded 4.29 g of a white solid (83%).

**R<sub>f</sub>**: 0.15 (Hexane/EtOAc, 10:1)

**Mp**: 71.5–72.5° C

**IR**: (KBr) cm<sup>-1</sup> 2990, 1680, 1470, 1290

**<sup>1</sup>H-NMR**: (CDCl<sub>3</sub>) δ 1.35 (d, 6H, J = 6.3 Hz), 5.24 (heptet, 1H, J = 6.3 Hz), 6.42 (d, 1H, J = 8.0 Hz), 7.46 (d, 1H, J = 8.0 Hz), 10.88 (s, 1H)

**<sup>13</sup>C-NMR**: (CDCl<sub>3</sub>) δ 21.8 (2 x CH<sub>3</sub>), 69.1 (CH), 100.7 (CH), 102.3 (CH<sub>2</sub>), 109.7 (C), 126.1 (CH), 134.2 (C), 146.0 (C), 153.3 (C), 169.4 (C)

**MS**: (EI, 70 eV) m/z (rel. intensity) 224 (M<sup>+</sup>) (10), 164 (100), 106 (20)

**Calcd for C<sub>11</sub>H<sub>12</sub>O<sub>5</sub>**: C 58.93% H 5.39% **Found**: C 59.10% H 5.39%.

### **Isopropyl 2-(2-ethoxymethoxy)-3,4-methylenedioxy-benzoate (216b).**

(**216a**) (4.09 g, 18.24 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and cooled to 0°C. EtNiPr<sub>2</sub> (7.50 g, 58.4 mmol) and chloromethyl ethylether (4.31 g, 45.6 mmol) were then added sequentially and the reaction was stirred. After 3 hours, the reaction was warmed to room temperature and stirred for 10 hours. The reaction was then diluted with water (100 ml). The layers were separated and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 50 ml). The combined organic layers were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. Chromatography (silica, gradient: Hexane/EtOAc 20:1 -> 10:1) yielded 5.05 g of a colorless oil (98%).

**R<sub>f</sub>**: 0.33 (Hexane/EtOAc, 10:1)

**IR**: (CHCl<sub>3</sub>) cm<sup>-1</sup> 2995, 1715, 1625, 1605, 1470, 1355

**<sup>1</sup>H-NMR**: (CDCl<sub>3</sub>) δ 1.29 (t, 3H, J = 7.0 Hz), 1.31 (d, 6H, J = 6.3 Hz), 3.20 (q, 2H, J = 7.0 Hz), 5.18 (heptet, 1H, J = 6.3 Hz), 5.28 (s, 2H), 5.95 (s, 2H), 6.58 (d, 1H, J = 8.4 Hz), 7.42 (d, 1H, J = 8.4 Hz)

**<sup>13</sup>C-NMR**: (CDCl<sub>3</sub>) δ 15.0 (CH<sub>3</sub>), 21.9 (2 x CH<sub>3</sub>), 65.0 (CH<sub>2</sub>), 68.1 (CH), 96.6 (CH<sub>2</sub>), 101.8 (CH<sub>2</sub>), 103.6 (CH), 119.3 (C), 126.3 (CH), 139.2 (C), 140.5 (C), 152.0 (C), 164.8 (C)

**MS:** (EI, 70 eV) *m/z* (rel. intensity) 282 ( $M^+$ ) (5), 210 (10), 164 (100), 106 (15)

**Calcd for  $C_{14}H_{18}O_6$ :** C 59.57% H 6.43% **Found:** C 59.36% H 6.44%.

**Isopropyl 2-(2-ethoxymethoxy)-6-hydroxy-3,4-methylenedioxy-benzoate (217).**

TMP (3.81 g, 27.0 mmol) was dissolved in THF (40 ml). *n*-BuLi (27.0 mmol) was then added dropwise at such a rate that refluxing did not occur. After the addition was complete, the LiTMP solution was stirred for another 10 minutes. In another dry flask, (**216b**) (4.77 g, 16.9 mmol) and trimethyl borate (2.98 g, 28.7 mmol) were dissolved in THF (85 ml). Both flasks were then cooled to  $-78^\circ\text{C}$  and the LiTMP solution was added over 10 minutes (via cannula) to the (**216b**) solution. The solution was stirred at  $-78^\circ\text{C}$  for 45 minutes and then warmed to  $0^\circ\text{C}$ . After 45 minutes, acetic acid (3 ml) and 30%  $\text{H}_2\text{O}_2$  (6 ml) were added. The reaction was then warmed to room temperature and stirred for 18 hours. The reaction solution was washed with a saturated solution of  $\text{NH}_4\text{Cl}$  containing 10% ferric ammonium sulfate (2 x 50 ml). The organic layer was washed with brine (1 x 100 ml), dried over  $\text{MgSO}_4$  and concentrated under reduced pressure. Chromatography (silica, Hexanes/EtOAc 20:1) yielded 3.28 g of a pale yellow oil (65%) which crystallized upon standing.

**R<sub>f</sub>:** 0.45 (Hexane/EtOAc, 1:1)

**Mp:** 62–63° C

**IR:** ( $\text{CHCl}_3$ )  $\text{cm}^{-1}$  3350, 2995, 1705, 1640, 1460

**$^1\text{H-NMR}$ :** ( $\text{CDCl}_3$ )  $\delta$  1.21 (t, 1H,  $J = 7.2$  Hz), 1.31 (d, 6H,  $J = 6.3$  Hz), 3.84 (q, 2H,  $J = 7.1$  Hz), 5.17 (hp, 1H,  $J = 6.3$  Hz), 5.18 (s, 2H), 5.98 (s, 2H), 6.01 (brs, 1H), 7.05 (s, 1H)

**$^{13}\text{C-NMR}$ :** ( $\text{CDCl}_3$ )  $\delta$  14.9 ( $\text{CH}_3$ ), 21.9 (2 x  $\text{CH}_3$ ), 65.1 ( $\text{CH}_2$ ), 68.5 (CH), 97.2 ( $\text{CH}_2$ ), 102.5 ( $\text{CH}_2$ ), 114.5 (CH), 118.7 (C), 134.8 (C), 135.3 (C), 138.9 (C), 140.9 (C), 164.9 (C)

**MS:** (CI, 70 eV) *m/z* (rel. intensity) 299 ( $M^{+1}$ ) (12), 269 (10), 240 (50), 180 (60)

**HRMS calcd for  $C_{14}H_{18}O_7$ :** 299.1131 **Found:** 299.1139, error 2.8 ppm

**Calcd for  $C_{14}H_{18}O_7$ :** C 56.37% H 6.08% **Found:** C 56.48% H 6.10%.



## VI. SELECTED SPECTRA

1. (1'R, 4'R, 5'S, 6'S)-Spiro-[2,5-cyclohexadiene-4-one-1'-chloro-5',6'-(isopropylidenedioxy)-1,3'-[2]-oxabicyclo[2.2.2]oct-7'-ene] (**163a**).  

$^1\text{H-NMR}$ , $^{13}\text{C-NMR}$	123
IR, MS	124
HETCOR	125
2. (1S, 2S, 3S, 4S, 4aR, 8aS)-1-Chloro-1,4-etheno-2,3-(isopropylidenedioxy)-1,2,3,4,4a,8a-hexahydro-naphthalene-5,8-dione (**164**).  

$^1\text{H-NMR}$ , $^{13}\text{C-NMR}$	126
IR, MS	127
3. (1S, 2S, 3S, 4S, 4aR, 9aS)-1-Chloro-1,4-etheno-2,3-(isopropylidenedioxy)-1,2,3,4,4a,9a-hexahydro-anthracene-9,10-dione (**165**).  

$^1\text{H-NMR}$ , $^{13}\text{C-NMR}$	128
IR, MS	129
4. (1R, 2S, 3S, 4R)-1-Chloro-1,4-etheno-2,3-(isopropylidenedioxy)-1,2,3,4-tetrahydro-naphthalene (**167**).  

$^1\text{H-NMR}$ , $^{13}\text{C-NMR}$	130
IR, MS	131
5. (3aR, 4S, 5S, 7aS)-6-Chloro-4,5-(isopropylidenedioxy)-3-methyl-3a, 4, 5, 7a-tetrahydro-1,2-benzisoxazole (**169**).  

$^1\text{H-NMR}$ , $^{13}\text{C-NMR}$	132
IR, MS	133
6. (3R, 4R, 5S, 6S)-1-Cyano-3,4-dihydroxy-5,6-(isopropylidenedioxy)-1,2-cyclohexene (**172a**).  

$^1\text{H-NMR}$ , $^{13}\text{C-NMR}$	134
--	-----
7. (1S, 2S, 3S, 4R, 5S, 6S)-3,4-dihydroxy-1,2-epoxy-5,6-(isopropylidenedioxy)-1-phenylcyclohexane (**173**).  

$^1\text{H-NMR}$ , $^{13}\text{C-NMR}$	135
--	-----

8. (3R, 4R, 5S, 6S)-3,4-Dihydroxy-1-(ethynylphenyl)-5,6-(isopropylidenedioxy)-cyclohexene (**174a**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 136
9. (1S, 2S, 3S, 4R, 5S, 6S)-3,4-Dihydroxy-1,2-epoxy-1-(ethynylphenyl)-5,6-(isopropylidenedioxy)-cyclohexane (**174b**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 137
10. (1S, 2S, 3S, 4R, 5S, 6S)-3,4-Dihydroxy-1,2-epoxy-5,6-(isopropylidenedioxy)-1-methylcyclohexane (**175**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 138
11. 5S, 6S)-1-Bromo-6-hydroxy-5-(thexyldimethylsilyloxy)-cyclohexa-1,3-diene (**191a**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 139
12. (5S, 6S)-1-Bromo-6-(2-ethoxymethyloxy)-5-(thexyldimethylsilyloxy)-cyclohexa-1,3-diene (**192a**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 140
13. (1R, 7R, 8S, 9S)-1-Bromo-9-(2-ethoxymethyloxy)-4-phenyl-8-(thexyldimethylsilyloxy)-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (**193a**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 141
14. 1R, 7R, 8S, 9S)-1-Chloro-9-(2-ethoxymethyloxy)-4-phenyl-8-(thexyldimethylsilyloxy)-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (**193b**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 142  
 IR, MS 143
15. (1R, 7R, 8S, 9S)-1-Bromo-9-(2-ethoxymethyloxy)-8-hydroxy-4-phenyl-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (**194a**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 144



16. (1R, 7R, 8S, 9S)-1-Chloro-9-(2-ethoxymethyloxy)-8-hydroxy-4-phenyl-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (**194b**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 145
17. (1R, 7R, 8R, 9S)-1-Bromo-9-(2-ethoxymethyloxy)-8-hydroxy-4-phenyl-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (**196a**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 146
18. (1R, 7R, 8R, 9S)-1-Chloro-9-(2-ethoxymethyloxy)-8-hydroxy-4-phenyl-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (**196b**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 147
19. (1R, 7R, 8R, 9S)-1-Bromo-8-(t-butyldimethylsilyloxy)-9-(2-ethoxymethyloxy)-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (**199a**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 148
20. (1R, 7R, 8R, 9S)-1-Chloro-8-(t-butyldimethylsilyloxy)-9-(2-ethoxymethyloxy)-2,4,6-triazolotricyclo-[5.2.2.0]-undec-10-ene-3,5-dione (**199b**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 149
21. (5R, 6S)-1-Bromo-5-(t-butyldimethylsilyloxy)-6-(2-ethoxymethyloxy)-1,3-cyclohexadiene (**200a**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 150
22. (5R, 6S)-5-(t-Butyldimethylsilyloxy)-1-chloro-6-(2-ethoxymethyloxy)-1,3-cyclohexadiene (**200b**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 151
23. (5R, 6R)-5-(t-Butyldimethylsilyloxy)-6-(2-ethoxymethyloxy)-1,3-cyclohexadiene (**200c**).  
<sup>1</sup>H-NMR, <sup>13</sup>C-NMR 152

24. Isopropyl 2-hydroxy-3,4-methylenedioxy-benzoate (**216a**).  
 $^1\text{H-NMR}$ ,  $^{13}\text{C-NMR}$  153
25. Isopropyl 2-(2-ethoxymethoxy)-3,4-methylenedioxy-benzoate (**216b**).  
 $^1\text{H-NMR}$ ,  $^{13}\text{C-NMR}$  154
26. Isopropyl 2-(2-ethoxymethoxy)-6-hydroxy-3,4-methylenedioxy-benzoate (**217**).  
 $^1\text{H-NMR}$ ,  $^{13}\text{C-NMR}$  155

bpe-1-47b-7-15-93

exp1 pulse sequence: stdsh


```
SAMPLE          DEC. & VT
date    Jul 15 93  on      HI
solvent  CDCl3  def      0
file    /home/arg-  sm      nnn
unic/data/bpe-1-47  sm      c
p-7-15-93  def      200
ACQUISITION  qmwr      30
-----
freq    399.952  PROCESSING
kn      HI      wfile
ac      3.744  proc      ft
rg      37440  fn      not used
sv      5000.0  math      f
fb      2800
ds      16  warr
tprw    56  wexp      wft
pw      4.1  wds      wft
d1      1.000  wnt
tqf     -250.0  DISPLAY
nt      128  sp      -78.7
ct      32  wd      3679.5
ajlock  s vs      90
gain    not used  sc      0
FLASS   n hsm      400
l1      n      ism      9.20
in      n      is      500.00
ap      y rfi      3229.2
ns      nn rfp      2885.7
th      20
ine     1.000
ns cdc ph
```





bpe-1-47c-AC

exp2 pulse sequence: spt

```
SAMPLE          DEC. & VT
date    Jul 8 93  on      HI
solvent  CDCl3  def      0
file    exp  sm      yyy
ACQUISITION  qmwr      43
-----
freq    100.577  def      9879
kn      C13  qmwr      43
nt      1.190  PROCESSING
ns      59908  lb      1.00
sv      25000.0  wfile
fb      13800  proc      ft
ds      32  fn      not used
tprw    53  math      f
pw      6.8
p1      27.0  warr
d1      1.000  wexp      wft
d2      0.007  wds      wft
d3      0.001  wnt
tqf     1500.0  DISPLAY
nt      500000  sp      -1336.5
ct      384  wd      22450.8
ajlock  s vs      92
gain    s vs      0
FLASS   n hsm      400
l1      n      ism      112.25
in      n      is      500.00
ap      y rfi      9180.2
ns      nn rfp      7744.4
th      7
ine     1.000
ns cdc ph
```









13c-1-182b

exp1 pulse sequence: sdd1b


```
SAMPLE          DEC. & UT
date    Sep 25 83  da      HI
solvent CDCl3  def      0
file     exp  da      nan
ACQUISITION    das      c
afreq    399.862  def    200
ls       HI  dpar     30
st       3.744  PROCESSING
ap       37440  wFile    f1
aw       5000.0  prec     f1
fs       2000  fs      not used
hs       16  msh      f
lpar     56
pw       4.1  warr
el       1.000  warr    wit
lef     -250.0  wbr     wit
xt       64  wnt
ct       64  DISPLAY
slack    0  sp      -6.0
gain    not used  sp    3281.1
FLAGS    vs      144
il       a  ac      0
ls       a  ac      200
dp       y  hnm     16.01
hs       na  is     500.00
          rfl     3227.3
          rfp     2395.7
          ls      20
          lna     1.000
          no  cdc  ph
```




13C QMORINE

exp2 pulse sequence: spt


```
SAMPLE          DEC. & UT
date    Sep 25 83  da      HI
solvent CDCl3  def      0
file     exp  da      gm
ACQUISITION    das      a
afreq    100.877  def    5070
ls       Cl3  dpar     43
st       1.199  PROCESSING
ap       52000  lb      1.00
aw       25000.0  wFile   f1
fs       12000  prec     f1
hs       32  fs      not used
lpar     53  msh      f
pw       6.8
pl       27.0  warr
el       1.000  warr    wit
e2       0.007  wbr     wit
e3       0.001  wnt
lef     1500.0  DISPLAY
st       50000  sp      -1331.0
ct       576  sp      22400.2
slack    a  vs      77
gain    e3  ac      0
FLAGS    vs      200
il       a  ac      112.25
ls       a  is     500.00
          rfl     9146.4
          rfp     7744.4
          ls      10
```







U885#24 x1 Bgd=18 30-SEP-93 13:00-0:02:55 70EHF C1+  
 BpM=0 I=6.7v Hm=0 TIC=270076992 Acnt: TH Sys: DICI  
 Text: BPM, I-102 PT=0 Cal: PFKSE30A  
 #24 1.0  
 43922000





```

kpe-181p
expd pulse sequence: stdkh

SAMPLE          DEC. & UT
date Sep 28 83 da      HI
solvent CDCl3 del      0
file exp da          NaN
ACQUISITION
afrc 300.962 del      200
to 41 dpar          20
at 3.744 PROCESSING
ap 37440 width
aw 5000.0 proc      ft
fb 2500 fa          not used
hs 16 msh          f
lpar 56
pw 4.1 wvrv
dl 1.000 wvrv      wft
lef -250.0 uba      wft
at 100 wnt
cl 64 DISPLAY
stack a ap          -162.6
gain not used up    2797.7
FLACS uc          125
il a ac          0
ia a uc          200
dp g hnm          18.24
hs m spt          540.00
p1 3227.0
dip 2895.7
ds 20
fna 1.000
ss cdc ph

```





```

kpe-181c
expd pulse sequence: spt


SAMPLE          DEC. & UT
date Sep 28 83 da      HI
solvent CDCl3 del      0
file exp da          NaN
ACQUISITION
afrc 100.577 del      100
to C13 dpar          43
at 1.199 PROCESSING
ap 50000 lb          1.00
aw 25000.0 width
fb 12000 proc      ft
hs 20 fa          not used
lpar 53 msh          f
pw 6.8
p1 27.0 wvrv
dl 1.000 wvrv      wft
lef 0.007 uba      wft
at 1000 wnt
cl 1024 DISPLAY
stack a ve          72
gain 23 uc          200
FLACS uc          125.00
il a hnm          125.00
ia a lo          500.00
dp v f1          9144.0
hs m spt          7744.4
p1 0
dip 0
ds 0
fna 1.000
ss ac ph

```






U886A#11 x1 Bgd=6 30-SEP-93 13:13:01:24 70EHF EI+  
 BpM=0 I=7.7v Hm=0 TIC=534538016 Acnt:TH Sys:DIEI  
 Text: BPM, I-101 PT=0 Cal: PFKSE30A  
 #11 1.0  
 50265000



MASS  
 #11 2.0  
 50265000





MASS

hpr-1-04cp

exp1 pulso sequence: st41h


```
SAMPLE          DEC. & UT
date    Sep  7 83  da      HI
solvent  CCl4      def      0
file     exp  da      nan
ACQUISITION  da      c
afreq    299.952  def      299
ta       HI      dpar      30
st       3.744    PROCESSING
ap       37440    wfile
ar       5000.0   prec      11
rb       2000    fa      not used
bs       16      mth      1
lpar     56
pr       4.1     werr
dl       1.000   wexp    w/L
lof      -250.0  wha     w/L
st       250     unt
ct       48
black    o      ap      -77.3
gain    not used up      2682.7
FLAGS   va      77
ll       a      ac      0
ln       a      uc      290
dp       y      hsmo    18.41
hs       aa     ie      500.00
                rfi      2027.8
                rfp      2395.7
                lb      20
                lna     1.000
                no     cdc  ph
```






hpr-1-04cc

exp2 pulso sequence: apt

```
SAMPLE          DEC. & UT
date    Sep  4 83  da      HI
solvent  CCl4      def      0
file     exp  da      nan
ACQUISITION  da      c
afreq    100.877  def      100
ta       C13     dpar      43
st       1.190    PROCESSING
ar       50000   lb      1.00
rb       13000   prec      11
bs       30      fa      not used
lpar     6.8
pr       27.0    werr
dl       1.000   wexp    w/L
dz       0.007   wha     w/L
dz       0.001   unt
lof      1500.0   DISPLAY
st       500000  up      -211.0
ct       900     up      18380.0
black    o      va      50
gain    20      ac      290
FLAGS   va      45.76
ll       a      uc      290
ln       a      uc      290
dp       y      hsmo    18.41
hs       aa     ie      500.00
                rfi      2155.6
                rfp      7744.3
                lb      6
                lna     1.000
                no     no  ph
```








hpar-100p

exp2 pulse sequence: sdd1h

```

SAMPLE          REC. & UT
date    Sep 30 83  da      HI
solvent  CDCl3  def      0
file     exp  da      nam
ACQUISITION    das      c
freq     299.822  def     290
ns       701  dpar     30
at       3.744  PROCESSING
ap       37440  wfile
aw       5800.0  pproc    ft
fb       2000  fa      not used
hs       15  msh      f
tproc    56
pw       4.1  wprp
d1       1.000  comp    wft
del      -250.0  sbs    wft
at       48  smt
ct       48
almsh    a  op      -80.5
gain     not used  up     3000.1
FLANS    ve      142
ll        a  ac      0
ls        a  ac     200
dp        g  hsm     16.43
hs        a  lo     500.00
          rfi     2000.0
          rfp     2000.7
          lb      20
          lsa     1.000
          no  adc  ph
  
```






hpar-100s

exp2 pulse sequence: spt

```

SAMPLE          REC. & UT
date    Sep 30 83  da      HI
solvent  CDCl3  def      0
file     exp  da      wpr
ACQUISITION    das      c
freq     100.677  def     9070
ns       213  dpar     43
at       1.100  PROCESSING
ap       50000  lb      1.00
aw       25000.0  wfile
fb       10000  pproc    ft
hs       32  fa      not used
tproc    83  msh      f
pw       0.8
pl       07.0  wprp
d1       1.000  comp    wft
d2       0.007  sbs    wft
d3       0.002  smt
del      1000.0  B1PPLAY
at       50000.0  op      -1220.3
ct       832  up     21400.3
almsh    a  ve      50
gain     83  ac      0
FLANS    ac      200
ll        a  hsm     107.00
ls        a  lo     500.00
dp        g  rfi     8144.0
hs        a  rfp     7744.4
          lb      7
          lsa     1.000
          no  no  ph
  
```







bpe-1-118c

exp1 pulse sequence: at4h


```
SAMPLE          DEC. & UT
date    Jan 22 94  da      HI
solvent CDCl3  def      0
file    exp  da      nnn
ACQUISITION  dae      c
sfrq    399.952  def    200
ta      M1  dpur     30
at      2.744  PROCESSING
np      37440  utfile
aw      5000.0  prec    ft
fb      2800   fa      not used
hs      16    meth    f
tpur    56
pw      4.1  werr
dl      1.000  wexp    wft
sol     -258.0  wba     wft
nt      48    wnt
ct      48    DISPLAY
clock   a  ap      -74.9
gain    not used  up    3668.5
FLAGS  a  va      100
ll      a  ac      0
ln      a  uc      200
dp      y  hmo    18.34
hs      nn  ia     500.00
              rfl    3225.3
              rfp    2895.7
              th     20
              ina    1.000
              no cdc ph
```



bpe-1-118cc

exp2 pulse sequence: opt

```
SAMPLE          DEC. & UT
date    Jan 22 94  da      HI
solvent CDCl3  def      0
file    exp  da      vvv
ACQUISITION  dae      a
sfrq    100.577  def    9879
ta      C13  dpur     43
at      1.190  PROCESSING
np      50000  lb      1.00
aw      25000.0  utfile
fb      13000  prec    ft
hs      32   fa      not used
tpur    53    meth    f
pw      5.8
pl      27.0  werr
dl      1.000  wexp    wft
d2      0.007  wba     wft
d3      0.001  wnt
sol     1500.0  DISPLAY
ct      500000  ep     -1331.0
              2272  up     19404.4
clock   a  va      100
gain    23  ac      0
FLAGS  a  uc      200
ll      a  hmo    97.00
ln      a  ia     500.00
dp      y  rfl    9145.6
hs      aa  rfp    7744.4
              th     8
              ina    1.000
              no no ph
```







bpe-1-121bp

exp3 pulse sequence: sdd1k


```
SAMPLE DEC. & UT
date Oct 26 93 dn HI
solvent CDCl3 dof 0
file exp de nnn
ACQUISITION sca c
sfrq 399.952 daf 200
tn -1 dpur 30
at 3.744 PROCESSING
np 37448 ulfile
aw 5800.0 proc ft
fb 2800 fn not used
ba 15 eath f
tpur 56
pw 4.1
d1 1.000 uexp wft
tof -250.0 uba wft
nt 20 unt
ct 20 DISPLAY -77.5
sleak a ap 3682.7
gain not used up 125
FLAGS wa 0
il h ac 200
in h uc 500.00
dp y hzsa 3227.9
ha na rfp 2895.7
th 20
ins 1.000
no cdc ph
```






bpe-1-121bc

sept pulse sequence: apt

```
SAMPLE DEC. & UT
date Oct 26 93 dn HI
solvent CDCl3 dof 0
file exp de umg
ACQUISITION sca a
sfrq 100.577 daf 5870
tn 213 dpur 43
at 1.199 PROCESSING
np 59968 lb 1.00
aw 25000.0 ulfile
fb 13800 proc ft
ba 32 fn not used
tpur 53 eath f
pw 6.8
p1 27.0 uexp
d1 1.000 uexp wft
d2 0.007 uba wft
d3 0.001 unt
tof 1500.0 DISPLAY -1402.0
nt 500000 ap -25000.0
ct 448 up 25000.0
sleak a va 80
gain 23 ac 0
FLAGS wa 200
il h hzsa 125.00
in h uc 500.00
dp y rfp 9146.4
ha na rfp 7744.4
th 20
ins 1.000
no no ph
```






```

BPM-I-2-3-5-04
mpd pulse sequence: apt

SAMPLE          SEC. & VT
date            Mar 5 94   01
solvent         CDCl3     Sol 0
file            exp 00    070
ACQUISITION    Low      1
n1rq           100.670    def 5870
ks             0.12      dpar 43
at             1.100     PROCESSING
ap             59000      1b 1.00
ar             25000.0    vfile 1
fb             12000      arcs 1
ks             64        fa  set named
lpar          53        kb 1
ps             0.0
st             271.0     warr wft
dl             1.000     warr wft
ds             0.007     warr wft
cs             0.001     warr 72
Lof            1000.0    DISPLAY
at             500000     ap -1029.0
cs             2752      ap -7817.4
sfsk          0        wa 72
gks          set named ac 0
FLACS          ac 200
ll            0        harr 89.50
ls            0        ra 500.00
dp            0        v fl 3643.0
hs            0        wa flp 7744.5
ls            1b
ss            1.000
ss ss ps
  
```







toluenediol peroxan. oxidation

oxy1 pulse sequence: std1h


```
SAMPLE DEC. & UT
date Jun 12 94 dn 399.951
solvent CDCl3 dn H1
file exp dpur 30
ACQUISITION dof 0
afreq 399.951 dn nnn
ta H1 dm c
at 3.744 dal 200
np 37448 daeq undefined
aw 5000.0 drea undefined
fb 2800 hooo n
hs 16 PROCESSING
tpur 55 vfile
pw 4.1 prec ft
dl 1.000 fa not used
tof -254.0 wath f
rt 48
ct 48 warr
slock a wexp wft
gain not used wba wft
FLAGS wnt
il n
in a
dp v
hs nn
DISPLAY
ap -77.2
sp 3271.0
va 150
ac 0
uc 200
homo 18.36
ia 500.00
rfl 3227.6
rfp 2895.6
lh 20
lms 1.000
na cdc ph
```





toluenediol-peroxan-ox1

oxy2 pulse sequence: opt


```
SAMPLE DEC. & UT
date Jun 12 94 dn H1
solvent cdcl3 def 0
file exp da vng
ACQUISITION dae w
afreq 100.578 def 0870
ta C13 dpur 43
at 1.190 PROCESSING
np 57005 lb 1.00
aw 25000.0 vfile
fb 13000 prec ft
hs 64 fa not used
tpur 53 wath f
pw 0.8
pl 27.8 warr
dl 1.000 wexp wft
d2 0.007 wba wft
d3 0.001 wnt
tof 1000.0 DISPLAY
at 50000.0 ap -1003.2
ct 640 ap 22025.2
slock a va 70
gain not used ac 0
FLAGS wnt
il a homo 110.13
in a ia 500.00
dp v rfl 9047.7
hs aa rfp 7744.5
lh 20
lms 1.000
na no ph
```




hpr-1-253p  
 OBSERVE H1  
 FREQUENCY 300.851 MHz  
 SPECTRAL WIDTH 5000.0 Hz  
 ACQUISITION TIME 3.744 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 4.1 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 64  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 5 minutes  
 Apr 19 94  
 Virginia Tech STC NMR Facility




hpr-1-253c  
 PULSE SEQUENCE spt  
 OBSERVE C13  
 FREQUENCY 100.576 MHz  
 SPECTRAL WIDTH 25000.0 Hz  
 ACQUISITION TIME 1.150 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 8.8 usec  
 FIRST PULSE WIDTH 27.0 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 256  
 DECOUPLE H1  
 HIGH POWER 43  
 DECOUPLER GATED ON DURING NOBSOBSITION  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 LINE BROADENING 1.0 Hz  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 9 minutes  
 Apr 19 94  
 Virginia Tech STC NMR Facility







13C NMR


PULSE SEQUENCE zgpg  
 NUCLEUS C13  
 FREQUENCY 100.628 MHz  
 SPECTRAL WIDTH 20000.0 Hz  
 ACQUISITION TIME 1.100 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE LENGTH 9.0 usec  
 FIRST PULSE LENGTH 27.0 usec  
 AQUEOUS TEMPERATURE  
 NS. REPEATS 128  
 SCANS 64  
 ACQ PULSES 43  
 SCANS 64 BY 43 BY 128  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 LINE BROADENING 1.0 Hz  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 4.00 min  
 Apr 18 84  
 Virginia Tech NMR Facility





hpa-1-256p  
 OBSERVE H1  
 FREQUENCY 300.051 MHz  
 SPECTRAL WIDTH 5000.0 Hz  
 ACQUISITION TIME 3.744 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 4.1 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 64  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 5 minutes  
 Apr 19 94  
 Virginia Tech STC NMR Facility




13C OBSERVE  
 PULSE SEQUENCE spt  
 OBSERVE C13  
 FREQUENCY 100.578 MHz  
 SPECTRAL WIDTH 25000.0 Hz  
 ACQUISITION TIME 1.100 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 6.0 usec  
 FIRST PULSE WIDTH 27.0 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 100  
 DECOUPLE H1  
 HIGH POWER 43  
 DECOUPLER GATED ON DURING ACQUISITION  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 LINE BROADENING 1.0 Hz  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 7 minutes  
 Apr 19 94  
 Virginia Tech STC NMR Facility



hsc-gb-1-45a  
 OBSERVE M1  
 FREQUENCY 300.051 MHz  
 SPECTRAL WIDTH 5000.0 Hz  
 ACQUISITION TIME 3.744 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 4.1 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 30  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 2 minutes  
 Aug 14 94  
 Virginia Tech STC NMR Facility




hsc-gb-11-45c  
 PULSE SEQUENCE spt  
 OBSERVE C13  
 FREQUENCY 100.628 MHz  
 SPECTRAL WIDTH 25000.0 Hz  
 ACQUISITION TIME 1.100 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 7.5 usec  
 FIRST PULSE WIDTH 30.0 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 512  
 DECOUPLE M1  
 HIGH POWER 43  
 DECOUPLER ON DURING ACQUISITION  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 LINE BROADENING 1.0 Hz  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 10 minutes  
 Sep 13 94  
 Virginia Tech STC NMR Facility








P-E




94/07/08 10:22 candace  
X: 4 scans, 2.0cm-1





kpc-1-058p  
 OBSERVE M1  
 FREQUENCY 300.051 MHz  
 SPECTRAL WIDTH 5000.0 Hz  
 ACQUISITION TIME 3.744 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 4.1 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 64  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 5 minutes  
 Apr 21 84  
 Virginia Tech STC NMR Facility



kpc-1-058c  
 PULSE SEQUENCE apt  
 OBSERVE C13  
 FREQUENCY 100.578 MHz  
 SPECTRAL WIDTH 25000.0 Hz  
 ACQUISITION TIME 1.100 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 8.8 usec  
 FIRST PULSE WIDTH 27.0 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 384  
 DECOUPLE M1  
 HIGH POWER 43  
 DECOUPLER ON/OFF DURING ACQUISITION  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 LINE BROADENING 1.0 Hz  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 14 minutes  
 Apr 21 84  
 Virginia Tech STC NMR Facility




gh/psm-1-09b  
 OBSERVE H1  
 FREQUENCY 300.621 MHz  
 SPECTRAL WIDTH 8000.0 Hz  
 ACQUISITION TIME 3.744 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 4.1 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 84  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 6 minutes  
 Aug 14 94  
 Virginia Tech STC NMR Facility





gh/psm-1-51c  
 PULSE SEQUENCE apt  
 OBSERVE C13  
 FREQUENCY 100.578 MHz  
 SPECTRAL WIDTH 25000.0 Hz  
 ACQUISITION TIME 1.199 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 6.8 usec  
 FIRST PULSE WIDTH 27.0 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 960  
 DECOUPLE H1  
 HIGH POWER 43  
 DECOUPLER GATED ON DURING ACQUISITION


DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 LINE BROADENING 1.0 Hz  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 35 minutes  
 Jul 26 94  
 Virginia Tech STC NMR Facility





BPM-I-285 ANAL. ANAL.




bpm-I-285  
 PULSE SEQUENCE sp4  
 CHANNEL C13  
 FREQUENCY 100.578 MHz  
 SPECTRAL WIDTH 85000.0 Hz  
 ACQUISITION TIME 1.190 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 6.0 nsec  
 FIRST PULSE WIDTH 27.0 nsec  
 AMBIENT TEMPERATURE  
 NO. REPEATITIONS 1000  
 DECOUPLE M0  
 HIGH POWER 43  
 DECOUPLER ON/DTN DURING ACQUISITION  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 LINE BROADENING 1.0 Hz  
 FT SIZE 65520  
 TOTAL ACQUISITION TIME 40 minutes  
 May 17 94  
 Virginia Tech STC NMR Facility



bpm/gb-1-57a  
 OBSERVE H1  
 FREQUENCY 300.051 MHz  
 SPECTRAL WIDTH 5000.0 Hz  
 ACQUISITION TIME 3.744 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 4.1 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 16  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 1 minutes  
 Jul 26 94  
 Virginia Tech STC NMR Facility





bpm/gb-1-57c  
 PULSE SEQUENCE apt  
 OBSERVE C13  
 FREQUENCY 100.578 MHz  
 SPECTRAL WIDTH 25000.0 Hz  
 ACQUISITION TIME 1.199 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 6.8 usec  
 FIRST PULSE WIDTH 27.0 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 704  
 DECOUPLE H1  
 HIGH POWER 43  
 DECOUPLER GATED ON DURING ACQUISITION  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 LINE BROADENING 1.0 Hz  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 25 minutes  
 Jul 26 94  
 Virginia Tech STC NMR Facility




bpe-11-12p

exp3 pulse sequence: stdtk



```
SAMPLE          DEC. & UT
date    Jun 12 94  dfrq    399.951
solvent  CDCl3  ds         M1
file     exp  dpar    30
ACQUISITION     dof         0
dfrq    399.951  ds         nnn
tn       M1  ds         c
sk       3.744  ds         200
ap       77440  ds         undefined
su       5800.0  ds         undefined
fb       2800  hase         n
hs       16      PROCESSING
tpr     55  ofile         ft
pr       4.1  prec         f
dl       1.000  fa         not used
tof     -250.0  math         f
nl       64
cl       64  werr
stack   a  wosp         wft
gain   not used  uba         wft
      FLAGS
il       n
in       n
dp       v
hs       nn
      DISPLAY
ap       -77.3
up       3271.9
vs       150
sc       0
wc       200
hase    16.26
ia       500.00
rfi     3227.8
rip     2395.6
th       20
ina     1.000
na  cdc  ph
```




```
bpe-11-12c
PULSE SEQUENCE xpt
OBSERVE C13
FREQUENCY 100.578 MHz
SPECTRAL WIDTH 25000.0 Hz
ACQUISITION TIME 1.109 sec
RELAXATION DELAY 1.000 sec
PULSE WIDTH 8.8 usec
FIRST PULSE WIDTH 27.0 usec
AMBIENT TEMPERATURE
NO. REPETITIONS 1664
DECOUPLE H1
HIGH POWER 43
DECOUPLER GATED ON DURING ACQUISITION
DOUBLE PRECISION ACQUISITION
DATA PROCESSING
LINE BROADENING 1.0 Hz
FT SIZE 65536
TOTAL ACQUISITION TIME 61 minutes
Jun 12 94
Virginia Tech STC NMR Facility
```



hpe-gb-1-47a  
 OBSERVE M1  
 FREQUENCY 300.951 MHz  
 SPECTRAL WIDTH 5000.0 Hz  
 ACQUISITION TIME 3.744 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 4.1 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 32  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 FT SIZE 85336  
 TOTAL ACQUISITION TIME 2 minutes  
 Aug 14 94  
 Virginia Tech STC NMR Facility





hpe-gb-11-47c  
 PULSE SEQUENCE spt  
 OBSERVE C13  
 FREQUENCY 100.628 MHz  
 SPECTRAL WIDTH 25000.0 Hz  
 ACQUISITION TIME 1.100 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 7.5 usec  
 FIRST PULSE WIDTH 30.0 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 512  
 DECOUPLE M1  
 HIGH POWER 43  
 DECOUPLER GATED ON DURING ACQUISITION  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 LINE BROADENING 1.0 Hz  
 FT SIZE 85336  
 TOTAL ACQUISITION TIME 18 minutes  
 Sep 13 94  
 Virginia Tech STC NMR Facility








gb-hm-1-71p  
 OBSERVE M1  
 FREQUENCY 300.951 MHz  
 SPECTRAL WIDTH 5000.0 Hz  
 ACQUISITION TIME 3.744 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 4.1 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 32  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 FT SIZE 60538  
 TOTAL ACQUISITION TIME 2 minutes  
 Aug 14 94  
 Virginia Tech STC NMR Facility





bp-gb-1-71c  
 PULSE SEQUENCE spt  
 OBSERVE C13  
 FREQUENCY 100.678 MHz  
 SPECTRAL WIDTH 25000.0 Hz  
 ACQUISITION TIME 1.190 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 8.0 usec  
 FIRST PULSE WIDTH 27.0 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 2000  
 DECOUPLE M3  
 HIGH POWER 43  
 DECOUPLER GATED ON DURING ACQUISITION  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 LINE BROADENING 1.0 Hz  
 FT SIZE 60538  
 TOTAL ACQUISITION TIME 87 minutes  
 Aug 14 94  
 Virginia Tech STC NMR Facility








bsm-11-37p  
 OBSERVE H1  
 FREQUENCY 399.951 MHz  
 SPECTRAL WIDTH 5000.0 Hz  
 ACQUISITION TIME 3.744 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 4.1 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 32  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 2 minutes  
 Jul 26 94  
 Virginia Tech STC NMR Facility




bsm-11-37c  
 PULSE SEQUENCE apr  
 OBSERVE CL3  
 FREQUENCY 100.578 MHz  
 SPECTRAL WIDTH 25000.0 Hz  
 ACQUISITION TIME 1.199 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 6.8 usec  
 FIRST PULSE WIDTH 27.0 usec  
 AMBIENT TEMPERATURE  
 NO. REPETITIONS 832  
 DECOUPLE H1  
 HIGH POWER 43  
 DECOUPLER GATED ON DURING ACQUISITION  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 LINE BROADENING 1.0 Hz  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 30 minutes  
 Jul 26 94  
 Virginia Tech STC NMR Facility





100-11-42  
 OPERATE M1  
 FREQUENCY 200.261 MHz  
 SPECTRAL WIDTH 6000.0 Hz  
 ACQUISITION TIME 3.744 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 4.1 sec  
 NUCLEAR TEMPERATURE  
 NO. REPETITIONS 32  
 SCALE PRECISION ACQUISITION  
 DATA PROCESSING  
 FT SIZE 6000  
 TOTAL ACQUISITION TIME 8 minutes  
 Jul 88 94  
 Virginia Tech STC NMR Facility




100-11-42a  
 PULSE SEQUENCE ap4  
 OPERATE C13  
 FREQUENCY 100.629 MHz  
 SPECTRAL WIDTH 6000.0 Hz  
 ACQUISITION TIME 1.100 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 8.0 sec  
 FIRST PULSE WIDTH 8.0 sec  
 NUCLEAR TEMPERATURE  
 NO. REPETITIONS 448  
 SCORPUS M2  
 HIGH PAPER 43  
 SCORPUS DATED ON DURING ACQUISITION  
 SCALE PRECISION ACQUISITION  
 DATA PROCESSING  
 LINE BROADENING 1.0 Hz  
 FT SIZE 6000  
 TOTAL ACQUISITION TIME 16 minutes  
 Jul 88 94  
 Virginia Tech STC NMR Facility




300-11-04g  
 OSIRIS 41  
 FREQUENCY 300.042 MHz  
 SPECTRAL WIDTH 8000.0 Hz  
 ACQUISITION TIME 3.764 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 4.1 sec  
 AQUEOUS TEMPERATURE  
 NO. REPETITIONS 30  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 8 minutes  
 Aug 8 84  
 Virginia Tech STC NMR Facility




300-11-04b  
 PULS 800000 4pt  
 OSIRIS 41  
 FREQUENCY 100.678 MHz  
 SPECTRAL WIDTH 8000.0 Hz  
 ACQUISITION TIME 1.100 sec  
 RELAXATION DELAY 1.000 sec  
 PULSE WIDTH 8.0 sec  
 FIRST PULSE WIDTH 87.0 sec  
 AQUEOUS TEMPERATURE  
 NO. REPETITIONS 640  
 SAMPLE IN  
 NEW PULSE 43  
 DEAMPLER ON IN PULS ACQUISITION  
 DOUBLE PRECISION ACQUISITION  
 DATA PROCESSING  
 LINE BROADENING 1.0 Hz  
 FT SIZE 65536  
 TOTAL ACQUISITION TIME 18 minutes  
 Aug 8 84  
 Virginia Tech STC NMR Facility




## VII. APPENDIX



Appendix 1. Charge Distribution as Calculated by AM1<sup>94</sup>



Appendix 2. FMO as Calculated by AM1<sup>94</sup>



Appendix 3. FMO Coefficients for the Unsubstituted Nitrile Oxide<sup>98</sup>

## VIII. REFERENCES

1. For reviews on biotransformations see:
  - a) *Preparative Biotransformations*; S. Roberts, K. Wiggins and G. Casey Eds., Wiley: New York, **1993**.
  - b) D. Drueckhammer, W. Hennen, R. Pederson, D. Barbas, C. Gautheron, T. Krach and D. Wong *Synthesis*, **1991**, 499.
  - c) A. Klibanov *Acc. Chem. Res.*, **23**, **1990**, 114.
2. *Biotransformations in Action*, S. Roberts, T. Hudlicky, N. Turner, G. Whited and A. Boyes Eds., Blacksburg, VA, **1994**.
3.
  - a) K. Faber *Biotransformations in Organic Chemistry*, Spronger Verlag: Heidelberg, **1992**.
  - b) *Microbial Reagents in Organic Synthesis*, S. Servi Ed., NATO ASI Series, Series C, **381**, Kluwer: London, **1992**.
4.
  - a) S. Roberts, R. MacKeith, R. McCague, H. Olivo and C. Palmer *J. Chem. Soc., Perkin Trans. I*, **1993**, 313.
  - b) S. Roberts, H. Olivo *unpublished*.
5. D. Illman, *Chem. Eng. News*, **72**, **1994**, 22.
6.
  - a) D. Gibson and V. Subbranianjan *Microbial Degradation of Organic Compounds*, D. Gibson Ed., Microbiology Series, vol 13, Marcel Dekker: New York, **1984**, Chapter 7.
  - b) D. Gibson, M. Hemsley, H. Yoshioka and T. Mabry *Biochemistry*, **9**, **1970**, 1626.
7.
  - a) D. Hanson, *Chem. Eng. News*, **71**, **1993**, 13.
  - b) P. Layman, *Chem. Eng. News*, **71**, **1993**, 14, 17.
  - c) M. Reisch, *Chem. Eng. News*, **71**, **1993**, 10, 15.
8. S. Ley, F. Sternfeld and S. Taylor *Tetrahedron Lett.*, **28**, **1987**, 225.
9. T. Hudlicky, H. Luna, G. Barbieri and L. Kwart *J. Amer. Chem. Soc.*, **110**, **1988**, 4735.
10. T. Hudlicky, J. Price, F. Rulin and T. Tsunoda *J. Amer. Chem. Soc.*, **112**, **1990**, 9439.
11. T. Hudlicky and J. Rouden *J. Chem. Soc., Perkin Trans. I*, **1993**, 1095.
12. Some Diols are available from a) Genencor Int. Inc. b) ICI Bioproducts c) Janssen Chimica d) Aldrich Chemical Co.
13. C. Pittol, R. Pryce, S. Roberts, G. Ryback, V. Sik and J. Williams *J. Chem. Soc., Perkin Trans. I*, **1989**, 1160.
14. S. Ley, A. Redgrave, S. Taylor, S. Ahmed and D. Ribbons *Synlett*, **1991**, 741.

15. T. Hudlicky, E. Boros, H. Olivo and J. Merola *J. Org. Chem.*, **57**, **1992**, 1026.
16. T. Hudlicky, C. Boros *Tetrahedron Lett.*, **34**, **1993**, 2557.
17. I. Stevens, S. Giliani and R. Cookson *J. Chem. Soc., C*, **1967**, 1905.
18. D. Gibson, V. Kobal, R. Davis and A Garza *J. Amer. Chem. Soc.*, **95**, **1973**, 4420.
19. D. Boyd, M. Dorrity, M. Hand, J. Malone, N. Sharma, H. Dalton, D. Gray and G. Sheldrake *J. Amer. Chem. Soc.*, **113**, **1991**, 666.
20. M. Banwell, J. Lambert and S. Richards *Aust. J. Chem.*, **44**, **1991**, 939.
21. J. Cotterill, S. Roberts, J. Williams *J. Chem. Soc., Chem. Commun.*, **1988**, 1628.
22. P. Geary, R. Pryce, S. Roberts, G. Ryback and J. Winders *J. Chem. Soc., Chem. Commun.*, **1990**, 205.
23. W. Downing, R. Latouche, C. Pittol, R. Pryce, S. Roberts, G. Ryback and J. Williams *J. Chem. Soc., Perkin Trans. I*, **1990**, 2613.
24. M. Mahon, K. Molloy, C. Pittol, R. Pryce, S. Roberts, G. Ryback, V. Sik, J. Williams and J. Winders *J. Chem. Soc., Perkin Trans. I*, **1991**, 1255.
25. J. Gillard and D.J. Burnell *J. Chem. Soc., Chem. Commun.*, **1989**, 1439.
26. T. Hudlicky and H. Olivo *Tetrahedron Lett.*, **32**, **1991**, 6077.
27. H. Olivo, Ph.D. Dissertation, Virginia Polytechnic Institute and State University, **1992**.
28. K. Schurrle, B. Beier and W. Piepersberg *J. Chem. Soc., Perkin Trans. I*, **1991**, 2407.
29. O. Werbitzky, K. Klier and H. Felber *Liebigs Ann. Chem.*, **1990**, 267.
30. T. Hudlicky and H. Olivo *J. Amer. Chem. Soc.*, **114**, **1992**, 9694.
31. I. Cotterill, S. Roberts and J. Williams *J. Chem. Soc., Chem. Comm.*, **1988**, 1628.
32. C. Pittol, R. Pryce, S. Roberts, G. Ryback, G. Sik and J. Williams *J. Chem. Soc., Perkin Trans. I*, **1989**, 1160.
33. T. Hudlicky, H. Olivo and B. McKibben *J. Amer. Chem. Soc.*, **116**, **1994**, 5108.
34. T. Hudlicky, C. Boros and E. Boros *Synthesis*, **1992**, 174.
35. T. Hudlicky, E. Boros and C. Boros *Synlett*, **1992**, 391.
36. T. Hudlicky, G. Seaone and T. Pettus *J. Org. Chem.*, **32**, **1989**, 4239.
37. H. Carless, J. Billinger, and O. Oak *Tetrahedron Lett.*, **30**, **1989**, 3113.



38. Y. Sutbeyat, H. Secene, and M. Balci *J. Chem. Soc., Chem. Commun.*, **1988**, 1330.
39. T. Hudlicky, H. Luna, G. Barbieri and L. Kwart *J. Amer. Chem. Soc.*, **110**, **1988**, 4735.
40. H. Carless, and O. Oak *Tetrahedron Lett.*, **30**, **1989**, 1719.
41. L. Dumortier, S. Dobbelaere, J. van der Eycken, M. Vanderwalle *Synlett*, **1992**, 241.
42. T. Hudlicky, J. Price, H. Luna and C. Anderson *Synlett*, **1990**, 309.
43. W. Downing, R. Latouche, C. Pittol, R. Pryce, S. Roberts, G. Ryback and J. Williams *J. Chem. Soc., Chem. Commun.*, **1987**, 1804.
44. N. Yang, T. Noh, H. Gan, S. Halfon and B. Hrnjez *J. Amer. Chem. Soc.*, **110**, **1988**, 5919.
45. W. Downing, R. Latouche, C. Pittol, R. Pryce, S. Roberts, G. Ryback and J. Williams *J. Chem. Soc., Perkin Trans. I*, **1990**, 2613.
46. M. Mahon, K. Molloy, C. Pittol, R. Pryce, S. Roberts, G. Ryback, V. Sik, J. Williams and J. Winders *J. Chem. Soc., Perkin Trans. I*, **1991**, 1255.
47. H. Mayr, U. Heigl *J. Chem. Soc., Chem. Commun.*, **1987**, 1804.
48. C. Pittol, R. Pryce, S. Roberts, G. Ryback, V. Sik and J. Williams *J. Chem. Soc., Perkin Trans. I*, **1989**, 1160.
49. O. Werbitzky, K. Klier and H. Felber *Liebigs Ann. Chem.*, **1990**, 267.
50. W. Piepersberg, B. Beier and K. Schurrle *J. Chem. Soc., Perkin Trans. I*, **1991**, 2407.
51. a) G. Wagner *J. Russ. Phys. Chem. Soc.*, **27**, **1895**, 219.  
 b) G. Wagner *Ber. Dtsch. Chem. Ges.*, **23**, **1880**, 2307.  
 c) G. Wagner *Ber. Dtsch. Chem. Ges.*, **21**, **1878**, 1230, 3347.
52. A. Fatiadi *Synthesis*, **1987**, 85.
53. a) R. Stewart *Oxidation Mechanisms: Application to Organic Chemistry*, W.A. Benjamin: New York, **1964**.  
 b) D. Lee in *Oxidation*, vol 1, R. Augustine Ed., Marcel Dekker: New York, **1969**. Chapter 1.  
 c) H. House *Modern Synthetic Reagents*, 2nd Edition, W.A. Benjamin: Menlo Park, CA, **1972**, 275-85.  
 d) D. Arndt in *Houben-Weyl*, 4th Edition, E. Muller Ed., Vol 4/1b, Georg Thieme Verlag: Stuttgart, **1975**, 579.  
 e) D. Lee *The Oxidation of Organic Compounds by Permanganate Ion and Hexavalent Chromium*, Open Court: Lasall, Ill., **1980**.
54. a) F. Freeman *Rev. React. Species Chem. React.*, **1**, **1976**, 179.

- b) N. Son, M. Jaky and L. Simandi *Inorg. Nucl. Chem. Lett.*, **12**, **1976**, 291.  
 c) F. Freeman, C. Fuselier, C. Armstead, C. Dalton, P. Davidson, E. Kerchesfski, D. Krochman, M. Johnson and N. Jones *J. Amer. Chem. Soc.*, **103**, **1981**, 1154.  
 d) F.A. Cotton *Adv. Inorg. Chem.*, 4th Edition, John Wiley and Sons: New York, **1980**, 747.  
 e) S. Wolfe, C. Ingold and R. Lemieux *J. Amer. Chem. Soc.*, **103**, **1981**, 938.
55. F. Gunstone, *Adv. Org. Chem.*, **1**, **1960**, 103.
56. For a review of phase transfer catalysis of permanganate oxidations see:  
 a) D. Lee in *Ox. in Organic Chem.*, Part D, W. Trahanovsky Ed., Academic Press: New York, **1982**, 147-206.
57. a) K.B. Sharpless, A. Feranishi and J. Backvall *J. Amer. Chem. Soc.*, **99**, **1977**, 3120.  
 b) A. Rappe and W. Goddard *J. Amer. Chem. Soc.*, **104**, **1982**, 448.
58. a) E. von Rudloff *Can J. Chem.*, **43**, **1965**, 1784.  
 b) T. Suga and E. von Rudloff *Can J. Chem.*, **47**, **1969**, 3682.
59. a) T. Ogino and K. Mochizuki *Chem. Lett.*, **1979**, 443.  
 b) T. Ogino *Tetrahedron Lett.*, **21**, **1980**, 177.
60. K. Gollnick, G. Schade and S. Schroeter *Tetrahedron*, **22**, **1966**, 139.
61. H. Sable, K. Powell, H. Katchian, C. Niewoehner, S. Kadlec *Tetrahedron*, **26**, **1970**, 1509.
62. E. Klein and W. Rojahn *Tetrahedron*, **21**, **1965**, 2353.
63. a) S. Wolfe and C. Ingold *J. Amer. Chem. Soc.*, **103**, **1981**, 938.  
 b) S. Wolfe, R. Lemieux and C. Ingold *J. Amer. Chem. Soc.*, **103**, **1981**, 940.
64. H. Sable, T. Anderson, B. Tolbert and T. Posternak *Helv. Chim. Acta.*, **46**, **1963**, 1157.
65. E. von Rudloff *Tetrahedron Lett.*, **7**, **1966**, 993.
66. M. Anastasia, A. Fiecchi and A. Scala *J. Org Chem.*, **44**, **1979**, 3657.
67. a) M. Mandel, T. Hudlicky, L. Kwart and G. Whited *J. Org Chem.*, **58**, **1993**, 2331.  
 b) M. Mandel and T. Hudlicky *J. Chem. Soc., Perkin I*, **1993**, 741.  
 c) M. Mandel and T. Hudlicky *Synlett*, **1993**, 418.  
 d) M. Mandel, T. Hudlicky, L. Kwart and G. Whited *Collect. Czech. Chem. Comm.*, **58**, **1993**, 2517.
68. D. Jerina, J. Daly *Science*, **185**, **1974**, 573.
69. a) M. Ganey, R. Padykula, G. Berchtold, A. Braun *J. Org. Chem.*, **54**, **1989**, 2787.

- b) R. Aleksejczyk, G. Berchtold, A. Braun *J. Amer. Chem. Soc.*, **107**, **1985**, 2554.
70. D. Jerina, H. Ziffer, J. Daly *J. Amer. Chem. Soc.*, **92**, **1970**, 1056.
71. K. Platt, F. Oesch *Synthesis*, **1977**, 449.
72. S. Ogawa, T. Takagaki *J. Org. Chem.*, **50**, **1985**, 2356.
73. a) H. Carless, K. Busia *Carbohydrate Res.*, **234**, **1992**, 207.  
 b) H. Carless, K. Busia *Tetrahedron Lett.*, **31**, **1990**, 1617.  
 c) H. Carless, K. Busia *Tetrahedron Lett.*, **31**, **1990**, 3449.  
 d) B. Beier, K. Schurrle, O. Werbitzky, W. Piepersberg *J. Chem. Soc., Perkin Trans. I*, **1990**, 2255.  
 e) K. Schurrle, B. Beier, O. Werbitzky, W. Piepersberg *Carbohydrate Res.*, **212**, **1990**, 321.
74. J. Hartwell *Lloydia*, **30**, **1967**, 379.
75. a) K. Gorter *Bull. Jard. Bot. Buitenzorg*, [3], I, **1920**, 352.  
 b) K. Gorter *Chem. Zentr.*, III, **1920**, 846.
76. G. Pettit, V. Gaddamidi, D. Herald, S. Singh, G. Cragg and J. Schmidt *J. Nat. Prod.*, **47**, **1986**, 995.
77. a) G. Pettit, V. Gaddamidi, G. Cragg, D. Herald and Y. Sagawa *J. Chem. Soc., Chem. Commun.*, **1984**, 1693.  
 b) G. Pettit, V. Gaddamidi and G. Cragg *J. Chem. Soc., Chem. Commun.*, **1984**, 1018.
78. T. Okamoto, Y. Torii and Y. Isogai *Chem. Pharm. Bull.*, **16**, **1968**, 1860.
79. a) L. Carrasco, M. Fresno and D. Vazquez *FEBS Lett.*, **52**, **1975**, 236.  
 b) A. Jimenez, L. Sanchez and D. Vazquez *FEBS Lett.*, **55**, **1975**, 53.  
 c) A. Baez and D. Vazquez *Biochem. Biophys. Acta*, **518**, **1978**, 95.  
 d) A. Mondon and K. Krohn *Chem. Ber.*, **108**, **1975**, 445.
80. a) C. Fuganti, J. Staunton and A. Battersby *J. Chem. Soc., Chem. Commun.*, **1971**, 1154.  
 b) C. Fuganti and M. Mazza *J. Chem. Soc., Chem. Commun.*, **1971**, 1388.  
 c) C. Fuganti and M. Mazza *J. Chem. Soc., Chem. Commun.*, **1972**, 239.
81. S. Danishefsky and J. Lee *J. Amer. Chem. Soc.*, **111**, **1989**, 4829.
82. C. Heathcock, R. Lopes and C. Lopes *Tetrahedron Lett.*, **33**, **1992**, 6775.
83. R. Thompson and J. Kallmerten *J. Org. Chem.*, **55**, **1990**, 6076.
84. a) S. Ohta and S. Kimoto *Chem. Pharm. Bull.*, **24**, **1976**, 2969.  
 b) S. Ohta and S. Kimoto *Chem. Pharm. Bull.*, **24**, **1976**, 2977.
85. a) H. Paulsen and M. Stubbe *Tetrahedron Lett.*, **23**, **1982**, 3171.

- b) H. Paulsen and M. Stubbe *Leibigs Ann. Chem.*, **1983**, 535.
86. R. Clark and M. Souchet *Tetrahedron Lett.*, **31**, **1990**, 193.
87. For reviews of the Diels-Alder reaction:
- a) L. Butz and A. Rytina *Org. React.*, **5**, **1949**, 136.
  - b) M. Kloetzel *Org. React.*, **4**, **1948**, 1
  - c) A. Wasserman *Diels-Alder Reactions*, American Elsevier: New York, **1965**.
  - d) R. Huisgen, R. Grashey and J. Sauer, In *Chemistry of Alkenes*, S. Patai Ed., Wiley-Interscience: New York, **1964**, pp 878-928.
  - e) W. Oppolzer *Synthesis*, **1978**, 793.
  - f) G. Brieger and J. Bennett *Chem. Rev.*, **1980**, **80**, 63.
  - g) E. Ciganek *Org. React.*, **1984**, **32**, 1.
  - h) W. Oppolzer *Angew. Chem. Int. Ed. Engl.*, **23**, **1984**, 876.
88. For reviews of FMO in the Diels-Alder Reaction:
- a) K. Houk *Acc. Chem. Res.*, **8**, **1975**, 361.
  - b) I. Fleming *Frontier Orbitals and Chemical Reactions*, Wiley-Interscience: New York, **1976**.
  - c) O. Eisenstein, J. Lefour, N. Anh and R. Hudson *Tetrahedron*, **33**, **1977**, 523.
89. For reviews of 1,3-dipolar cycloaddition:
- a) G. Bianchi, C. DeMicheli and R. Gandolfi. In *The Chemistry of Double Bonded Functional Groups*, S. Patai Ed., Wiley-Interscience: New York, **1977**, part 1, supplement A, pp 369-532.
  - b) A. Padwa (ed.) *Dipolar Cycloaddition Chemistry*, Wiley: New York, **1984**.
90. For a review of intramolecular 1,3-dipolar cycloaddition reactions:
- a) A. Padwa (ed.) *Angew. Chem. Int. Ed. Engl.*, **15**, **1976**, 123.
91. For reviews of FMO in 1,3 dipolar cycloaddition reactions:
- a) K. Houk, J. Sims, B. Duke, R. Strozier and J. George *J. Amer. Chem. Soc.*, **95**, **1973**, 7287, 7301.
  - b) K. Houk. In *Pericyclic Reactions*, A. Marchand and R. Lehr Eds., Academic Press: New York, **1977**, pp 181-271.
92. J. Bruce. In *The Chemistry of Quinonoid Compounds*; A. Padwa (ed.), John Wiley and Sons: New York, **1974**, part 1, pp 465-538.
93. J. Baltrop and B. Hesp *J. Chem. Soc.*, **1965**, 5182.
94. Special thanks to James Tanko (Virginia Tech) for his help with AM1 calculations (MOPAC, version 5.0, developed by Dewar).
95. R. Hoffman. In *Dehydrobenzenes and Cycloalkynes*, Academic Press: New York, **1967**.
96. a) T. Hudlicky, H. Olivo, and B. McKibben *J. Amer. Chem. Soc.*, **116**, **1994**, 5108.  
b) T. Hudlicky and Bryan McKibben *J. Chem. Soc., Perkin Trans. I*, **1994**, 485.

97. T. Mukaiyama and T. Hoshino *J. Amer. Chem. Soc.*, **82**, **1960**, 5339.
98. K. Houk, B. Duke, R. Strozier, J. George *J. Amer. Chem. Soc.*, **95**, **1973**, 7287, 7301.
99. I. Fleming *Frontier Orbitals and Chemical Reactions*, Wiley-Interscience: New York, **1976**, pp 215-216.
100. T. Hudlicky, K. Pitzer *unpublished results*.
- 101 T. Hudlicky, S. Brown. In *Organic Synthesis: Theory and Applications*, JAI Press: Greenwich, **1993**, pp 113-176.
102. a) M. Lane, J. Ripoll *Synthesis*, **1985**, 121.  
b) A. Ichihara *Synthesis*, **1987**, 207.
103. D. Barton, T. Shioiri, D. Widdowson *Chem. Commun.*, **1970**, 939.
104. a) D. Barton, T. Shioiri, D. Widdowson *J. Chem. Soc. (C)*, **1971**, 1968.  
b) D. Barton, X. Lusinchi, J. Ramirez *Tetrahedron Letters*, **24**, **1983**, 2995.  
c) D. Barton, X. Lusinchi, J. Ramirez *Bull. Soc. Chim. Fr.*, **1985**, 849.
105. G. Stork, T. Takahashi *J. Amer. Chem. Soc.*, **99**, **1977**, 1275.
106. a) O. Mitsunobu *Synthesis*, **1981**, 1.  
b) D. Hughes. In *Organic Reactions*. L. Paquette Ed. John Wiley and Sons Inc:New York, vol. 42, **1992**, 335.
107. J. Denver, D. Hart, S. Ramesh *J. Org. Chem.*, **53**, **1988**, 6022.
108. C. Willis *Tetrahedron Letters*, **28**, **1987**, 6705.
109. S. Giliani, D. Triggle *J. Org. Chem.*, **31**, **1966**, 2397.
110. In addition to our own efforts in this area, we are aware of at least 3 additional approaches: Professors Gary Keck at University of Utah, Carl Johnson at Wayne State University and Clayton Heathcock at the University of California at Berkley.
111. S. Ohta, S. Hayakawa, M. Okamoto *Tetrahedron Lett.* **25**, **1984**, 5681.
112. E.J. Corey, A. Gross *Tetrahedron Lett.*, **25**, **1984**, 495.
113. J. Martin, T. Krizan *J. Amer. Chem. Soc.*, **105**, **1983**, 6155.
114. S. Ley, A. Redgrave, S. Taylor, S. Ahmed, D. Ribbons *Synlett*, **1991**, 741.
115. J. Stille *Angew. Chem. Int. Ed. Engl.*, **1986**, 508.
116. a) V. Farina, S. Baker, D. Benigni, S. Hauck, C. Sapino *J. Org. Chem.*, **55**, **1990**, 5833.  
b) V. Farina, S. Baker, C. Sapino *Tetrahedron Lett.*, **29**, **1988**, 6043.

117. G. Cook, W. Hornback, C. Jordan, J. McDonald, J. Munroe *J. Org. Chem.*, **54**, **1989**, 5828.
118. a) A. Suzuki *Pure and Appl. Chem.*, **1986**, 459.  
b) K. Tomao, K. Sumitani, M. Kumada, A. Suzuki *J. Amer. Chem. Soc.*, **94**, **1972**, 4374.
119. D. Knight. In *Comprehensive Organic Synthesis*. B. Trost, I Fleming, G. Pattenden Eds. Pergamon Press:New York, vol. 3, **1991**, pp.481-520.

## IX. VITA

Bryan Patrick McKibben was born September 18, 1968 to Mr. and Mrs. Robert George McKibben. He was raised Roman Catholic in suburban Washington D.C. Bryan graduated from Bishop McNamara High School in the spring of 1986 and enrolled at Loyola College in Maryland the following fall. In May, 1990 Bryan earned a Bachelor of Science degree in chemistry. Bryan began graduate studies at Virginia Polytechnic Institute and State University in 1990 under the direction of Dr. David Becker. His research was directed towards the synthesis of novel enediyne antibiotics and rearrangements of oxocycloalkenylisoxazolium anhydrobases. In June 1993, Bryan changed research advisors from Dr. David Becker to Dr. Tomas Hudlicky because of Dr. Beckers resignation from Virginia Polytechnic Institute and State University and acceptance of a faculty position at Florida International University. In the summer of 1993, Bryan married Denise Marie Hammond. His accomplishments while at Virginia Polytechnic Institute and State University are listed below:

### **Publications:**

- 1) David Becker, Frank Anderson, Bryan McKibben, Joseph Merola and Thomas Glass, "Oxocycloalkenyl Isoxazolium Anhydrobases: Synthesis and Reactivity Studies," *Synlett*, **1993**, 866.
- 2) Tomas Hudlicky and Bryan McKibben, "New Cycloaddition Chemistry of 1-Chloro-5,6-cis-isopropylidenedioxy cyclohexa-1,3-diene Derived from the Oxidation of Halogenobenzenes by *Pseudomonas putida* 39D," *J. Chem. Soc., Perkin I*, **1994**, 485.
- 3) Tomas Hudlicky, Horacio Olivo, and Bryan McKibben, " Microbial Oxidation of Aromatics in Enantiocontrolled Synthesis. 3. Design of Aminocyclitols (exo-Nitrogenous) and Total Synthesis of (+)-Lycoricidine via Acylnitrosyl Cycloaddition to Polarized 1-Halo-1,3-cyclohexadienes," *J. Amer. Chem. Soc.*, **1994**, *116*, 5108.

- 4) Bryan P. McKibben, George S. Barnosky and Tomas Hudlicky, "Unusual Dehalogenation of a Bridgehead Halide, Conversion of Arene-*cis*-diols to the *trans*-isomers and Synthesis of Optically Pure Cyclohexadiene-*trans*-diols," *J. Org. Chem.*, in press.

**Presentations:**

- 1) Bryan McKibben and David Becker, "A Synthetic Approach to a New Eneidyne Antibiotic," The Fifth Symposium on the Latest Trends in Organic Chemistry, Blacksburg, VA, September, 1992.\*
- 2) Bryan McKibben and Tomas Hudlicky, "Cycloadditions of 5,6-Isopropylidenedioxy-cyclohexa-1,3-diene," The 45<sup>th</sup> ACS Southeast Regional Meeting, Johnson City, TN, October, 1993.
- 3) George Barnosky, Bryan McKibben and Tomas Hudlicky, "Potassium Permanganate Oxidation of Arene-*cis*-diols," The 6<sup>th</sup> Annual ACS Symposium on Undergraduate Research, Blacksburg, VA, March, 1994.
- 4) Bryan McKibben, George Barnosky and Tomas Hudlicky, "Arene-*cis*-diols in Organic Synthesis: Potassium Permanganate Mediated Oxidation and Unusual Cycloaddition Chemistry," Gordon Conference on Biocatalysis, Meriden, NH, July, 1994.\*
- 5) Bryan McKibben, George Barnosky and Tomas Hudlicky, "Arene-*cis*-diols in Organic Synthesis: Potassium Permanganate Mediated Oxidation and Unusual Cycloaddition Chemistry," The Sixth Symposium on the Latest Trends in Organic Chemistry, Blacksburg, VA, September, 1994.\*
- 6) Bryan McKibben, George Barnosky and Tomas Hudlicky, "Synthesis of Arene-*trans*-diols from the Corresponding Arene-*cis*-diols," 46<sup>th</sup> ACS Southeast Regional Meeting, Birmingham, AL, October, 1994.

(Note: \* denotes poster)

Bryan P. McKibben